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ABSTRACT 
 
RACHAEL BAKER: Diverse Mechanisms of G Protein Regulation by 
Monoubiquitination 
(Under the direction of Henrik Dohlman and Sharon Campbell) 
 
Cell signaling pathways convert information from the extracellular environment 
into an intracellular response.  It is essential that these pathways be turned on and off on 
the appropriate timescales.  Post-translational modifications are one essential mechanism 
used to maintain proper signaling.  One post-translational modification that is emerging 
as a key regulator of cell signaling is monoubiquitination.  Monoubiquitination is 
dynamic and reversible, making it ideal for temporal and spatial regulation.  It has 
recently become evident that monoubiquitination regulates G proteins, which are the 
molecular switches that turn signaling pathways on and off.  However, the mechanisms 
by which monoubiquitination acts on these enzymes is not known.   
We used a chemical ubiquitination approach coupled with biochemical and 
biophysical assays to elucidate the mechanisms by which two G proteins, the small G 
protein Ras and the heterotrimeric G protein Gpa1, are regulated by monoubiquitination.  
Monoubiquitination at one position activates K-Ras by impeding regulator-mediated 
hydrolysis while monoubiquitination at a distinct site activates H-Ras by increasing 
intrinsic nucleotide exchange.  Together, these results demonstrate that 
monoubiquitination contributes to isoform-dependent regulation of Ras in a site-specific 
manner.  Furthermore, we found that the site of ubiquitination on Gpa1 was in a unique 
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domain that is essential for trafficking but does not contribute to enzymatic activity. The 
G protein substrates we chose exhibited diverse mechanisms of regulation by 
monoubiquitination including altering protein interactions (K-Ras), intrinsic activity (H-
Ras), and localization (Gpa1). In summary, our results represent the first mechanistic 
study of G protein regulation by monoubiquitination and contribute to understanding Ras 
and Gpa1 regulation specifically as well as regulation of G proteins by 
monoubiquitination generally.    More broadly, these results illustrate the diverse roles for 
monoubiquitination in the regulation of cell signaling. 
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CHAPTER I 
 
INTRODUCTION1 
 
When cells receive a signal, it is crucial that they respond correctly and limit the 
time frame of their response.  The regulation of all cellular events requires careful 
maintenance of proper protein levels and activity, a crucial balance that is determined by 
the control of protein synthesis, localization, activation, and degradation.  Many of these 
levels of control are fine-tuned by post-translational modification of proteins by 
mechanisms such as lipidation, glycosylation, phosphorylation, monoubiquitination, and 
polyubiquitination.  While monoubiquitination is similar in name to polyubiquitination, it 
is more similar in function to conditional post-translational modifications like 
phosphorylation.  The dysregulation of ubiquitination is implicated in many diseases 
including cancer, autoimmune disorders, neurodegenerative diseases, and developmental 
disorders.  However, particularly in the case of monoubiquitination, we have yet to 
understand the full extent of the mechanisms by which this modification is used to 
regulate proper cellular signaling and response.  The potential functional diversity of this 
signal is staggering, and our ability to understand its mechanism of action is in many 
cases limited only by our ability to generate enough modified substrate to study by 
biochemical and biophysical methods.  This thesis will focus specifically on the study of 
monoubiquitination of key components of signaling pathways, G proteins, using a 
                                                 
1 All figures contributed by Rachael Baker 
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chemical approach to generate monoubiquitinated substrate.  This approach allows us to 
couple the mechanistic understanding of a protein developed from biochemical and 
biophysical studies to data that demonstrate the importance of monoubiquitination for 
maintaining proper cellular signaling in vivo.  This introductory chapter will specifically 
focus on what is known about regulation by monoubiquitination and limitations in our 
knowledge and available resources to study monoubiquitinated proteins. 
 
Monoubiquitination 
Monoubiquitination is a dynamic, reversible post-translational modification that 
involves attaching the 76 amino acid protein Ubiquitin to a targeted substrate.  Even 
though monoubiquitination involves modifying a protein with a distinct protein, it is used 
in a manner similar to post-translational modification by phosphorylation.  
Phosphorylation is central to the regulation of cell signaling pathways (1-4) and can even 
be required as a precursor for ubiquitination (5).  Given the similarities between the ways 
these two post-translational modifications can be used and their effects on substrates, it is 
now evident that monoubiquitination is also emerging as a major player in cell signaling 
regulation.   
Evidence for regulation by monoubiquitination is present in a number of key cell 
pathways, including regulation of DNA expression through modification of histones and 
processivity factors, regulation of signaling through endocytosis, and regulation of 
viruses (6).  However, our understanding of the mechanisms by which 
monoubiquitination can be used in cellular regulation is still limited.  Furthermore, we 
lack an understanding of the changes in protein structure, dynamics, and activity that 
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occur when a protein is monoubiquitinated and that could contribute to understanding the 
mechanisms through which substrates are regulated by monoubiquitination.   
One challenge to advancing our understanding of the breadth of regulation by 
monoubiquitination is the lack of a resource that consolidates published information on 
substrates of monoubiquitination.  As of April 2013 there have been 10,787 non-
redundant substrates of ubiquitination (all species)  published in the literature, and while 
this is less than the 207,569 non-redundant phosphorylation sites identified on 19,807 
different proteins, it is a number that will continue to grow as detection methods improve 
and the diversity and importance of this modification is more fully appreciated (7).  
However, while there are databases that seek to document substrates of ubiquitination in 
general, as of the time of publication, there is no database that separately documents and 
categorizes substrates of monoubiquitination.  In the future, considering 
monoubiquitination as a post-translational modification distinct from polyubiquitination 
will be crucial for understanding and appreciating the complex and elegant way in which 
monoubiquitination aids in orchestrating proper cell function.   
History of Discovery of Monoubiquitination 
The discovery of the first monoubiquitinated substrate pre-dates the discovery that 
polyubiquitination is used for the regulation of protein abundance (8).  The first protein 
known to be modified by Ubiquitin was histone H2A, although in the initial publication 
in 1977, Ubiquitin was not mentioned by name; the authors established that histone H2A 
could be linked through an isopeptide linkage to a peptide of non-histone origin (9).  The 
conjugate was later shown to be Ubiquitin (10).  In the early 1980s, Ubiquitin was 
rediscovered in the form of polyubiquitination, a post-translational modification that led 
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to protein degradation (8, 11, 12).  It was polyubiquitination and degradation that 
dominated the next years of Ubiquitin research, eventually leading to the Nobel Prize in 
2004 (12).  While our understanding of the regulation of protein abundance by 
polyubiquitination expanded, studies also began to show that monoubiquitination played 
a diverse role in the regulation of proper cellular function.   
In 1986, a lymphocyte homing receptor was shown to be monoubiquitinated on its 
extracellular domain, suggesting a more general role of monoubiquitination in the non-
degradive regulation of cell surface proteins (13, 14).  There was also early evidence that 
plasma membrane proteins were modified with Ubiquitin and that this modification could 
direct proteins into the endocytotic pathway (15, 16).  More recent reports have 
demonstrated the functional importance of monoubiquitination for inhibiting the ability 
of endocytotic adaptor proteins to bind to other monoubiquitinated proteins and regulate 
endocytosis (17-19). 
The early discoveries and knowledge of the first identified functions of 
ubiquitination shaped our perception of the way the monoubiquitination is used to 
regulate proteins in the cell.  It is only more recently, as techniques for the detection and 
study of ubiquitinated substrates have improved, that it has become apparent that 
monoubiquitination could be more than a binding partner for endocytotic signaling 
proteins and could directly modulate protein activity.  These recent findings suggest a 
more careful study of monoubiquitinated substrates and the ways monoubiquitination is 
used to regulate cell functions is required.  The rest of the introduction chapter will 
describe what is known about the process and outcomes of monoubiquitination, focusing 
on areas where our knowledge of this post-translational modification is still limited.   
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How Substrates are Monoubiquitinated 
Proteins are ubiquitinated by a three component enzyme cascade that includes  a 
Ubiquitin activating enzyme (E1), Ubiquitin conjugating enzyme (E2), and Ubiquitin 
protein ligase (E3) (Figure 1.1) (20-24).  Ubiquitin is first activated by the E1 enzyme in 
an ATP-dependent reaction in which a thioester bond is formed between the c-terminal 
glycine of Ubiquitin and a cysteine on the E1 (25).  After activation by the E1 enzyme, 
Ubiquitin is transferred to a cysteine on the E2 enzyme through trans-esterification (26).  
The E3 ligase is then used to transfer the Ubiquitin either directly or indirectly to the 
substrate, depending on which type of E3 is used.  The final result is a substrate modified 
with Ubiquitin through an isopeptide linkage between the lysine side chain of the 
substrate and the c-terminal glycine of Ubiquitin (Figure 1.1).  
E3 enzymes can be divided into two classes based on their mechanisms of 
Ubiquitin conjugation: HECT (Homologous to E6-ap Carboxyl Terminus) E3s and RING 
(Really Interesting New Gene) E3s, which are further subdivided depending on whether 
they are single-subunit or multi-subunit RING E3s (21).  HECT domain-containing E3s 
first bind to the E2, and then Ubiquitin is transferred from the E2 to the active cysteine on 
the E3 (27).  The E3 then binds the substrate and directly catalyzes ubiquitination through 
the transfer of the Ubiquitin from the active site cysteine to the lysine residue on the 
substrate (21).  RING domain-containing E3s differ from HECT domain-containing E3s 
in that they have no enzymatic activity.  They act as scaffolds to bring together the 
Ubiquitin-containing E2 and substrate to be ubiquitinated (28, 29).  Single-subunit RING 
E3s have the RING E3 activity and substrate binding domain in one protein, while multi-  
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Figure 1.1.  Monoubiquitination by the Ubiquitin Ligase Complex.  Ubiquitin is 
activated by the E1 enzyme and then transferred to the E2 enzyme through 
transthiolation.  If a RING Ubiquitin ligase is being used, the E2 with the activated 
Ubiquitin interacts with the RING E3, which provides substrate specificity, to transfer 
Ubiquitin to a lysine on the substrate.  If a HECT Ubiquitin ligase is used, the activated 
Ubiquitin is first transferred directly to the E3, which both binds the Ubiquitin and 
contains the substrate specificity, before being transferred to a lysine on the substrate. 
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subunit RING E3s consist of multiple proteins, one of which contains the RING E3 and 
another that has the substrate binding specificity (29). 
Ubiquitination is a specific and selective process.  Monoubiquitination can target 
a single isoform of highly conserved proteins in a defined region of cell space.  The 
specificity of substrate selection is primarily provided by the number of E3 ligases that 
exist in the cell (30, 31).  There are 500 E3s in mammals, while there are 30 E2s and only 
a few E1s (6, 30, 32-34).  Each E2 can therefore provide Ubiquitin for a number of  
different E3 ligases, and the E3 ligases can recognize distinct substrates, thus providing 
careful control over which substrates are ubiquitinated (35).   
While the process of substrate ubiquitination has been extensively characterized, 
less is understood specifically about how monoubiquitinated signals (as opposed to 
polyubiquitinated signals) are generated. Cells adopt several strategies to ensure that a 
substrate is monoubiquitinated.  The first mechanism involves using an E2 that only leads 
to monoubiquitination.  For example, when the E2 Rad6 is used, histone H2B is only 
monoubiquitinated because this E2 does not remain associated with the E3, which is 
necessary for additional rounds of ubiquitination to occur (36).  In a similar mechanism, 
Ubiquitin chain elongation could be restricted by coupling an E2 and E3 that do not 
strongly interact with each other.  For example, when the E2 Cdc34 is coupled with the 
E3 Rag1, an unusual mode of interaction is used that does not favor re-association 
between the E2 and E3 after the first Ubiquitin has been transferred to the substrate (37).  
For polyubiquitination to occur, reassociation between the E2 and E3 must occur (37).  
Finally, monoubiquitination can also be achieved by linking ubiquitination and low 
affinity Ubiquitin binding, which is referred to as coupled monoubiquitination (38).  An 
8 
 
example of this mechanism is the substrate Eps15.  When Eps15 is monoubiquitinated, it 
undergoes a conformational change and folds back on itself, binding to Ubiquitin with its 
own ubiquitin-interacting motif (UIM).  The conformational change that Eps15 
undergoes inhibits the Ubiquitin ligase, Nedd4, from further interactions with Eps15, 
which are required for Ubiquitin chain elongation (39). 
The complexity exhibited in the process of ubiquitination extends to a complex 
network of mechanisms that regulate ubiquitination.  The activity of the Ubiquitin ligases 
themselves is carefully regulated.  Some Ubiquitin ligases are constitutively active, but 
have an adaptor protein that must be recruited before the E3 can bind to the E2 (27).  
Other Ubiquitin ligase complexes are not active until they have been post-translationally 
modified (most often, phosphorylated).  Phosphorylation often serves to release 
inhibitory interactions between the domains of an E3 so it can bind E2 or substrate and 
transfer Ubiquitin (27).  Regulation of ubiquitination can also occur through localization 
of the Ubiquitin ligase complex, which ensures that only specific pools of a protein or 
only specific isoforms are ubiquitinated.  Finally, ubiquitination can be regulated by first 
requiring alternative post-translational modification of the substrate.  For example, many 
substrates of  Skp1-Cullin-F-box Ubiquitin ligase complex (SCF) must be phosphorylated 
before they are recognized as substrates for ubiquitination (29). 
Similar to phosphorylation, monoubiquitination is not a permanent post-
translational modification.  Deubiquitinating enzymes (DUBs), which are akin to the 
phosphatases that remove phosphorylation, can also regulate cellular processes by 
removing Ubiquitin from a substrate by cleaving the bond between the substrate and 
Ubiquitin (5, 27).  The human genome codes about 80 DUBs, which are also involved in 
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recycling and processing polyubiquitin chains (40, 41).  The large number of DUBs 
suggest that the act of removing Ubiquitin, similar to adding Ubiquitin, is both tightly 
controlled and substrate specific. The DUBs themselves are regulated by mechanisms 
such as conformational changes that occur when the DUB binds to a substrate, a 
requirement for an adaptor protein to recognize and bind to a substrate, or post-
translational modification of the DUB itself, in some cases by monoubiquitination (42).  
The presence of DUBs highlights the exciting possibility that monoubiquitination can be 
used to transiently alter protein localization, binding partners, or even function or 
activity. 
Substrates of Monoubiquitination 
Very little is known about what makes substrates amenable to 
monoubiquitination.  There is some general evidence that the amino acid composition 
and local structure surrounding the ubiquitination site on the substrate is crucial to the 
process of protein targeting.  A recent analysis of almost 150 ubiquitination sites in yeast 
demonstrated that some Ubiquitin ligase complexes have a strong sequence bias for 
lysines surrounded by polar acidic and uncharged residues (43).  However, the sites of 
ubiquitination identified in this study were primarily substrates of the HECT Ubiquitin 
ligase Rsp5, so this may not represent a universal observation about sites of 
ubiquitination.  In support of amino acid sequence directing ubiquitination, a study by 
Sadowski et al. showed that the propensity of Ubiquitin for a lysine within a substrate can 
be altered by mutating residues around the known ubiquitination site (44).  These studies 
demonstrate that the sequence surrounding lysines in a substrate is a determinant for 
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ubiquitination and can in some cases be used to predict where ubiquitination can occur 
(45).   
Understanding what makes a good site for ubiquitination also requires 
consideration of structural elements of the substrate.  A recent study by Hagai et al. 
showed that ubiquitination sites of a large number of substrates of monoubiquitination are 
targeted toward structured regions of proteins (46).  Ubiquitination sites appear to favor a 
helix or a coil over a strand, and ubiquitination sites that exist on helices or strands are 
most often surrounded by ordered residues (46).  Other studies focused on 
polyubiquitination observe a preference for ubiquitination of lysines in stretches of amino 
acid sequence that are likely to be disordered (43, 45, 47-50).  One reason it may be 
challenging to identify conserved patterns for sites of ubiquitination is that, as noted in a 
recent study of the evolutionary development of ubiquitination, in many cases it appears 
that Ubiquitin ligases evolve to modify existing lysines rather than lysines of substrates 
evolving to become favorable sites of ubiquitination (51).  Thus, preference for targeting 
may be specific for a particular Ubiquitin ligase complex.  It is also important to note that 
while the studies described give information about protein sites that are amenable to 
ubiquitination, they fail to provide information about whether those identified sites will 
actually become ubiquitinated in vivo. 
Outcomes of Monoubiquitination 
It is clear from the literature that monoubiquitination is a more important and 
versatile post-translational modification than was initially predicted (43).  There is 
evidence for monoubiquitination regulating processes as diverse as gene transcription, 
protein localization, and protein activity. There is also evidence of substrates, Ubiquitin 
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ligases, and DUBs being mutated or misregulated in disease and cancerous states.  In 
many cases, a key determinant of the outcome of monoubiquitination is the presence of 
proteins or domains that recognize the post-translational modification (5, 52).  Ubiquitin 
has also been shown to adopt distinct conformations depending on its binding partner, 
which can aid in recognition by distinct regulators of the monoubiquitinated substrate 
(Figure 1.2a) (53).  In some cases, monoubiquitination alters interactions with pre-
existing protein binding partners, but in other cases, the modified substrate is recognized 
by a new protein, often containing a Ubiquitin binding domain (UBD).  There are sixteen 
different types of UBDs that mediate most of the interactions with  ubiquitinated 
substrates and that can form interactions with multiple surfaces of Ubiquitin (53, 54).  
Most UBDs interact with a hydrophobic patch on Ubiquitin (Leu8, Ile44, and Val70) 
(Figure 1.2b) (53).   
There are numerous reviews on the well-characterized cellular functions of 
monoubiquitination, and these outcomes will be only briefly discussed here (52, 55).  A 
summary of the known outcomes of monoubiquitination is shown in Figure 1.2c.  
Monoubiquitination is clearly involved in three distinct cellular functions: gene and 
protein expression through histone and transcription regulation, endocytosis, and 
retroviral budding.  Monoubiquitination may also control the activity of the endocytotic 
machinery (15, 55, 56).  Monoubiquitination can act on these systems through 
mechanisms as diverse as regulating the activity of transacting endocytotic proteins (57, 
58) and transcription factors in the nucleus (59), or regulating protein-protein interactions 
(60). 
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Figure 1.2.  Recognition and Outcomes of Monoubiquitination.  (a) When Ubiquitin 
(2K39) is in solution, it exhibits conformational diversity.  UBDs recognize different 
conformations of Ubiquitin, and the side chains of the hydrophobic amino acids (Leu8, 
Ile44, and Val70) most frequently recognized by the UBDs are highlighted in purple.  (b)  
Surface of Ubiquitin (1UBQ) with the C-terminal region where ligation to substrate 
occurs shown in gray, the hydrophobic patch recognized by most UBDs shown in red 
(centered on Ile44).  In orange is a diglycine patch that is also recognized by some UBDs 
(centered on Asp56).  (c) Substrate monoubiquitination leads to the regulation of a 
variety of processes including endocytosis, DNA repair, gene expression, nuclear export, 
and virus budding (examples given in italics).  Monoubiquitination also regulates protein 
activity, although this function of monoubiquitination has not been well-characterized. 
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Monoubiquitination is intricately involved in the regulation of gene expression in 
the nucleus.  This post-translational modification is one of many (including methylation 
and acetylation) that can modify histones and alter chromatin structure, which directly 
alters gene expression (17, 59).  Furthermore, monoubiquitination regulates gene 
expression by targeting enzymes involved in DNA repair and transcription.  When the 
DNA processivity factor Proliferating Cell Nuclear Antigen (PCNA) is 
monoubiquitinated, it recruits Translesion DNA synthesis (TLS)-specific DNA 
polymerases, which allow PCNA to bypass a DNA lesion (17, 61-63).  In another 
example, the transcription factor NF-κB, which controls expression of genes involved in 
cell growth and immunity (64, 65), is regulated by IB Kinase (IKK), which block NF-κB 
inhibitors by marking them for polyubiquitination and degradation (66).  For IKK to be 
activated, it must first be phosphorylated, which also makes it a substrate for 
monoubiquitination in chronically activated cells (67, 68).  IKK that cannot be 
monoubiquitinated is resistant to chronic activation (69). 
Many of the best characterized substrates of monoubiquitination are involved in 
membrane protein trafficking and receptor internalization through endocytosis (Figure 
1.3) (30, 58, 70).  In endocytosis, monoubiquitination is a sorting signal for Receptor 
Tyrosine Kinases (RTKs), G Protein Coupled Receptors (GPCRs), transporters, and ion 
channels (17, 18, 58, 71).  For example, the yeast GPCR, Ste2, is ubiquitinated after 
binding to its ligand, pheromone, and monoubiquitination promotes its entry into 
endocytotic vesicles and its rapid removal from the plasma membrane (15, 72).  
Endocytosis of membrane proteins is important because it regulates signaling by quickly 
removing the protein from the site at which it mediates activity (15).  Monoubiquitinated 
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Figure 1.3.  Monoubiquitination Leads to Receptor Endocytosis.  When a receptor is 
monoubiquitinated, the Ubiquitin is recognized by a protein with a Ubiquitin interacting 
motif (UIM), which also binds to a clathrin-coated pit.  At the early endosome, the 
receptor can continue through the process of endocytosis, or be recycled back to the 
membrane.  The receptor can also be recycled back to the membrane from the late 
endosome.  Finally, endocytosis can lead to receptor degradation at the lysosome. 
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proteins, like Ste2, can in some cases be degraded through the lysosomal system after 
endocytosis occurs (13).  The Ubiquitin moiety fused to a membrane protein carries with 
it the necessary information for endocytosis facilitated by endocytotic adaptor proteins 
(73, 74).  Ubiquitin binding endocytotic adaptor proteins are also themselves regulated by 
monoubiquitination (17).  One example of this type of regulation is β-arrestin, which 
binds phospholipids and clathrin and is important for the endocytosis of activated 
GPCRs.  β-arrestin itself is monoubiquitinated after the β2-adrenergic receptor is 
activated, and this monoubiquitination is required for the rapid internalization of the 
receptor (75, 76).  In fact, monoubiquitination of β-arrestin is sufficient for β2-adrenergic 
receptor endocytosis (77).   
Monoubiquitination is also important in the process of virus budding.  Enveloped 
viruses exit the cell by budding from the cell membrane, and it is known that reducing 
cellular levels of Ubiquitin inhibits budding (55).  One example of this regulatory process 
is monoubiquitination of the protein Gag, which is an essential component of 
retroviruses.   The Gag protein has an embedded sequence, termed a late domain, which 
is essential for budding.  This late domain is known to be an interaction motif for the 
Ubiquitin ligase Nedd4, leading to ubiquitination when Gag is properly localized to the 
membrane (78, 79).  When Gag cannot be monoubiquitinated, viral budding does not 
occur (80, 81).   
The above examples describe the well-documented uses of monoubiquitination in 
cell regulation.  There are, however, a number of substrates that have been identified in 
vivo and in vitro that either do not yet have clear physiological outcomes or whose 
outcomes do not fit easily into one of these three primary categories (55, 82).  For 
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example, monoubiquitination has been shown to directly regulate the activity of the DUB 
ataxin-3, leading to an enhancement of its enzymatic activity (83).  On the other hand, 
monoubiquitination of dihydrofolate reductase, an enzyme involved in DNA synthesis, 
suppresses its enzymatic activity (84).  Finally, monoubiquitination of the tumor 
suppressor p53 leads to a conformational change in the protein that exposes a previously 
buried nuclear export signal (85).  Other substrates, like the small GTPase Rac1, have 
been identified as substrates of monoubiquitination, but the physiological role of the post-
translational modification is not yet known (86).  It is likely that as our ability to detect 
and study monoubiquitinated substrates improves, new cellular functions for the 
modification will be discovered. 
One challenge that exists in understanding the role of monoubiquitination in cell 
regulation is that there is no online resource that consolidates information on all 
monoubiquitinated substrates.  There are databases that list all currently identified 
substrates of ubiquitination, but they do not distinguish between polyubiquitination and 
monoubiquitination.  As we have previously discussed, the outcomes of these two types 
of post-translational modifications are clearly distinct.  Mass spectrometry and other large 
scale approaches are being adapted to generate large databases of monoubiquitinated 
proteins (87, 88).  However, it is important not just to document occurrences of this post-
translational modification, but to understand and categorize the ways this post-
translational modification is being used in cellular regulation.  A resource containing this 
type of analysis would allow continued identification of patterns and trends in the way 
monoubiquitination is used in vivo.  
 
17 
 
Ubiquitination and Disease 
Understanding the diverse mechanisms by which monoubiquitination is used to 
regulate substrate localization, binding, and activity becomes more important as a role for 
ubiquitination is emerging in the study of cancer and developmental disorders.  For 
example, sequence preferences surrounding the ubiquitination sites of Rsp5 have been 
identified, and many known protein mutations that lead to disease alter these potential 
ubiquitination sites (43).  There is evidence that ubiquitination is also involved in  
sensing of neuropathic pain and its misregulation in disease (89).  Mutations of Ubiquitin, 
Ubiquitin ligases, and DUBs are all found in human diseases and disorders.  For example, 
many Ubiquitin ligases are proto-oncogenes (90, 91).  Receptor Tyrosine Kinases that are 
not ubiquitinated or lack proper ubiquitination can lead to constitutive receptor signaling 
and carcinogenesis (92). 
There is already some precedence for targeting similar post-translational 
modification for disease treatment.  Targeting the post-translational phosphorylation for 
drug development has been successful, and there are currently over 150 drugs in various 
stages of clinical trials (93).  There are many parallels between the phosphorylation and 
ubiquitination systems suggesting the ubiquitination may prove to be just as important a 
pathway to target for drug development.  For example, the human genome contains more 
E3 Ubiquitin ligases than protein kinases (93).  Furthermore, there is significant interplay 
between phosphorylation and ubiquitination that is critical for cell regulation.  For 
example, some E3 ligases require substrate phosphorylation before ubiquitination can 
occur (93).   
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In fact, there are already drugs that successfully target the ubiquitination system.  
There are some therapies involving monocolonal antibodies that act by promoting 
Ubiquitin-dependent receptor degradation (94).  However, a detailed knowledge of the 
mechanisms by which ubiquitination regulates these pathways is required for the design 
of effective inhibitors (95).  Some of the most promising targets in the ubiquitination 
pathway are the E3 Ubiquitin ligases, which are crucial for ubiquitination and are also the 
critical point for substrate specificity (96).  Currently, there has been some success in 
finding small molecule inhibitors of E3 substrate interactions, for example the interaction 
of the E3 MDM2 with its substrate p53 (96).  There are also drugs already on the market 
that block the downstream effects of substrate ubiquitination downstream.  For example, 
Bortezomib is a small molecule inhibitor of the 20S proteasome (97, 98).  Bortezomib is 
used to treat multiple myeloma, likely by limiting cell immortality by blocking the 
degradation of pro-apoptotic proteins (97, 98). Another promising target for drug 
development is deubiquitinases; there are known small molecule inhibitors for some 
deubiquitinases already, but it remains to be seen whether they will become successful 
new anticancer therapies in the near future (99).  In fact, deubiquitinases, which have a 
clear protein binding pocket and enzymatic activity, may represent the best targets for 
future drug development studies (99).   
One of the challenges facing drug development targeting the Ubiquitin system is 
that there is no general approach for disrupting E3 ligase substrate interactions. While 
many compounds have been developed to target enzymes such as protein kinases, it is 
more challenging to disrupt a protein-protein interaction (93).  Designing inhibitors to 
disrupt protein-protein interactions, which would lead to successful targeting of E3s and 
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ubiquitinated substrates, requires knowledge of the structures and interactions that are 
formed between E3s, Ubiquitin, and substrates.  As our understanding of the structural 
aspects of ubiquitination improves, drug development should prove more fruitful.   
Success in this regard will require information about protein-protein interactions, the 
impact of Ubiquitin on substrate structure, and the mechanisms of deubiquitination. 
However, despite extensive characterization of the outcomes of ubiquitination in 
vivo, questions remain about how specific lysines on a substrate are ubiquitinated, how 
ubiquitination directly affects the structure and properties of the substrate, and how 
changes to the structure or dynamics of the substrate may contribute to the function of 
different substrates (100, 101).  The answers to these questions are essential to fully 
understanding the roles ubiquitination plays in proper (normal signaling) and improper 
(disease and cancer) cellular functions. 
 
New Approaches to Study Ubiquitination 
As discussed in the previous section, an advance in our ability to understand and 
target the process of ubiquitination requires a clearer structural and mechanistic 
knowledge of monoubiquitination, including how it may lead to changes in the structure 
and activity of the substrates that it modifies.  While significant effort has been focused 
on characterizing the outcomes of monoubiquitination in vivo, very little has been done to 
understand what this modification does to the biochemical and biophysical properties of 
its substrates.  There is, however, precedence for the value of information obtained from 
asking these types of questions.  For example, the charge introduced by another 
conditional post-translational modification, phosphorylation, is known to lead to a 
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perturbation of the biophysical properties of a protein structure, which can lead to a 
conformation change that alters activity and protein-protein interactions (52, 102, 103).   
There are some recent studies that focus on the structural and biophysical aspects 
of ubiquitination.  Computational modeling of the ubiquitinated substrate Ubc7 suggests 
that ubiquitination changes the thermodynamic stability of a protein in a site-specific and 
modification-specific manner (104).  Furthermore, Ubc7 was most thermodynamically 
destabilized by ubiquitination at the  known site of polyubiquitination in vivo (104).  
Studies of the interaction between Ubiquitin and the Ubiquitin binding domains (UBDs) 
of proteins that recognize monoubiquitinated substrates suggest that different UBDs 
recognize and stabilize slightly different conformations of Ubiquitin (53).  In solution, 
Ubiquitin is a dynamic molecule, and it is possible that when a substrate is ubiquitinated 
it stabilizes a conformation of Ubiquitin that is recognized by UBDs.  These studies 
illustrate that knowledge of how structure and dynamics change lead to insight into the 
mechanism by which a monoubiquitinated substrate is recognized.  Other structural 
studies have shown how Ubiquitin associated (UBA) domains recognize and bind to 
specific hydrophobic patches on Ubiquitin (105).  These biochemical and structural 
analyses of interactions between Ubiquitin and Ubiquitin-binding proteins have helped 
develop a mechanistic understanding of the link between the modification, the process 
that it regulates, and the proteins that recognize the modified substrate (17).  
Despite insights gained using biochemical and biophysical approaches, few 
studies of monoubiquitinated substrates have been conducted.  Two of the primary 
reasons are that [1] it is difficult to obtain enough natively modified substrate from cells 
to study by biochemical and biophysical methods and [2] many of the current synthetic 
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methods are highly technical and may not be accessible to a molecular and cellular 
biologist.  This is a problem not only for the study of monoubiquitination, but for other 
post-translational modifications as well.  There are now over 200 documented post-
translational modifications, a number of which involve modifying a substrate with 
another protein (like Sumoylation) that have the same constraints on the ability to 
perform mechanistic studies (17, 52, 63). 
Use of Chemical Modification to Study Monoubiquitinated Substrates 
One particularly promising approach to gaining a mechanistic understanding of 
regulation by monoubiquitination is through the use of synthetic methods to generate 
monoubiquitinated substrates.  There are three approaches to generate ubiquitinated 
substrate suitable for study by biophysical methods: non-natural amino acids coupled 
with organic synthesis, semi-synthesis, and chemical modification that takes advantage of 
amino acid chemistry.  The simplest approach to chemical modification is to form a 
disulfide bond between Ubiquitin and the substrate (106).  The advantages and 
disadvantages, especially relating to ease of use, of these approaches are discussed in 
Chapter V of this dissertation. 
Currently, there are a few examples of using chemical modification to study 
monoubiquitinated substrates by biophysical methods.  Many of the successful studies of 
monoubiquitinated substrates have come from the use of either isopeptide bond 
surrogates, or the semi-synthesis of a monoubiquitinated substrate.  Histone H2B, the 
first known substrate of monoubiquitination, was also one of the first proteins to be 
studied using one of these approaches (107, 108).  Biochemical analysis of synthetically 
generated monoubiquitinated H2B showed that monoubiquitinated H2B directly activates 
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methylation of histone H3, demonstrating the importance of cross-talk between post-
translational modifications.  Studies of PCNA were also performed using multiple 
chemical approaches to modification (109, 110).  By solving the crystal structure of 
monoubiquitinated PCNA, the authors found that monoubiquitination does not change 
the structure of PCNA itself, suggesting ubiquitination recruits alternative binding 
partners to PCNA, but that Ubiquitin does display limited conformational flexibility 
relative to PCNA, constraining the ways in which binding partners can interact with the 
protein (111-113).  Finally, a semi-synthesis approach was also used to study α-
synuclein, a protein central in the development of Parkinson’s disease.  Using 
monoubiquitinated α-synuclein, the authors directly demonstrated that ubiquitination led 
to the inhibition of fibril formation (114), which was consistent with previous in vivo 
studies suggesting that N-terminal monoubiquitination stabilizes the monomeric form of 
the protein.  Furthermore, additional studies of this protein using cysteine mutations 
showed that different ubiquitination sites had different effects on the formation of fibrils 
(115). 
 We are currently at an exciting time in the study of monoubiquitinated substrates.  
New approaches to study these substrates are available as well as evidence suggesting 
that monoubiquitination regulates substrates through mechanisms more diverse than the 
three primary categories described previously.  In the future, it will be important to 
continue to systematically study and characterize the mechanisms by which 
monoubiquitination regulates substrate localization, binding, and activity.  Mechanistic 
studies, such as the ones described above, will be particularly important for substrates 
where the role of monoubiquitination in in vivo regulation is challenging to elucidate.  
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The recent advances in chemical ubiquitination approaches described above provide the 
opportunity to study monoubiquitinated substrates.  Chemical ubiquitination will be 
especially important in the cases where the population of monoubiquitinated substrate 
might be too small to purify efficiently from cells or the Ubiquitin ligase is not known or 
cannot be reconstituted in vitro.   
 
Regulation of GTPase Signaling by Monoubiquitination 
One prominent family of proteins that promises to be particularly interesting for 
mechanistic studies of signaling regulation by monoubiquitination is GTPases.  There is 
evidence in the literature for diverse mechanisms of GTPase regulation by ubiquitination 
and there are also a number of instances where monoubiquitination can regulate protein 
function by mechanisms other than protein localization.  GTPases regulate cell signaling 
pathways, and are enzymes with a well-characterized guanine nucleotide binding and 
hydrolysis activity.  These proteins are also integral in driving many types of cancer and 
developmental diseases.  The remainder of this thesis will focus on the regulation of 
particular GTPases by monoubiquitination. The implications from these studies for the 
larger field of monoubiquitination will be considered in Chapter V. 
GTPases as Regulators of Signaling Pathways 
GTPases are a family of molecular switches that regulate cell signaling pathways.  
This family includes monomeric Ras-like GTPases and heterotrimeric Gα proteins, all of 
which have a conserved GTPase domain (Figure 1.4a-b) (116-118).  The Ras-like 
GTPases were named after the founding members of this class of GTPases, H-Ras and K-
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Ras, which were first discovered due to their oncogenic potential in retroviruses (119).  
Ras-like GTPases are divided into five subfamilies: Ras, Rho, Rab, Arf, and Ran (120).  
Each subfamily has different localization in the cell and different downstream effectors, 
leading to much of their observed functional specificity.  Ras superfamily GTPases 
regulate a number of pathways, including cell cycle progression and gene expression 
(Ras), cytoskeletal rearrangement (Rho), nuclear import (Ran) and cellular trafficking 
(Rab and Arf) (120, 121).  Small GTPases also have significant roles in driving cancer 
and, in some cases, developmental disorders.  In particular, Ras is activated in over 30% 
of all human cancers. Germline mutations of Ras are found in Noonan syndrome, 
Costello syndrome, and Cardiofacio-cutaneous syndrome (122).  
Heterotrimeric Gα proteins are coupled directly to cell-surface receptors and are 
responsible for receptor-mediated communication between the exterior and interior of the 
cell (121).  There are four classes of heterotrimeric Gαs that are based on their homology 
and downstream effectors: Gαs, Gαi/o, Gαq, and Gα12/13 (123).  Gαs proteins activate 
adenylyl cyclase, while Gαi are known to inhibit adenylyl cyclase and act in opposition to 
Gαs (124).  Gαi GTPases are also coupled to taste and odor receptors, and facilitate vision 
through phototransduction. Gαq proteins activate phosphoinositide-specific 
phospholipase C isozymes. This leads to the generation of the second messenger signals 
inositol 1,4,5-trisphosphate and diacylglycerol (124).  Finally, Gα12/13 proteins regulate 
the GTPase RhoA  from the Rho family of small GTPases (125).  These heterotrimeric G 
proteins mediate signaling pathways such as protein-protein phosphorylation, gene 
transcription, cytoskeleton reorganization, membrane depolarization, and secretion (126). 
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Figure 1.4.  Domains of Small and Heterotrimeric GTPases.  (a) Ribbon diagram of 
representative Ras domain of a small GTPase (1CRR).  GDP-bound switch regions are 
shown in light green, while GTP-bound switch regions are shown in dark green.  The p-
loop is highlighted in purple.  Magnesium shown in red and GDP in various colors.  (b)  
Ribbon diagram of a heterotrimeric Gα protein (1GIA).  Ras-like domain is shown in 
green and the α-helical domain is shown in blue.  (c) Ribbon diagram of a small GTPase 
(5P21) showing the four binding motifs important for nucleotide coordination, DXXG, 
GXXXXGKS, SAX, and NKXD. 
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The primary mechanism by which GTPases signal is by switching between GDP- 
and GTP-bound states, which results in conformational changes that allow interactions 
with downstream effectors when the GTPase is in the GTP-bound state (127-133).  Small 
GTPases bind nucleotide with a Kd in the picomolar to nanomolar range.  While there are 
variations in their c-terminal targeting sequences, the core Ras domain is highly 
conserved (119).  The Ras domain consists of  an α/β Rossman fold of about 20 KDa and 
contains the basic function of guanine nucleotide binding and hydrolysis (118).  There are 
four regions in the Ras domain that are directly involved in guanine nucleotide binding 
(Figure 1.4c) (119). The NKXD motif forms interactions with the nucleotide base and is 
crucial for nucleotide binding affinity.  The other most important interaction for 
nucleotide binding is the GXXXXGKS motif, which forms interactions with the α, β, and 
γ phosphate of GDP and GTP and provides a serine or threonine for coordination with the 
cofactor Magnesium (121, 134).  Specificity for guanine over other nucleotides comes 
from two motifs, the asparagine side chain of the DXXG motif and a main chain 
interaction with the alanine in the SAX motif (118).  There are also three primary 
structural elements that define the protein’s activity and ability to be regulated: switch I, 
switch II, and the phosphoryl loop (p-loop), which is also part of the GXXXXGKS motif 
(Figure 1.4b).  The main conformational changes occur in the switch regions of the 
proteins.  Ras-like GTPases have two switch regions that sense changes in nucleotide 
binding (117, 132, 135).  The switch regions are conformationally dynamic in the GDP 
bound state, but less so (and much more conserved between GTPases) in the GTP-bound 
state of the protein (118).  The slower time scale and reduced population of conformers in 
the GTP-bound state of the protein is due to additional hydrogen bonds that form between 
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key residues (G60 and T35 on Ras) and GTP (118).  Downstream effectors recognize and 
bind preferentially to the GTP-bound state of the GTPases through the switch regions. 
 On their own, GTPases are not very good enzymes; their enzymatic activity does 
not occur on a timescale fast enough to allow them to respond appropriately to 
extracellular signals.  Therefore, signaling is regulated both by Guanine Nucleotide 
Exchange Factors (GEFs) and GTPase Activating Proteins (GAPs) (Figure 1.5).  GEFs 
facilitate GDP release by stabilizing the nucleotide-free state of the GTPase (118).  The 
reaction is driven in the forward direction by the presence of excess GTP over GDP in the 
cell (136).  The GEFs interact with the switch regions of the GTPase and residues close 
to the p-loop and magnesium binding region, leading to structural changes in the 
GTPases that do not favor binding to phosphates and magnesium.  The release of 
magnesium and additional structural disturbances in the p-loop region account for the 
increased rate of GDP release in the presence of the GEF (118, 137). The mechanism of 
GAP-mediated hydrolysis depends on a conserved glutamine residue located near the γ 
phosphate of the nucleotide.  The glutamine residue facilitates the formation of the 
transition state interaction by priming a catalytic water for in-line nucleophilic attack on 
the γ phosphate (138) .  GAPs supply an arginine finger that binds in the active site (138, 
139).  The mechanisms of regulation are highly conserved, but not universal for all small 
GTPases.  Some small GTPases, particularly the Rho and Rab families, are also regulated 
by guanine nucleotide dissociation inhibitors (GDIs), which recognize a prenylated c-
terminus and allows sequestration of, and recycling of, the GTPases between different 
cell membrane compartments (118). 
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Figure 1.5.  Small GTPase Enzymatic Cycle.  Small GTPases cycle between a GDP-
bound “off” state (light green) and a GTP-bound “on” state (dark green).  The rate of 
GDP dissociation in increased by GEF (brown).  The rate of GTP hydrolysis is increased 
by GAP (purple). 
 
  
29 
 
 While in many ways the activity of heterotrimeric Gα proteins is similar to Ras-
like GTPases, there are some differences (Figure 1.6).  Nucleotide binding still occurs 
primarily within the Ras-like domain, but recent data have demonstrated that the α-
helical domain also contributes to the activity of Gα proteins.  Evidence for α-helical 
domain involvement includes the observation of a major displacement of the α-helical 
domain during receptor activation (140).  Furthermore, recent structural analysis has also 
shown that the α-helical domain is highly flexible in the absence of nucleotide, 
suggesting that this domain undergoes a nucleotide-dependent transition to a stabilized 
state (141).  Gα proteins, along with the canonical switch I and switch II regions, also 
have an extra structural element called switch III (116, 118).  The switch I region also 
serves as one of the two connections between the Ras-like and α-helical domains (142).  
Conformational changes occur in all three switch regions upon changes in the nucleotide 
binding state, similar to the mechanism of small GTPases (143).  However, the 
mechanism for hydrolysis is slightly different.  The amino acid sequence of the Gα 
protein already contains the arginine finger which is provided by the GAPs for small 
GTPases, leading to faster observed rates of intrinsic hydrolysis (almost 100 times faster 
than small GTPases) (144). Heterotrimeric G proteins are regulated by GAPs, commonly 
referred to as regulators of G protein signaling (RGS) proteins (145). While RGS proteins 
do not contain an arginine finger, they do stabilize the active conformation of the 
transition state required for increasing the rate of hydrolysis (146).  GPCRs serve as 
GEFs for Gα proteins, catalyzing GDP for GTP exchange when activated (142).  
Heterotrimeric GTPases use the β and γ subunits as their GDIs (118, 145). They are 
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coupled to Gβγ when the Gα is GDP-bound.  Upon GTP binding, the βγ interaction is 
released, allowing signaling through both Gα and Gβγ to occur.   
GTPases as Substrates of Monoubiquitination 
 GTPases are known to undergo a number of post-translational modifications that 
are crucial for their localization and proper signaling.  Some examples of these include 
phosphorylation (147), myristoylation (148), prenylation, and palmitoylation (147).  
Ubiquitination is also important for the regulation of many GTPases, not only to control 
total substrate levels but to target and regulate these proteins in a temporal and spatial 
manner (149, 150).  Two isoforms of Ras, H-Ras and K-Ras, are substrates of 
monoubiquitination, but monoubiquitination has distinct outcomes.  Monoubiquitination 
of H-Ras in CHOK-1 cells is necessary to stabilize its association with the endosome and 
allow signaling to occur (151, 152).  Monoubiquitination of K-Ras in HEK293T cells 
activates K-Ras and contributes to Ras-mediated tumorigenesis (153).  Ubiquitination of 
Rap1B, another Ras-like GTPase, induces relocalization of the protein from the plasma 
membrane to a subcellular compartment, which is required for the establishment of 
neuronal polarity (154).  It was also shown that Rap2A is monoubiquitinated by Nedd4, 
which acts as a positive regulator of dendrite development (155).  In this case, 
ubiquitination disrupts Rap2A interactions with effector proteins and blocks signaling.  
However, the authors were not able to determine if monoubiquitination altered the 
biochemical activity of Rap2A.  Monoubiquitination is specifically targeted to the active, 
GTP-bound state of Rap2A.  To reduce Rap2A ubiquitination, it was necessary to mutate 
lysines 5, 94, 148, and 150; expression of a mutant lacking these four lysines impaired 
neurite development (155).  
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Figure 1.6.  Heterotrimeric Gα Protein Enzymatic Cycle.  Ligand binding to the G 
protein coupled receptor causes the Gα subunit to exchange GDP for GTP.  When Gα is 
bound to GAP, it no longer interacts with Gβγ.  When dissociated, both Gα and Gβγ can 
interact with downstream effector proteins.  When Gα hydrolyzes GTP to GDP, signaling 
is inactivated.  The duration of signaling can be regulated by RGS proteins, which act as 
GAPs for Gα proteins. 
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The small GTPases RalA and RalB are also substrates of 
monoubiquitination(156). RalA is important for anchorage-independent proliferation as 
well as tumor growth while RalB contributes to cancer cell survival.  In this case, 
activation of RalA does not affect the ubiquitination state of the protein, however, 
monoubiquitinated RalA was significantly enriched in the GTP-bound state (156).  RalA 
ubiquitination increases when a cell is detached from its substrate (156).  No single lysine 
of the 21 lysines within RalA appear key for ubiquitination based on systematic single 
and multiple mutations of the lysines to arginines, suggesting RalA can be ubiquitinated 
on multiple lysines (156).  Monoubiquitination selectively modulates RalA and RalB 
localization, which is critical for their differences in the roles they play in cell signaling 
regulation.  Finally, Rac1 monoubiquitination has been observed to occur at a single 
lysine, K147 (86, 157, 158) that lies within an insert region that is conserved in the Rho 
family of small GTPases.  Rac1 is also polyubiquitinated, but when Cav1, which 
regulates Rac1 polyubiquitination, is lost, a monoubiquitinated species appears.  The data 
suggests that monoubiquitination may have a distinct role to play in Rac1 regulation, but 
this mechanism has not yet been pursued (86). 
While there are multiple examples of monoubiquitination of small GTPases, less 
is known about how monoubiquitination regulates Gα proteins.  A number of Gα proteins 
are known to be regulated by polyubiquitination and degradation, including Gαo (159), 
Gαi3 (160), Gαi2 (161), and Gαs (162).  However, currently, the only Gα currently known 
to be monoubiquitination is Gpa1, a Gα in Saccharomyces cerevisiae.  There is a long 
history of discoveries made in yeast that have shaped our understanding of signaling 
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pathways in more complex systems, suggesting that as detection techniques are refined, 
other examples of Gα monoubiquitination may come to light. 
This brief summary focuses primarily on monoubiquitination of the GTPases 
themselves, when in fact regulators of GTPase signaling are also known to be 
monoubiquitinated (163, 164).  There are many examples of monoubiquitination and 
subsequent endocytosis of GPCRs being critical in a number of pathways (16, 58, 70, 
77).  Targeting the ubiquitination or deubiquitination of these GTPases and their 
regulators may represent an exciting new possibility for drug development, but first 
requires that the mechanisms of regulation by monoubiquitination be clearly understood 
(163).   
 
Thesis Summary 
GTPases undergo multiple forms of ubiquitination that lead to a variety of 
different outcomes.  G proteins should serve as an excellent model system to study the 
effect of ubiquitination on substrate structure, dynamics, and thermodynamic stability.  
GTPases are of interest particularly because of the key role they play in cell signaling, 
which makes them good candidates for drug targeting.  However, while we have 
extensive knowledge of the role of GTPases in signaling pathways and the structural and 
mechanistic details that drive their in vivo activity, we have a very limited knowledge of 
the role monoubiquitination plays in their regulation.  It is clear monoubiquitination is 
involved in the regulation of a number of these GTPases and that it may modulate 
signaling or localization.  However, no studies beyond the in vivo observations of 
monoubiquitination have been done to understand the mechanism through which this 
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post-translational modification may act.  In this thesis, we have employed biochemical 
and biophysical methods to understand the molecular basis through which GTPases can 
be regulated by monoubiquitination.   
 To be able to perform our studies of monoubiquitinated substrates in vitro, we 
first had to optimize a method to generate enough monoubiquitinated substrate.  As 
described previously, chemical ubiquitination was the most promising approach to suit 
our needs.  We used a simplified and optimized version of a disulfide chemistry 
ubiquitination approach present in the literature.  Our new approach gave us the ability to 
drive modification of our substrate to completion, as seen in Chapters II and III.  One 
limitation of this type of approach is that, until recently, it has not been applied to 
studying other ubiquitinated substrates, in part because it was not known if the 
differences in the linkage type would alter the behavior of the monoubiquitinated 
substrate.  As discussed in Chapter II, we employed computational modeling to show that 
chemically monoubiquitinated protein accurately mimics natively ubiquitinated protein. 
 We chose this approach in the study of two GTPases.  In Chapter II, we look at 
the effects of monoubiquitination on the structure and activity of K-Ras, which was 
recently shown to be monoubiquitinated (153).  Using our biochemical approach, we 
elucidate the mechanism by which K-Ras is activated by monoubiquitination, which 
included a change in switch region dynamics.  By collaborating with another lab to do 
assays in cell lysates, we verified that the observed mechanism of activation in vitro 
reflected the mechanism by which monoubiquitinated Ras is activated in vivo.  In Chapter 
III, we use the power and versatility of the chemical ubiquitination approach to study 
isoform dependent site-specific monoubiquitination.  We show that in H-Ras 
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monoubiquitination at a different lysine than K-Ras results in protein activation through a 
distinct mechanism. 
 Finally, in Chapter IV, we turn our attention to a heterotrimeric GTPase, the yeast 
Gα Gpa1.  Gpa1 is an interesting protein because it is both monoubiquitinated and 
polyubiquitinated at the same site.  There are very few known substrates where this 
occurs, but they include PCNA (63), a processivity factor, and p53, a well-known tumor 
suppressor (165).  Structural studies of a substrate like this will likely offer insights into 
structural determinants and outcomes of monoubiquitination versus polyubiquitination.  
Choosing a yeast protein afforded us the ability to couple our biochemical and 
biophysical approach to a system where we can also perform genetic studies.  Gpa1 was a 
challenging substrate to study, and much of our effort was focused on optimizing 
methods to obtain pure, stable substrate.  While we have not completed the studies of 
ubiquitinated Gpa1, we have gained insight into the ways in which this protein has 
evolved to allow it be targeted for monoubiquitination 
 In the discussion section of Chapter V, I will highlight not only what we have 
learned from these studies about Ras and Gpa1, and regulation of GTPases in general, but 
also what implications this work has for the field as a whole.  There is much to be gained 
by using in vitro approaches to study regulation by monoubiquitination, and the simple 
method of chemical ubiquitination we have developed should make it feasible to expand 
our mechanistic understanding to other substrates of monoubiquitination. 
  
      
 
CHAPTER II 
 
SITE-SPECIFIC MONOUBIQUITINATION ACTIVATES RAS BY IMPEDING 
GTPASE ACTIVATING PROTEIN FUNCTION1,2 
 
 Cell growth and differentiation are controlled by growth factor receptors coupled 
to the GTPase Ras. Oncogenic mutations disrupt GTPase activity leading to persistent 
Ras signaling and cancer progression. Recent evidence indicates that monoubiquitination 
of Ras leads to Ras activation. Mutation of the primary site of monoubiquitination 
impairs the ability of activated K–Ras to promote tumor growth. To determine the 
mechanism of human Ras activation we chemically ubiquitinated the protein and 
analyzed its function by NMR, computational modeling, and biochemical activity 
measurements. We established that monoubiquitination has little effect on Ras GTP 
binding, GTP hydrolysis, or exchange factor activation, but severely abrogates the 
response to GTPase activating proteins in a site–specific manner. These findings reveal a 
new mechanism by which Ras can trigger persistent signaling in the absence of receptor 
activation or an oncogenic mutation. 
                                                 
1 Elements of the work referenced in this chapter have been published in: 
Baker, R., Lewis, S. M., Sasaki, A. T., Wilkerson, E. M., Locasale, J. W., Cantley, L. C., 
Kuhlman, B., Dohlman, H. G., and Campbell, S. L. (2013) Site-Specific Monoubiquitination 
Activates Ras by Impeding GTPase-Activating Protein Function, Nature Strucutural and 
Molecular Biology 20, 46-52. 
2 Figures contributed by: 
Rachael A. Baker: 2.1, 2.3, 2.4, 2.6, 2.7, 2.8, 2.9a-b, 2.9d-f, 2.10, 2.12, 2.13b-d, 2.14a 
Steven M. Lewis: 2.5, 2.9c, 2.13a, 2.15 
Atsuo T. Sasaki: 2.2, 2.9c, 2.11 
Emily M. Wilkerson: 2.14b 
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Introduction 
Ras plays a central role in cell growth, differentiation, and apoptosis and is a 
member of a large superfamily of guanine nucleotide binding proteins whose activity is 
regulated by cycling between inactive GDP–bound and active GTP–bound states (166). 
Conformational changes associated with the GDP– and GTP–bound states are localized 
primarily to two regions, Switch I (residues 30–37) and Switch II (60–76), and these 
conformational changes direct specific interactions with regulators and effectors (167, 
168). Ras effectors recognize the GTP–bound state of Ras with higher affinity than the 
GDP–bound state, and these effectors serve to initiate downstream signaling events. Ras 
has weak intrinsic GTPase activity, but it does not act alone (138). The guanine 
nucleotide state of Ras is regulated by two distinct types of protein modulators, which act 
in opposition to one another. Guanine nucleotide exchange factors (GEFs) facilitate 
exchange of GDP with GTP to promote Ras activation (169) whereas GTPase–activating 
proteins (GAPs) stimulate the hydrolysis of GTP and Ras deactivation (121). Ras is the 
most prevalent oncogene found in human cancer; about 30% of human tumors contain an 
activating Ras mutation (170, 171). Most commonly, transforming Ras mutations 
decrease the sensitivity of the protein to GAP–mediated regulation (172). 
While the roles of GEFs and GAPs have been extensively characterized, it is less 
clear how some post–translational modifications, like monoubiquitination, contribute to 
Ras function and signaling. Monoubiquitination is a dynamic and reversible modification 
that can orchestrate cellular events including DNA repair, gene expression, endocytosis, 
and nuclear export (55). Emerging evidence suggests that monoubiquitination regulates 
large and small GTPases, including Ras (86, 155, 157, 173). Monoubiquitination of K–
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Ras at position 147 has been shown to promote tumorigenesis (153); mutation of 
oncogenic K–Ras to prevent monoubiquitination (RasK147L) impaired its ability to 
promote tumor growth when ectopically expressed in NIH 3T3 mouse fibroblasts. These 
findings suggest that Ras activity and signaling are modulated by monoubiquitination, in 
the manner of an oncogenic mutation or receptor stimulus. Left unresolved is the 
mechanism by which monoubiquitination leads to activation of Ras. 
Here, we set out to identify the molecular mechanism through which Ras activity 
is regulated by monoubiquitination.  We first developed a method to chemically 
ubiquitinate Ras using conditions that drove post-translational modification to 
completion.  Furthermore, we used computational modeling to validate the chemical 
ubiquitination approach.  Using our system, we show that monoubiquitination at position 
147 does not alter the intrinsic biochemical properties of Ras, but severely disrupts 
regulation of Ras by GAPs. This effect is specific to monoubiquitination at position 147 
and is not observed when Ras is monoubiquitinated at other adjacent lysines. The loss of 
GAP–mediated hydrolysis accounts for the accumulation of Ras–GTP in vivo. Thus 
monoubiquitination reversibly renders the protein resistant to GAP–mediated regulation. 
 
Results 
Monoubiquitination of Ras 
We conducted a series of in vitro studies to elucidate the mechanism of Ras 
regulation by monoubiquitination. These studies required fully ubiquitinated protein that 
was exclusively modified at Lys147 and in quantities sufficient for detailed biochemical 
and biophysical analysis. Recent investigations of monoubiquitinated substrates and 
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ubiquitinating enzymes employed multiple methods of direct chemical ligation to 
generate the protein–Ubiquitin linkage (109, 110, 174-177). In our approach, we replaced 
the native Ubiquitin linkage with a disulfide bond between a substituted cysteine at 
position 147 of Ras (RasK147C) and a cysteine at the carboxyl–terminus (c–terminus) of 
Ubiquitin (UbiquitinG76C). A surface accessible cysteine (Cys118) in Ras was replaced 
with serine to avoid unwanted modification (RasC118S, hereafter “Ras”). We previously 
showed that the C118S mutation did not alter Ras structure or biochemical properties 
(178). The chemical ligation method does not require complicated intermediate chemical 
or enzymatic steps but instead provides a simple, specific approach to ubiquitination. The 
disulfide ligation strategy, using a more complicated cysteamine intermediate, was 
validated in previous studies of Proliferating Cell Nuclear Antigen (PCNA), where it was 
shown that chemically and enzymatically monoubiquitinated PCNA exhibit identical 
catalytic properties (109). As seen in Figure 2.1a, we drove Ubiquitin modification of 
Ras at position 147 to completion by the addition of a ten–fold excess of UbiquitinG76C at 
pH 8.0.  We conducted our experiments using H–Ras (1–166), for which the biochemical 
and structural (NMR and X–Ray) properties are best established, but corroborated the 
results using K–Ras (1–166) as indicated. All three mammalian isoforms H–, K–, and N–
Ras show similar biochemical properties in the absence of the hypervariable c–terminus 
(128, 179). Furthermore, we used immunoprecipitation assays to show that, in the 
absence of c–terminal modification, monoubiquitination still leads to an increase in the 
GTP–bound population of H–Ras or K–Ras in HEK293T cells (Figure 2.2). 
 Downstream effectors of Ras, like Raf, have a Ubiquitin–like fold (180). Thus, 
we considered whether Ubiquitin could bind to Ras in the manner of an effector. To this 
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end, we used NMR in the presence of free unlabeled Ubiquitin to determine whether 
Ubiquitin altered spectral features associated with Ras backbone amides. A 1H–15N 2D 
HSQC overlay of 15N–enriched H–RasK147C in the absence and presence of Ubiquitin is 
shown in Figure 2.1b. The assignments for H–Ras (1–166) were previously determined 
(181) and we verified the shifted backbone amide resonances of H–RasK147C using 3D 
HNCACB data (Figure 2.3). Comparison of the position and intensity of the backbone 
amide resonances indicates that Ras is not altered by the presence of free Ubiquitin. In 
support of these observations, as shown in Figure 2.4a–b, we found that the intrinsic rate 
of GDP dissociation and GTP hydrolysis were unaffected by the presence of Ubiquitin.   
Furthermore, the presence of Ubiquitin dimers in solutions also had no effect on 
measuring thermal stability, intrinsic GDP dissociation, or GTP hydrolysis, as shown in 
Figure 2.4d-f.  These results indicated that Ras did not specifically interact with 
Ubiquitin. Therefore, for subsequent analyses, we did not separate monoubiquitinated 
Ras (mUbRas) from free Ubiquitin. 
Monoubiquitinated Ras Retains Intrinsic GTPase Activity 
Previous computational studies predicted that the stability of a ubiquitinated 
substrate depends on the site of ubiquitination and type of Ubiquitin–Ubiquitin linkage 
(104). To determine if monoubiquitination alters Ras, we compared the thermal stability 
of unmodified Ras and mUbRas. To this end, we employed the Quantitative Cysteine 
Reactivity (fQCR) assay (182), which uses a cysteine reactive dye to measure rates of 
protein unfolding as a function of temperature. Because Ubiquitin does not have any 
native cysteines, it is invisible by this method. As shown in Figure 2.4c, we found that 
monoubiquitination decreases the thermal stability of Ras by 3.5 degrees (43.1± 0.2 oC, 
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39.2 ± 0.3 oC, and 39.6 ± 0.2 oC for Ras, RasK147A, and mUbRas, respectively), a change 
that is not likely to have a substantial effect on this otherwise highly stable protein in 
vivo. These data suggest that, despite the size of Ubiquitin, monoubiquitination at 
position 147 does not lead to thermal destabilization of Ras. 
While monoubiquitination of Ras does not substantially affect thermal stability, it 
could alter intrinsic activity. For example, it is possible that ubiquitination impairs 
guanine nucleotide binding, similar to mutations at the adjacent residue, Ala146 (183, 
184). To measure rates of nucleotide dissociation, we equilibrated Ras and mUbRas with 
the fluorescent analog N–methylanthraniloyl (MANT)–GDP and measured fluorescence 
over time in the presence of excess unlabeled GDP. We observed a slight increase (2–3 
fold) in the intrinsic rate of nucleotide dissociation for RasK147C as compared to native 
Ras, while the rate for mUbRas was unaltered (Figure 2.4a). This result suggests that 
ubiquitination of Ras does not have the same impact on nucleotide binding as a point 
mutation at the same residue.  
We next sought to establish whether monoubiquitination alters the intrinsic rate of 
GTP hydrolysis. To this end we measured single turnover GTP hydrolysis using Flippi, a 
fluorescent sensor that detects free phosphate (185). As shown in Figure 2.4b, neither 
mutation of Lys147 nor monoubiquitination of Ras affected the intrinsic rate of GTP 
hydrolysis (calculated as 0.012 ± 0.002 min–1 for all variants). Taken together, these 
results indicate that monoubiquitination does not alter the activity of Ras, and that 
another mechanism must account for the accumulation of mUbRas in the GTP–bound 
state in vivo. 
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Figure 2.1.  Monoubiquitination of Ras. (a) Reaction of UbiquitinG76C with Ras or a 
RasK147C mutant, under non–reducing conditions. The product of the reaction contains 
mUbRas, Ras, Ubiquitin–Ubiquitin dimer (Ub–Ub), and free Ubiquitin (Ub). (b) HSQC 
spectra of 15N–RasK147C bound to Mg–GDP in the absence (black) and presence (red) of 
ten–fold excess free Ubiquitin.  
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Figure 2.2.  Raf-RBD Pull-Down from HEK293T Cells Indicates that Ubiquitination 
Increases the Fraction of GTP-Bound Ras.  Either (a) K-Ras or (b) H-Ras Flag-His-
RasWT or Caax-mutated-Ras mutants were co-expressed with HA-Ubiquitin in HEK293T 
cells. Ras proteins were either immunoprecipitated with an anti-Flag antibody or GST-
Raf-RBD.  Each precipitate was then dissolved in 8 M urea and further purified on a Co2+ 
affinity column to eliminate antibody and GST-Raf-RBD contamination.  Western blots 
with anti-Flag and anti-HA antibodies revealed the relative fraction of total Ras and 
mUbRas.   
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Figure 2.3.  NMR Comparison of Ras and RasK147C.  (a) HSQC overlay of 15N-Ras 
bound to Mg-GDP (black) and 15N-RasC118SK147C bound to Mg-GDP (red).  Assigned 
residues that shift are labeled.  (b) Ribbon representation of the structure of Ras-GDP 
(1CRR) showing assigned residues that shift for the K147C mutation in red. 
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Figure 2.4.   Monoubiquitinated Ras Retains Intrinsic Stability and Activity. (a) Intrinsic 
nucleotide dissociation rates for Ras, RasK147C, and mUbRas loaded with MANT–GDP. 
Dissociation was monitored following the addition of unlabeled GDP by the decrease in 
fluorescence emission over time. Data were fit to an exponential dissociation curve, and 
the results are the mean ± s.d. (n=4). (b) Intrinsic single–turnover GTP hydrolysis for 
Ras, RasK147C, and mUbRas. Hydrolysis was initiated by the addition of Mg2+ and 
monitored by the change in fluorescence of Flippi when bound to free phosphate. Data 
were converted to a phosphate concentration using a standard curve. The concentration of 
phosphate equal to 100% GTP hydrolyzed was determined in the presence of GAP. 
Results are the mean ± s.d. (n=6). (c) Thermal stability of Ras, RasK147A, and mUbRas 
measured by ABD–F incorporation as a function of temperature. The data were 
normalized using the maximum fluorescence intensity. Results are the mean ± s.d. (n=4).  
(d) Intrinsic nucleotide dissociation rates for Ras loaded with MANT-GDP in the absence 
and presence of Ub-Ub measured as described in (a). (e) Intrinsic single-turnover GTP 
hydrolysis for Ras in the absence and presence of Ub-Ub measured as described in (b). 
(f) Thermal stability of Ras and Ubiquitin dimer (Ub-Ub) alone measured as described in 
(c).  Rather than normalizing the fluorescent output, the raw fluorescent signal is shown.  
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Chemical Ubiquitination Mimics Native Ubiquitination 
 We found that monoubiquitination does not alter the intrinsic biochemical activity 
of Ras, even though mUbRas accumulates in the GTP–bound state in vivo. Previous 
studies have shown that chemically ubiquitinated PCNA functions similarly to the 
enzymatically ubiquitinated protein (109). To further establish that chemical 
ubiquitination of Ras is a good mimic of native ubiquitination, we built computational 
models of Ubiquitin ligated to Ras. To create the model, we used a recently developed 
module of the Rosetta protein modeling software suite (186, 187) that samples the 
conformational space available to ligated proteins. We modified Rosetta to consider 
disulfide and native isopeptide ubiquitination linkages and generated model structures of 
mUbRas using both linkages. We generated these models without the use of 
experimentally–derived constraints.  
Shown in Figure 2.5a-b are the ten lowest scoring structures of each type of 
linkage, sorted by Rosetta total score from populations of approximately 2000 models. 
Comparison of these models indicates that the two systems behave similarly; Ubiquitin 
samples a wide range of conformations when ligated to Ras and all Ubiquitin positions 
are allowed at low energy scores (Figure 2.5c-d). This modeling result suggests that 
chemical ubiquitination is a good surrogate for native ubiquitination of Ras. The data also 
suggest that Ubiquitin does not bind with high affinity to any single site on Ras, which is 
consistent with our findings by NMR that Ubiquitin does not specifically interact with 
Ras when the two proteins are free in solution.  
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Monoubiquitination Affects the Switch Regions of Ras 
Results obtained from computational modeling suggest that there is no single 
preferred interaction between Ubiquitin and Ras. To test this prediction experimentally, 
we used NMR to examine spectral differences between Ubiquitin and Ras upon 
monoubiquitination. First, we 15N–enriched UbiquitinG76C and examined the 1H–15N 2D 
HSQC spectrum of Ubiquitin when ligated to RasK147C. By this method we observed 
partial to complete resonance broadening of eleven backbone amides, but no substantial 
chemical shifts within Ubiquitin (Figure 2.6a). By mapping these spectral changes onto 
the structure of Ubiquitin in Figure 2.6b, it is evident that one face of Ubiquitin is  
primarily altered upon ligation with Ras. A possible explanation for the inability to detect 
a subset of Ubiquitin amide resonances is that Ras ligation restricts conformational 
sampling, leading to exchange broadening. 
We next reversed our labeling scheme and 15N–enriched Ras prior to ligation with 
Ubiquitin and collected a 1H–15N 2D HSQC spectrum (Figure 2.7a). Eighty–four of the 
137 detectable backbone amide resonances dispersed across mUbRas exhibited multiple 
populations rather than a single, Lorentzian shaped peak (Figure 2.7b-c). The multiple 
populations indicate that Ubiquitin adopts more than one position relative to Ras on a 
timescale detectable by NMR. We also observed a substantial number of residues that 
broadened and, in some cases, could no longer be detected in mUbRas (Figure 2.7a). The 
broadened peaks primarily localize to the switch regions (Figure 2.7d). In the NMR 
spectra of Ras–GTP, backbone amides associated with residues in Switch I and Switch II 
are not detectable because they are in intermediate exchange on the NMR timescale 
(188).   
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Figure 2.5.  Rosetta Model of Native and Chemical Ubiquitination of Ras. (a) The ten 
lowest scoring Rosetta models of the native linkage of Ras monoubiquitination at 
position 147 lacking constraints to bias the model. Ras (5P21) is shown in grey with 
switch regions (SWI and SWII) highlighted in black. Ubiquitin (1UBQ) conformers 
shown in colors. Inset: native linkage between Ras Lys147 and Ubiquitin G76. (b) The 
ten lowest scoring Rosetta models of the chemical linkage of Ras monoubiquitination at 
position 147 lacking any constraints to bias the model. Ras and Ubiquitin colored as in 
panel (a). Inset: chemical linkage between Ras K147C and Ubiquitin G76C.  (c) The 
distribution of Ubiquitin orientations relative to Ras plotted against Rosetta energy scores 
for the native linkage. The Y axis shows the dihedral angle, in degrees, of the torsional 
angle between the center of mass of Ubiquitin, the linking Ras residue (147), the center 
of mass of Ras and an arbitrary Ras reference atom.  (d) The distribution of Ubiquitin 
orientations relative to Ras plotted against Rosetta energy scores for the chemical 
linkage. Axes are the same as described in panel (c).  
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Figure 2.6.  Surfaces of Ubiquitin Affected by Monoubiquitination. (a) HSQC spectra of 
15N–UbiquitinG76C free (black) or ligated to RasK147C (blue). Residues that broaden are 
labeled based on previous assignments (189). (b) Space filling model of the structure of 
Ubiquitin (1UBQ) with residues that show decreased intensity when ligated to Ras (blue). 
Residues with no information are colored black.  
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Figure 2.7.  Surfaces of Ras Affected by Monoubiquitination. (a) HSQC spectra of 15N–
RasK147C bound to Mg–GDP alone (black) and when monoubiquitinated (green). Inset 
(Top): enhancement of one expanded region showing residues that broaden and 
disappear. Inset (Bottom Left): SDS–PAGE gel showing integrity of mUbRas sample 
after HSQC analysis. Inset (Bottom Right): close up of Arg135, which exhibits multiple 
populations. (b)  Expansion of a region within the HSQC spectrum (panel a) highlighting 
the multiple populations of residues in the mUbRas spectrum (green).  Assignments for 
RasK147C are shown in black.  (c) Mapping of Ras backbone amides that exhibit multiple 
populations upon monoubiquitination onto the structure of Ras (5P21) in purple.  GDP is 
shown as a stick and magnesium as a sphere.  Residues with no information in the HSQC 
spectrum are colored black.  (d) Mapping of Ras backbone amides that disappear upon 
monoubiquitination onto the structure of Ras. Darker green indicates more appreciable 
broadening (primarily in the SW I and SW II). Residues with no information are colored 
black. 
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The observed broadening in the GDP–bound state of mUbRas suggests a change 
in backbone dynamics, possibly due to conformational exchange or dynamic sampling of 
the switch regions.  This hypothesis is supported by the observation that when an HSQC 
of mUbRas is collected on a 500 MHz spectrometer, some of the broadened residues in 
the switch regions and p-loop become visible, as seen in Figure 2.8.  This suggests that 
the switch regions are beginning to shift from intermediate exchange back to fast 
exchange on the NMR timescale.  Since Ras regulators and effectors interact through the 
switch regions, monoubiquitination could alter the population of active Ras by changing 
how mUbRas interacts with regulators.  
Monoubiquitination of Ras Inhibits GAP–Mediated Hydrolysis 
In cells, the nucleotide–bound state of Ras is regulated both by GEFs, which 
increase the rate of GDP dissociation, and GAPs, which enhance the rate of GTP 
hydrolysis. Our NMR data suggest that monoubiquitination affects the switch regions of 
Ras, which in turn could alter interactions with GEFs and GAPs. Thus the increased 
GTP–bound population of mUbRas in vivo could be caused by either an increased 
sensitivity to GEFs or decreased sensitivity to GAPs. 
We first determined if the rate of GEF–mediated GDP dissociation is altered 
when Ras is monoubiquitinated. For these experiments, we equilibrated RasK147C, 
mUbRas, and Ras with MANT–GDP and measured the rate of GDP dissociation in the 
presence of a catalytic fragment from the Ras GEF, Sos (Soscat) (190). While the rate of 
GEF–mediated GDP dissociation was faster for RasK147C than Ras, the percent increase 
compared to the intrinsic rate of dissociation was the same, indicating that mutation at 
position 147 does not change the overall sensitivity of Ras to GEF–mediated regulation. 
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However, we observed a decrease in the rate of GEF–mediated nucleotide dissociation 
for mUbRas compared to unmodified Ras (Figure 2.9a).  
We next considered the effect of Ras monoubiquitination on GAP–mediated 
hydrolysis. To this end we compared the rate of GTP hydrolysis for Ras and mUbRas in 
the presence of the catalytic domains of two GAPs, NF1 (NF1333) and p120GAP (GAP–
334)(138, 191). At a GAP–to–Ras ratio of 1:500, we observed an order of magnitude 
increase in the rate of GTP hydrolysis for unmodified Ras relative to the intrinsic rate of 
GTP hydrolysis. No increase in the rate of GTP hydrolysis was observed for mUbRas in 
the presence of the same GAP–to–Ras ratio (Figure 2.9b). Therefore, mUbRas is 
insensitive to GAP–mediated regulation, similar to an oncogenic RasG12V mutation (172). 
We obtained similar results using K–Ras (Figure 2.10), indicating that the effects of 
monoubiquitination on Ras are not isoform–specific when the proteins are modified at the 
same lysine. 
To validate the use of an in vitro system to dissect the mechanism of Ras 
regulation, we measured the sensitivity of mUbRas to GAP–mediated hydrolysis in a 
cellular reconstitution system. We immunoprecipitated Ras from HEK293T cells and 
compared the sensitivity of the monoubiquitinated and unmodified fractions of Ras to 
regulation by GAP. As seen in Figure 2.9c, monoubiquitinated K–Ras is less sensitive 
than the unmodified protein to GAP–mediated GTP hydrolysis. These data support our in 
vitro findings that monoubiquitination increases the population of active, GTP–bound 
Ras through a defect in sensitivity to GAP–mediated regulation. 
To determine if the reduced response to regulators is due to a change in binding 
affinity for mUbRas, we first measured the extent to which monoubiquitination disrupts 
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the interaction between Ras and Soscat (Figure 2.9d). Results from these analyses 
indicated that the binding affinity between mUbRas and Soscat is 8.3 ± 0.9 μM, which is 
half the observed binding affinity between Ras and Soscat (4.2 ± 0.4 μM), consistent with 
the small reduction in the rate of GDP dissociation observed. However, a decrease in the 
rate of GDP dissociation would favor the GDP–bound state of Ras. Thus, the minor 
differences in GEF binding do not account for the accumulation of Ras–GTP in vivo.  
To determine whether ubiquitination also leads to a reduction in GAP binding 
affinity, we compared the ability of Ras and mUbRas to bind to NF1333 in the presence of 
AlF4–. As seen in Figure 2.9e, in the presence of AlF4– almost 100% of NF1333 bound to 
Ras, which was present in slight excess. In contrast, about 50% of the NF1333 bound to 
mUbRas under the same conditions (Figure 2.9f), which suggests that the binding 
affinity between GAP and mUbRas is reduced relative to unmodified Ras.  
While monoubiquitination affects both GEF– and GAP–mediated activity, the 
GAP defect has a greater influence on the enzyme kinetics and as such is predicted to 
have a dominant effect on the contribution to GTP–bound Ras.  We created a kinetic 
model that measured the effects of GEF and GAP activity on the observed population of 
activated Ras.  These data show that at the difference in GEF and GAP activity measured 
experimentally, the amount of GTP-bound Ras will increase relative to unmodified Ras 
(Figure 2.11). Taken together, our data reveal a substantial reduction in GAP activity as 
a consequence of Ras monoubiquitination, which accounts for the accumulation of 
activated Ras in vivo.    
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Figure 2.8.  Increased Detection of mUbRas Backbone Amides at 500 MHz.  (a) HSQC 
spectra of 15N–RasK147C bound to Mg–GDP when monoubiquitinated (black).  (b) 
Mapping of Ras backbone amides that disappear upon monoubiquitination onto the 
structure of Ras. Darker green indicates more appreciable broadening (primarily in the 
SW I and SW II). Residues with no information are colored black.  Residues in purple 
represent peaks where broadening is reduced and amide resonances can again be detected 
at 500 MHz. 
 
 
      
 
Figure 2.9.  Monoubiquitination Decreases the Sensitivity of Ras to Downregulation by GAPs. (a) Nucleotide dissociation 
reaction for Ras, RasK147C, and mUbRas loaded with MANT–GDP in the presence of a 1:1 molar ratio of Ras to Soscat. Data 
were fit to an exponential dissociation curve, and the results are the mean ± s.d. (n=4). (b) Single–turnover GTP hydrolysis for 
Ras, RasK147C, mUbRas, and RasG12V in the presence of NF1333 or GAP–334 at a molar ratio of 1:500 GAP:Ras. Results are the 
mean ± s.d. (n=6). (c) Immunoblotting of GTP-bound Ras and GTP-bound mUbRas in cell extract in the presence of 
increasing concentrations of RasGAP.  Anti–Flag and anti–HA antibodies reveal the relative fraction of total Ras and mUbRas, 
respectively. (d) Titration of Ras with Soscat. Experiments were performed as described panel a, except the concentration of 
Soscat was varied while Ras was held constant at 0.2 μM. Data plotted as a function of the Soscat concentration. Results are the 
mean ± s.d. (n=3). (e) Gel filtration of Ras and NF1333 in the absence (dotted line) and presence (solid line) of AlF4–. (f) Gel 
filtration of mUbRas and NF1333 in the absence (dotted line) and presence (solid line) of AlF4–.  
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Figure 2.10.  GAP-Mediated Hydrolysis of Monoubiquitinated K-Ras.  Intrinsic and 
GAP-mediated single-turnover GTP hydrolysis of Ras in the absence and presence of 
GAP-334 (intrinsic, 1:500 GAP:Ras, and 1:200 GAP:Ras).   Rates of GTP hydrolysis 
were measured for K-Ras, K-Ras with free Ubiquitin (K-Ras+Ub), and 
monoubiquitinated K-Ras (mUbK-Ras).  Data were fit to a single exponential association 
curve with the maximum determined by the highest phosphate concentration reached in 
the presence of the GAP.  Results are the mean ± s.d. (n=6). 
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Figure 2.11.  Kinetic Modeling of Changes in Ras Activity Due to Monoubiquitination.  
(a) Ras transitions through four states: GDP or GTP-loaded, unmodified, and 
monoubiquitinated.  Each transition is determined via enzyme kinetics involving a GEF, 
GAP, E3 ligase (E3) and deubiquitinating enzyme (DUB).  Two additional parameters, α 
and β, account for the relative effects of monoubiquitination on GAP and GEF activity, 
respectively.  (b) The effects of monoubiquitination on the total amount of GTP-bound 
Ras.  A scatterplot of resulting simulations is shown using 6562 log-uniform sampled 
parameter values varying the catalytic rate (vmax) and Michaelis Constant (Km) of the 
deubiquitinating enzyme over four orders of magnitude.  The fraction of GTP-loaded Ras 
is plotted as a function of the fraction of mUbRas.  The red line represents a linear 
(additive) effect in which each modified Ras contributes additively to the total amount of 
GTP-loaded Ras.  For small amounts of ubiquitination (Fraction mUb < 0.01, shaded 
area), data points lie above the red line indicating that mUbRas contributes cooperatively 
to the steady state levels of total GTP-bound Ras.  (c)  Modeled effects of mUbRas on 
GEF and GAP activity.  The fraction GTP-loaded is plotted against different values of α.  
Six values of β (legend) are also considered.  For each case, the amount of activated Ras 
increases (white area) with increasing relative disruption of GAP activity.  The star 
indicates the differences in GEF and GAP activity measured experimentally.   
58 
 
Modifying Ras with PDZ2 Impairs GAP–Mediated Hydrolysis  
 Our computational and NMR data suggest that Ubiquitin does not form a specific, 
high–affinity interaction with Ras. If this observation is correct, then modification of Ras 
with any protein similar to Ubiquitin should also impair GAP–mediated hydrolysis. As a 
test of this model, we chemically ligated Ras to PDZ2 (RasPDZ2), a 9 kDa protein with a 
Ubiquitin–like fold but no obvious sequence similarity to Ubiquitin (192).  We replaced 
the unstructured c-terminal extension of PDZ2, defined as the region after the folded 
domain ends in the crystal structure, with that of Ubiquitin (PDZ2UL). Therefore, all 
differences between PDZ2UL and Ubiquitin are contained in the folded regions of the two 
proteins. 
 Modeling of PDZUL on Ras shows that PDZ adopts a similar spread of possible 
conformations as Ubiquitin (Figure 2.12a-b), suggesting that it could have an impact on 
Ras activity that is comparable to that of Ubiquitin ligation. As seen in Figure 2.12c, 
mUbRas and RasPDZ2UL have identical melting temperatures, indicating that neither 
ubiquitination nor PDZ2UL ligation substantially alters the thermal stability of Ras. 
Similar to ubiquitination, PDZ2UL ligation does not alter intrinsic Ras nucleotide 
dissociation rates, and GEF–mediated dissociation is reduced to the same extent as for 
mUbRas (Figure 2.12d). Finally, RasPDZ2UL retains intrinsic GTP hydrolysis activity, 
but is insensitive to GAP–mediated GTP hydrolysis (Figure 2.12e). These data indicate 
that non–specific interactions between Ras and Ubiquitin are responsible for the 
insensitivity of mUbRas to GAPs. 
 In the studies described in the previous paragraph, we replaced the c-terminus of 
PDZ with the c-terminus of Ubiquitin.  This was done so that the differences between the 
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two proteins would be isolated to the structured region and not due to differences in the 
conformational motility of the PDZ domain compared to Ubiquitin.  Preliminary Rosetta 
models of Ras modified with PDZ with the native c-terminus (RasPDZ) suggest that the 
shorter and stiffer c-terminal region of the PDZ leads to changes in proximity of Ras and 
its modifier.  As seen in Figure 2.13a, the PDZ domain does not appear to make contact 
with as much of the surface of Ras as Ubiquitin or PDZUL.  If access to the switch regions 
is important for the mechanism by which ubiquitination regulates Ras, then modification 
with PDZ should not alter regulator-mediated activity to the same extent as modification 
with PDZUL.  As seen in Figure 2.13b, mUbRas and RasPDZ2 have identical melting 
temperatures, indicating PDZ2 ligation does not substantially alter the thermal stability of 
Ras.  Consistent with ubiquitination, PDZ2 ligation to Ras also does not alter intrinsic 
nucleotide dissociation or hydrolysis (Figure 2.13c-d).  However, RasPDZ2 was more 
responsive to Soscat and GAP-334 than mUbRas.  As seen in Figure 2.13c, RasPDZ2 
shows a six-fold increase in the rate of GDP-dissociation in the presence of Soscat, in 
comparison to the three-fold increase observed for mUbRas. However, RasPDZ2 is still 
less responsive to Soscat than unmodified Ras, which exhibits a fourteen-fold increase in 
dissociation under the same conditions.  Additionally, while RasPDZ2 retains GAP 
sensitivity, it is almost ten-fold less responsive than unmodified Ras to GAP-334 
mediated GTP hydrolysis (Figure 2.13d).  Thus, these results indicate that RasPDZ2, 
while not identical to mUbRas, is less sensitive than Ras to GEF- and GAP-mediated 
regulation. 
 The difference between the response of mUbRas and RasPDZ2 to GAPs was 
likely due to the observed differences in length and flexibility of the c-termini of 
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Ubiquitin and PDZ2.  Therefore, we wanted to verify that the differences between the 
enzymatic and chemical ubiquitination linkers (seven bonds and five bonds, respectively) 
were not large enough to alter GAP-responsiveness.  We placed an additional cysteine at 
the c-terminus of Ubiquitin (UbC77) thereby creating a linker slightly longer than the 
native linker.  We measured the rate of GAP-mediated GTP hydrolysis and observed that 
the response of Ras ligated to Ub77C is identical to Ras ligated to UbG76C (Figure 2.13d).  
These results indicate that variations in the linker length on this scale (1-2 bonds) do not 
influence the sensitivity of mUbRas to GAP downregulation.   
 Therefore, chemical ubiquitination is a good surrogate for enzymatic 
ubiquitination.  Our data indicate that ubiquitination activates Ras by impairing GAP-
mediated hydrolysis.  Essential to this mechanism of activation is the ability of Ubiquitin 
to have access to a particular surface of Ras.  The interactions between Ras and Ubiquitin 
are non-specific, but lead to a reduction in catalytic efficiency of Ras GAPs.   
The Effect of Ubiquitination is Site–Specific 
Finally, while the GAP insensitivity of modified Ras is not specific to Ubiquitin, 
it could be specific to modification at position 147. To address this possibility, we chose 
two other lysines on Ras that were not identified as sites of monoubiquitination in the 
mass spectrometry screen of monoubiquitinated K–Ras(153). We chose position 88 
because it is near the switch regions of Ras, similar to position 147, and could have a 
similar effect as monoubiquitination at position 147. We chose position 101 because the 
side chain is oriented toward the opposite face of Ras and would likely be less disruptive 
to the Ras active site and switch regions if monoubiquitinated (Figure 2.14a).  
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Figure 2.12.  Modification of Ras with PDZ2UL Resembles Modification with Ubiquitin. 
(a) Rosetta model of Ras (5P21) in grey modified at position 147 with Ubiquitin (1UBQ) 
in green and PDZUL (3LNX) in purple. (b) The distribution of PDZUL orientations relative 
to Ras plotted against Rosetta energy scores for the chemical linkage. This plot follows 
the scheme of Figure 3B. (c) Thermal stability of Ras and RasPDZ2 with the Ubiquitin 
linker (RasPDZ2UL) measured by ABD–F incorporation as a function of temperature. 
Results are the mean ± s.d. (n=4). (d) Nucleotide dissociation reaction for RasPDZ2UL 
and mUbRas loaded with MANT–GDP in the absence and presence of a 1:1 molar ratio 
of Ras to Soscat. Results are the mean ± s.d. (n=4). (e) Single–turnover GTP hydrolysis 
for Ras, RasPDZ2UL, and mUbRas in the presence of GAP–334 at a molar ratio of 1:500 
and 1:200 GAP:Ras. Results are the mean ± s.d. (n=6).   
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Figure 2.13.  Modification of Ras with PDZ is Distinct from Modification with 
Ubiquitin.  (a) The ten lowest scoring Rosetta models of the native linkage of Ras 
monoubiquitination at position 147 lacking constraints to bias the model. Ras (5P21) is 
shown in grey with switch regions (SWI and SWII) highlighted in black. PDZ2 (3LNX) 
conformers shown in colors.  (b) Thermal stability of mUbRas and RasPDZ2 measured 
by ABD–F incorporation as a function of temperature. Results are the mean ± s.d. (n=4).  
(c) Nucleotide dissociation reaction for Ras, RasPDZ2 and mUbRas loaded with MANT–
GDP in the absence and presence of a 1:1 molar ratio of Ras to Soscat. Results are the 
mean ± s.d. (n=4).  (d) Single–turnover GTP hydrolysis for Ras, RasPDZ2, mUbRas, and 
mUbRas modified with UbiquitinC77 (mUb77Ras) in the presence of GAP–334 at a molar 
ratio of 1:500 and 1:200 GAP:Ras. Results are the mean ± s.d. (n=6).  
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Figure 2.14.  The Impaired GAP–Sensitivity of mUbRas is Site–Specific. (a) Ribbon 
diagram of Ras–GDP (1CRR) with the switch regions highlighted in black and the side 
chains of Lys147, Lys88, and Lys101 represented as spheres in green, fuchsia, and blue, 
respectively. (b) Single–turnover GTP hydrolysis for Ras mutated and ubiquitinated at 
position 147, 88, or 101 in the absence and presence of GAP–334 at a molar ratio of 
1:200 GAP:Ras. Results are the mean ± s.d. (n=4).  
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Figure 2.15.  Monoubiquitination Does not Sterically Occlude GAP Binding to Ras. 
The five lowest energy models from the chemical ubiquitination Rosetta model of 
mUbRas in the presence of GAP-334 (1WQ1).  Ras is represented as grey spheres and 
GAP-334 in salmon. Ubiquitin (1UBQ) conformers are shown in green, cyan, fuchsia, 
pink, and yellow. (a) Monoubiquitination at position 147. (b) Monoubiquitination at 
position 88. (c) Monoubiquitination at position 101.   
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Using Rosetta models, we found that monoubiquitination of Ras at position 88 or 
101 does not cause steric clashes with GAP–334, similar to monoubiquitination at 
position 147 (Figure 2.15). To determine whether monoubiquitination at position 88 or 
101 could affect GAP–mediated regulation, we mutated each of these residues to 
cysteine, modified them with UbiquitinG76C, and measured the effect of Ubiquitination on 
intrinsic and GAP–mediated GTP hydrolysis. As seen in Figure 2.14b, only 
monoubiquitination at position 147 impairs GAP–mediated hydrolysis, indicating that the 
outcome of monoubiquitination is site–specific. 
In summary, we used a combination of biochemical, structural, and computational 
approaches to uncover the mechanism of Ras regulation by monoubiquitination. Our data 
indicate that ubiquitination activates Ras by impairing the catalytic efficiency of Ras 
GAPs. Furthermore, the most commonly ubiquitinated position in vivo, position 147, is 
the only lysine tested that impairs GAP–mediated hydrolysis. More broadly, our findings 
reveal how monoubiquitination promotes sustained signaling and cell transformation. 
 
Discussion 
It was established recently that monoubiquitination increases the proportion of 
Ras that is in the activated (GTP–bound) state, that monoubiquitination enhances 
association with the downstream effectors Raf and PI3–Kinase, and that mutation of the 
primary site of monoubiquitination impairs oncogenic Ras–mediated tumorigenesis. Here 
we show that monoubiquitination decreases the sensitivity of Ras to GAP–mediated 
hydrolysis. A major advance was our ability to easily generate mUbRas, modified at a 
single site, in a form suitable for detailed biophysical studies.  This chemical ligation 
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strategy will likely be useful for the study of other monoubiquitinated proteins. 
Surprisingly, monoubiquitination did not alter the intrinsic activity of Ras, despite the 
size of the modification. Our modeling and NMR analyses indicated that Ubiquitin 
dynamically samples a broad surface area of Ras that alters switch region dynamics. 
These results led us to examine the effect of monoubiquitination on the interaction of Ras 
with its cognate GEF and GAPs, which also target the switch domains. The analysis 
revealed that monoubiquitination abrogates GAP–mediated GTP hydrolysis. All other 
activities, including the ability to bind regulators, were largely preserved and our kinetic 
modeling suggests that the GAP defect will dominate. Furthermore, this outcome was 
specific to monoubiquitination at position 147. Thus our work establishes an entirely new 
mode of Ras activation in which signaling is sustained even in the absence of hormone 
stimulus or oncogene mutation. 
It will be interesting to determine how monoubiquitination affects other signaling 
proteins including other Ras–family GTPases. Known targets of monoubiquitination 
include K–Ras (153), H–Ras, and N–Ras (173). Monoubiquitination disrupts interactions 
of Rap2A with effector proteins and inhibits the ability of Rap2A to promote dendrite 
development (155). Monoubiquitination has also been observed in Rac1, although the 
biological consequence of this modification is not yet known (86, 157). Our chemical 
ligation strategy and multi–dimensional approach will be useful for the study of these 
targets, particularly in cases where the relevant ubiquitin ligase has not been identified. 
Another question concerns the role of the preferred site of monoubiquitination, 
Lys147 (153). Whereas ubiquitination of this site has severe consequences for GAP 
function, targeted ubiquitination of two other candidate sites left GAP–mediated 
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hydrolysis unperturbed. Lys147 is part of the SAX motif, and a lysine at the third 
position in this motif is conserved in Ras proteins across species, as well as in other Ras–
family GTPases including RhoA, RhoB, RhoC, Rap, Ral, Rab, Rheb and Ran (120). It 
has been shown previously that mutation of the highly conserved adjoining residue, 
Ala146, leads to enhanced GDP exchange, GTP loading and cellular transformation (183, 
184, 193). In contrast, we have shown that a mutation of the ubiquitination site itself, Lys 
147, has little effect on nucleotide binding or regulator–mediated activity. We speculate 
that the lysine has been conserved to allow regulation through monoubiquitination. It will 
be interesting to determine whether other members of the Ras subfamily are also 
ubiquitinated at this position and whether ubiquitination in such cases leads to sustained 
activation.  
We have demonstrated that monoubiquitination of Ras impedes the function of 
GTPase activating proteins. Key to our analysis was the ability to generate 
monoubiquitinated protein, modified at a single residue, suitable for biophysical analysis. 
Through multi–disciplinary computational, structural and biochemical approaches we 
identified a novel mechanism of Ras activation, one that is independent of any oncogenic 
mutation or a sustained receptor stimulus. Given the established importance of Ras in the 
control of cell growth and differentiation, our findings may reveal opportunities for new 
pharmaceuticals that target the ubiquitination machinery. 
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Methods 
Protein Purification  
The Ras domains (1–166) of H–Ras and K–Ras were expressed in the pQlinkH 
vector (Addgene) with a histidine purification tag in Escherichia coli BL21 (DE3) RIPL 
cells (Stratagene: La Jolla, CA). Proteins were purified following standard Qiagen nickel 
affinity purification procedures. The His tag was cleaved overnight with Tobacco Etch 
Virus. Ras proteins were further purified by removal of uncleaved protein using Ni–NTA 
agarose beads (Qiagen). The final product was judged > 95% pure by SDS–PAGE. 
Proteins were stored in 20 mM HEPES, pH 8.0, 50 mM NaCl, 500 μM TCEP, 50 μM 
GDP and 5 mM MgCl2. 
Soscat (John Kuriyan; University of California, Berkeley) was purified as 
previously described(190). The catalytic domains of p120GAP (GAP–334) (138) and 
NF1 (NF1333)(191), were expressed in pQlinkH and purified as described for Ras. 
Purified proteins were stored in 20 mM HEPES, pH 8.0, 50 mM NaCl and 500 μM 
TCEP. Full length UbiquitinG76C and hPTPe–PDZ2 ULG97C (c–terminal residues KGQSPC 
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replaced with the Ubiquitin residues VLRLRGC)(192) were expressed in the pQlinkH 
vector system and purified as described for Ras. Proteins were stored in 20 mM HEPES, 
pH 8.0, 50 mM NaCl and 500 μM TCEP.  
Ligation of UbiquitinG76C and PDZ2 ULG97C to RasK147C 
The chemical ligation strategy used to link Ras to UbiquitinG76C or PDZ2ULG97C 
was adapted from Merkley et al.(174). Briefly, a ten–fold excess of UbiquitinG76C or 
PDZ2 ULG97C was added to RasK147C and dialyzed into 20 mM Tris, pH 8.0, 50 mM NaCl, 
5 mM MgCl2, and 50 μM GDP at 4 oC overnight. The amount of disulfide complex 
formation was determined by non–reducing SDS–PAGE and considered complete by the 
absence of modified Ras.  
Thermal Stability of Ras 
The fast quantitative cysteine reactivity (fQCR) method(182) was employed to 
measure changes in Ras thermal stability. Briefly, 2 μM Ras was incubated with 1 mM 4-
fluoro-7-aminosulfonylbenzofurazan (ABD–F, Anaspec) at pH 7.0 in the presence of 20 
μM GDP and 2 mM MgCl2 at the desired temperature for five minutes. Fluorescent 
intensity was measured on a PHERAstar plate reader (BMG Labtech). The data were 
normalized and fit to determine the temperature at which half the protein was unfolded, 
representing the Tm. Results are the mean ± s.d. (n=3). 
Ras Nucleotide Dissociation and Hydrolysis Assays 
The rate of nucleotide dissociation was measured using MANT–GDP (BioLog: 
San Diego, CA) as previously reported(194, 195). Briefly, MANT–GDP–bound Ras (2 
μM) was added to 1 mL assay buffer (50 mM Tris, pH 7.4, 50 mM NaCl and 5 mM 
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MgCl2) and exchange initiated by addition of 2 mM GDP. MANT–GDP dissociation was 
measured as a change in fluorescence intensity over time (excitation: 360 nm, emission: 
440 nm) (LS50B Perkin–Elmer Luminescence Spectrometer). Fluorescence data were fit 
in GraphPad Prism (GraphPad Software; San Diego, CA) to a one–phase exponential 
decay curve. For GEF–mediated dissociation and binding, 200 nM Ras and 0.2 μM to 20 
μM Soscat were used. The nucleotide dissociation rate was plotted as a function of Soscat 
concentration and fit to one site binding to determine the binding affinity between Ras or 
mUbRas and Soscat. Results are the mean ± s.d. (n=4).  
Single–turnover GTP hydrolysis assays were performed as previously 
described(196), except that the phosphate binding protein Flippi 5U (Addgene) was used 
to detect inorganic phosphate released upon GTP hydrolysis(185). Flippi 5U was purified 
as previously described(185). All buffers were made phosphate free by dialysis with 1 U 
nucleoside phosphorylase (Sigma, USA) and 2 mM inosine (Sigma, USA). For GAP–
mediated hydrolysis, 50 μM Ras and 0.1 μM (1:500) and 0.25 μM (1:200) NF1333 and 
GAP–334 were used. The ratio of fluorescence emission was measured at 480 nm and 
530 nm with an excitation of 435 nm on a SpectraMax M5 (Molecular Devices). 
Fluorescence ratios were converted to phosphate concentrations using a standard curve. 
Hydrolysis curves were fit in GraphPad Prism (GraphPad Software; San Diego, CA) to a 
one–phase exponential association curve. Results are the mean ± s.d. (n=6).  
GAP binding was monitored as previously described(197). Briefly, 50 μM Ras 
and 40 μM NF1333 were mixed in the presence or absence of AlF4– (10 mM NaF, 450 μM 
AlCl3) on ice. The sample was run on an S75 column in 30 mM Tris, pH 7.5 and 5 mM 
MgCl2. Data was normalized to the amount of free NF1333 in the absence of AlF4–. 
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GST–RBD Immunoprecipitation Assay 
Ras activation was measured as described previously(153). Flag–His–K–Ras or 
the c–terminal mutants Flag–His–K–RasC185S and Flag–His–H–RasC186S were co–
expressed with HA–Ubiquitin in HEK293T cells. The cells were rinsed with cold PBS 
and lysed with Buffer A (0.5% NP–40, 40 mM HEPES [pH 7.4], 150 mM NaCl, 10% 
glycerol, 1 mM DTT, 1 µg ml–1 leupeptin, 2 µg ml–1 aprotinin, 1 µg ml–1 pepstatin A, 100 
µM AEBSF, Halt phosphatase inhibitor cocktail (Thermo Scientific), 10 mM 
iodoacetamide (IAA) and 5 mM N–ethylmaleimide (NEM)). The soluble fraction from 
the cell lysates were isolated by centrifugation at 13,000 rpm for 10 min, split, and 
subjected to anti–Flag agarose immunoprecipitation or incubated with 10 µg of GSH–
Sepharose bound GST–Raf–RBD in the presence of 1 mg ml–1 BSA for 30 min as 
described previously15. The immunoprecipitated proteins were washed three times with 
Buffer A and eluted by the addition of 8 M urea. To ensure detection of mUbRas, a 
secondary purification on Co2+ Talon metal affinity chromatography beads (Clontech) 
was performed. Flag–His–Ras was eluted with sample buffer containing 50 mM EDTA. 
For the GAP sensitivity assay, bacterially produced GAP–334 was incubated with the cell 
lysate for 20 min at room temperature and subjected to analysis using GST–Raf–RBD.  
NMR Experiments  
For NMR studies, 15N– and 15N,13C–enriched samples of Ras and Ubiquitin were 
produced using standard protocols in M–9 minimal media(181). 1H–15N 2D HSQC 
experiments were conducted on a Varian 700 MHz and a Bruker 500 MHz with a 
cryoprobe in 20 mM MOPs, pH 6.8, 100 mM NaCl, 5 mM MgCl2, 0.01% sodium azide, 
10% D2O, 1 mM DPTA, and 2 mM GDP at 25oC and with 500 μM protein.  
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Rosetta Modeling 
The modeling strategy used was adapted from Saha et al.(186). The previous 
protocol modeled a thioester linkage between Ubiquitin Gly76 and cysteine on a 
Ubiquitin E2 enzyme. Modifications include altering the linkage type to disulfide or 
isopeptide linkages and replacing the pre–existing system–specific constraints with 
optional command–line defined constraints. Further modifications include the reporting 
of specific Ubiquitin–Ras residue pair distances and Ubiquitin–Ras positional metrics 
used to quantify mUbRas conformational ensembles. Also added was the ability to 
include arbitrary nonmoving atoms in the simulation, used to include the guanine 
nucleotide, magnesium ion, and in some cases, GAP during simulations. A chemically 
conjugated model of Ras and Ubiquitin was created and the torsion angles within the 
linker region were modeled while sampling side chain conformations throughout the 
interface.  For the isopeptide linker, protocol UBQ_Gp_LYX–cterm was used. Torsions 
allowed to vary included: the chi angles of Lys147 of Ras (sampled from Rosetta’s 
implementation of Dunbrack’s 2002 rotamer library (198, 199)), the isopeptide bond, and 
both phi and psi for the Gly76, Gly75, and Arg74 of Ubiquitin. For the disulfide linker, 
protocol UBQ_Gp_CYD–CYD was used. Torsions sampled include the chi angles for 
K147C on Ras and G76C on Ubiquitin (from the Dunbrack library and explicit sampling 
of chi 2), the disulfide bond, phi of Ubiquitin G76C, and both phi and psi for Gly75 and 
Arg74 of Ubiquitin.  Sampling was performed with a standard Rosetta Metropolis–Monte 
Carlo search protocol(198). For each combination of ligand, attachment chemistry, and 
Ras attachment location, the protocol was run for 2400 hours on a 2.66 MHz chip. This 
produces about 1500–3000 structures using 20,000 Monte Carlo cycles per trajectory. 
  
CHAPTER III   
ISOFORM-SPECIFIC DIFFERENCES IN THE REGULATION OF K-RAS AND  
H-RAS BY MONOUBIQUITINATION1 
 
The major Ras isoforms that regulate important cell processes such as 
proliferation, differentiation, and survival are highly conserved, yet have distinct 
biological outputs.  Post-translational modification of Ras contributes to the differences 
in isoform dependent signaling outputs through regulation of Ras activity and subcellular 
localization.  Ubiquitination is one post-translational modification that regulates all three 
Ras isoforms.  Monoubiquitination of H-Ras in CHOK-1 cells promotes endosomal 
transport and signal dampening.  In K-Ras, monoubiquitination specifically at lysine 147 
impairs GAP-mediated hydrolysis, leading to GTPase activation and increased signaling 
output. Intriguingly, the sites of monoubiquitination for H-Ras and K-Ras differ in 
HEK293T cells. Here, we further explore the role of site-specific monoubiquitination in 
isoform-specific regulation of Ras.  We find that monoubiquitination of H-Ras at lysine 
117 activates the protein by enhancing the intrinsic rate of nucleotide dissociation. These 
findings reveal that monoubiquitination activates H-Ras by a mechanism unique from K-
Ras.  Furthermore, the site at which monoubiquitination occurs dictates the mechanism 
                                                 
1 Figures contributed by: 
Rachael A. Baker: 3.1a-b, 3.1d, 3.2a-b, 3.3a-b, 3.3d, 3.4a-b, 3.4d 
Atsuo T. Sasaki: 3.5 
Emily M. Wilkerson: 3.1c, 3.2c, 3.3c, 3.4c  
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by which Ras is regulated.  More broadly, these results identify a role for 
monoubiquitination in the regulation of isoform-specific Ras activity and signaling. 
 
Introduction 
The small GTPase Ras is a signaling switch that controls a number of cellular 
processes, including gene expression, cell differentiation, and programmed cell death 
(168).    To control the activation of these essential pathways, Ras binds and hydrolyzes 
GTP.  Ras is active when it is GTP-bound and becomes inactive when GTP is hydrolyzed 
to GDP (127, 200).  The conformational changes that are associated with the most 
significant differences between the GDP- and GTP-bound states of Ras are primarily 
localized to the switch I and switch II regions.  These switch regions are less 
conformationally dynamic in the GTP-bound state, and populate conformers critical for  
downstream effector recognition (167).  On its own, Ras is not a very good enzyme, and 
requires regulators to respond to signals on an appropriate timescale.  The primary 
regulators of Ras cycling are guanine nucleotide exchange factors (GEFs), which increase 
the rate of GDP dissociation (201, 202), and GTPase activating proteins (GAPs)  that 
increase the rate of GTP hydrolysis (200, 203).  These regulators also primarily interact 
with the switch regions of Ras.  Due to its essential role in regulating cell growth and 
differentiation, Ras mutations are common in cancer.  Over 30% of all human tumors 
contain an activating Ras mutation (170, 204, 205).  Ras mutations are particularly 
prevalent in three of the four most common types of cancer, pancreatic (~90%), colon 
(~50%), and lung cancer (~30%) (206). 
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There are three distinct isoforms of Ras: K-Ras (two splice variants, K-Ras4A and 
K-Ras4B), H-Ras, and N-Ras.  While these isoforms share a core domain that contains 
the enzymatic activity (>90% identical in the first 168 amino acids), there are differences 
in their c-terminal targeting domains.  The c-terminal domain, or hypervariable region 
(HVR) is a short region of the protein (about 20 amino acids) that contains lipid 
modification sites.   K-Ras is only farnesylated while N-Ras and H-Ras are also 
palmitoylated at one and two additional sites, respectively (207-210).  The differential 
lipidation of the Ras isoforms is essential for membrane targeting, which is necessary for 
signaling.  Post-translational modification of the Ras isoforms dictates their localization 
and trafficking (211-214). Inactive H-Ras has been identified in cholesterol rich 
microdomains within the plasma membrane (214, 215).  When H-Ras is activated, it 
appears to move to more disordered plasma membrane regions (216, 217).  In an 
opposing example, it is active, GTP-bound N-Ras that is found in cholesterol rich 
microdomains (218).  K-Ras4B, on the other hand, is most often found outside of lipid 
rafts or sometimes in cholesterol-independent microdomains that are distinct from the 
lipid rafts where H-Ras is localized (215, 219).   
Localization of Ras is important; there are distinct biological outcomes from 
downstream signaling pathway activation in different subcellular compartments (220-
222). At steady state levels, H-Ras and N-Ras are localized at both the Golgi and plasma 
membrane, while K-Ras is only at the plasma membrane (223).  There is evidence that 
these variations in compartmentalization modulate signaling outputs, in part due to 
differential localization of the effectors and regulators with which Ras interacts.  
Activation of Ras at the plasma membrane is very rapid, while activation at the Golgi 
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membrane is both delayed and sustained (224).  Because K-Ras is not shuttled between 
multiple membranes, more protein is present at the plasma membrane, which makes K-
Ras a more potent activator of the downstream effector Raf than H-Ras (225).   
The differential localization of the Ras isoforms leads to differences in the 
biology regulated by these isoforms, including different patterns of mutation in various 
human diseases (211-214).  K-Ras is the most commonly mutated isoform in human 
cancers (206).  Activating mutations of H-Ras are common in bladder cancer, whereas 
mutations of K-Ras occur at high frequency in pancreatic cancers, and mutations of N-
Ras occur frequently in acute myeloid leukemia (211, 226, 227).  Moreover, activating 
mutations in K-Ras cause syndromes such as Noonan syndrome and cardio-facio-
cutaneous syndrome (122, 228, 229). H-Ras mutations are common in Costello syndrome 
(230) and mutations in N-Ras lead to autoimmune lymphoproliferative syndrome (211).  
Furthermore, the Ras isoforms are not interconvertable.  For example, oncogenic N-Ras 
mutations are not able to drive colon cancers that are commonly driven by the same 
activating mutation in K-Ras (231).   
Mounting evidence indicates that post-translational modification by ubiquitination 
contributes to differentiation between Ras isoforms in a cell-line and isoform-specific 
manner.  H-Ras and N-Ras have long been known to be substrates of ubiquitination 
(173).  Ubiquitination of H-Ras results in the stabilization of its association with the 
endosomes and, therefore, a change in signaling output due to inhibited membrane 
recycling and increased protein accumulation in the endosome (173).  However, it is not 
known whether the ubiquitinated and consequently endosome-localized Ras proteins 
continue to signal through downstream pathways (226).  Evidence for a change in 
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signaling output consists of showing that a mutant of H-Ras that could not be 
ubiquitinated was more efficient at specifically recruiting Raf-1 and activating the ERK 
mitogen-activated protein kinase (232).  Regulation of H-Ras by ubiquitination was 
observed in CHOK-1 cells and did not appear to depend on GTP loading (173).  No K-
Ras ubiquitination was observed in the same cell line (173).  In the early studies of H-Ras 
and N-Ras ubiquitination, it was shown that the membrane anchoring domain of the 
protein was necessary and sufficient to direct monoubiquitination, but did not contain the 
site of monoubiquitination (173). For H-Ras to fail to be ubiquitinated, it must lack 8 
surface exposed lysines including 5, 42, 88, 101, and 147 in the core GTPase domain 
(173).  The modification appears to be conserved between D. melanogaster and  human 
cell lines (232, 233) and represents a new way of controlling the spacial sorting of H-Ras 
(234). 
We and others have more recently shown that ubiquitination also acts as a 
reversible mechanism of K-Ras regulation (153, 235).  Monoubiquitination leads to 
activation of K-Ras through inhibition of GAP-mediated GTP hydrolysis as well as 
increased interactions with select downstream effectors (153, 235).  We showed that this 
mechanism of Ras activation is specific to ubiquitination at K147 (235).  In these studies, 
H-Ras was also identified as a substrate of monoubiquitination by mass spectrometry in 
HEK293T cells.  K-Ras ubiquitination was not detected in CHOK-1 cells, consistent with 
previous studies of H-Ras ubiquitination (153). 
There appears to be very divergent ways by which H-Ras and K-Ras are regulated 
by monoubiquitination.  When H-Ras is monoubiquitinated in CHOK1 cells, the 
restricted ability of the protein to signal could be due to sequestration from particular 
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effectors (211).  This is distinct from K-Ras ubiquitination, which did not appear to 
change the subcellular localization of the protein but did alter Ras activity.  Sasaki et al. 
observed monoubiquitination in H-Ras as well as K-Ras in HEK293T cells.  
Furthermore, varying degrees of activation for H-Ras and K-Ras were observed, which 
suggests that the isoforms may be regulated by monoubiquitination through two distinct 
mechanisms (153).  In support of this hypothesis, Sasaki et al. observed by mass 
spectrometry that H-Ras, but not K-Ras, could be monoubiquitinated at K117 and that 
there were minor instances of K-Ras ubiquitination at K104.  Since we previously 
showed that the mechanism by which K-Ras is activated by monoubiquitination is site-
specific, it is likely that ubiquitination at these other two lysines has, if any, an alternative 
mechanism of regulating Ras. 
 Here, we fully characterize two alternative sites of monoubiquitination, K104 (K-
Ras) and K117 (H-Ras).  We show that ubiquitination at K104 does not lead to a change 
in Ras activity, demonstrating that site specificity is key for the regulation of Ras by 
ubiquitination.  Furthermore, we show that monoubiquitination at K117 upregulates H-
Ras activity by increasing the intrinsic rate of nucleotide exchange, a mechanism distinct 
from K-Ras ubiquitination.  Experiments in cell lysates exhibit a phenotype of 
monoubiquitinated H-Ras that is consistent with modification at K117.  More broadly, 
our results describe an isoform-specific mechanism of Ras post-translational 
modification, which may play a role in isoform-dependent differences in Ras activation 
and signaling. 
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Results 
Ras Monoubiquitinated at K104 Retains the Activity of Unmodified Ras 
 Monoubiquitination of K-Ras occurs primarily at K147 (153).  However, 
monoubiquitination was also observed, albeit infrequently, at K104.  We hypothesized 
that since K104 was a secondary site of K-Ras monoubiquitination and was not in the 
same proximity to the switch regions as K147, the enzymatic activity of Ras would not 
change upon modification at this site.  To measure the effect of ubiquitination on Ras 
activity, we used our recently published chemical ubiquitination approach to modify the 
protein (235).  Briefly, this method requires making a cysteine mutation at the site of Ras 
to be ubiquitinated (RasK104C) and at the c-terminus of Ubiquitin (UbiquitinG76C).  These 
studies were done in a RasC118S background (hereafter, Ras) which does not alter the 
biochemical properties of Ras (178).  We first measured the effect of mutation at K104 
on intrinsic and regulator-mediated Ras activity.  As shown in Figure 3.1a, while K104 
is not adjacent to the switch regions, it is near the edge of the surface of Ras involved in 
binding to the GEF.  Therefore, a change at position 104 could alter GEF-mediated 
dissociation.  In Figure 3.1b, we show that the K104C mutation does not alter Ras 
thermal stability (Tm=51 oC).  We also measured rates of intrinsic and GEF-mediated 
GDP dissociation in the presence and absence of a Ras K104C mutation.  As seen in 
Figure 3.1c, RasK104C maintains the intrinsic rate of GDP dissociation of Ras 
(0.13±0.02x10-3 s-1).  However, while the addition of the GEF, Sos, increases the rate of 
Ras GDP dissociation 10-fold (1.3±0.1x10-3 s-1), it only increases the rate of RasK104C 
dissociation 2-3 fold (0.30±0.05x10-3 s-1).  In contrast, neither intrinsic nor GAP-
mediated GTP hydrolysis was altered by the K104C mutation. 
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 We chemically monoubiquitinated K104 on Ras (mUbRasK104)  and repeated the 
assays described above to determine if the effect of monoubiquitination on Ras at this 
position was different from a mutation at the same position (Figure 3.2a).  As seen in 
Figure 3.2b, the thermal stability of mUbRasK104 is similar that of Ras (Tm=50.8±0.4 oC), 
indicating that monoubiquitination does not thermally destabilize Ras.  We next 
measured intrinsic and Sos-mediated rates of GDP dissociation and observed no 
difference between Ras and mUbRasK104 (Figure 3.2c).  It is interesting to note that, 
similar to modification at K147,  monoubiquitination has a distinct effect on Ras activity 
from a mutation at the same site (235).  Mutation of lysine to cysteine alters either 
intrinsic (K147) or Sos-mediated (K104) exchange, but mUbRas has the same rates of 
dissociation as unmodified Ras.  While we have not yet measured intrinsic and GAP-
mediated hydrolysis for mUbRasK104, we do not expect any significant differences from 
unmodified Ras.  Taken together, these data demonstrate that some sites on Ras can be 
monoubiquitinated without altering intrinsic or regulator-mediated activity. 
Monoubiquitination at K117 Activates Ras by Increasing Guanine Nucleotide 
Dissociation 
 While K-Ras can be ubiquitinated at two distinct lysines in vivo (K147 and 
K104), only the more prevalent site of ubiquitination leads to a change in the active state 
of the protein.  The mechanism of Ras regulation by monoubiquitination is site-specific, 
suggesting that monoubiquitination at K117 on H-Ras could have a distinct effect from 
monoubiquitination at K104 or K147.  Lysine 117 is part of the NKxD motif of Ras-like 
GTPases that contributes to nucleotide affinity by forming interactions with the guanine 
nucleotide base (Figure 3.3a).  Oncogenic mutations at K117 (K117R and K117N) are.   
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Figure 3.1.  Mutation of Ras at Lysine 104.  (a) Structure of Ras (PDB 1CRR) with 
nucleotide and Magnesium shown in grey and the K104 sidechain highlighted in 
magenta.  Backbone residues in yellow make contact with GEF when it is bound, 
backbone residues in blue make contact with the GAP when it is bound, and backbone 
residues in green make contact with both the GEF and the GAP.  (b) Thermal stability of 
Ras and RasK104C in the presence of GTPγS measured by ABD–F incorporation as a 
function of temperature. The data were normalized using the maximum fluorescence 
intensity. Results are the mean ± s.d. (n=4).  (c) Intrinsic nucleotide dissociation rates for 
Ras and RasK104C loaded with MANT–GDP. Dissociation was monitored following the 
addition of unlabeled GDP by the decrease in fluorescence emission over time.  
Nucleotide dissociation was also measured in the presence of a 1:1 molar ratio of Ras to 
Soscat. Data were fit to an exponential dissociation curve, and the results are the mean ± 
s.d. (n=4).  (d) Intrinsic single–turnover GTP hydrolysis for Ras and RasK104C. Hydrolysis 
was initiated by the addition of Mg2+ and monitored by the change in fluorescence of 
Flippi when bound to free phosphate. Single-turnover GTP hydrolysis of Ras was 
measured in the absence and presence of GAP-334 (intrinsic and 1:500 GAP:Ras).  Data 
were converted to a phosphate concentration using a standard curve. The concentration of 
phosphate equal to 100% GTP hydrolyzed was determined in the presence of GAP. 
Results are the mean ± s.d. (n=6).   
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Figure 3.2.  Monoubiquitination of Ras at Position 104.  (a)  SDS-PAGE gel under non-
reducing (NR) and reducing (R) conditions showing the formation of monoubiquitinated 
Ras (mUbRas) and Ubiquitin-Ubiquitin dimers (Ub-Ub) after dialysis.  (b) The thermal 
stability of Ras and mUbRasK104 measured by fQCR as described in Figure 3.1b.  (c)  
Intrinsic and Sos-mediated GDP dissociation rates for Ras and mUbRasK104 measured as 
described in Figure 3.1c. 
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present in human cancers and developmental disorders (183, 236, 237).  Mutations at 
K117 reduce Ras nucleotide binding affinity, resulting in increased protein activation due 
to increased rates of nucleotide exchange (183, 236, 237).  Therefore, it is possible that 
ubiquitination at K117 could also lead to Ras activation through a similar mechanism. 
We first mutated K117 to cysteine (RasK117C) and measured the effects of this 
substitution on thermal stability, nucleotide dissociation, and nucleotide hydrolysis.  As 
seen in Figure 3.3b, mutation of K117 decreases the thermal stability of the protein by 
almost 10 degrees (Tm=43.8±0.9 oC).  The intrinsic rate of GDP dissociation is also 
affected by the K117C mutation (11.0±0.4x10-1 s-1), increasing 100-fold over the rate of 
Ras dissociation (Figure 3.3c).  The observed increase in intrinsic hydrolysis is 
consistent with other mutations previously characterized at position 117 (238).  We also 
measured the rate of GEF-mediated GDP dissociation in the presence of Sos.  Although 
the intrinsic rate of GDP dissociation is at the limits of detection of our assay, making it 
difficult to quantify, RasK117C does appear to be GEF-responsive.  Finally, we also 
measured the rate of intrinsic and GAP-mediated GTP hydrolysis.  Due to protein 
instability, we were not able to perform single turnover assays, but instead measured 
multi-turnover rates of GTP hydrolysis in the presence of various GAP concentrations, as 
previously described (238).  While RasK117C is still GAP responsive, it appears to be less 
sensitive to GAP-mediated regulation than Ras.  The apparent binding affinity between 
the GAP and Ras decreases from 0.19±0.06 μM to 4.0±0.9 μM when Ras is mutated at 
position 117, leading to the observed decrease in sensitivity to GAP-mediated hydrolysis. 
 The significant change in the rate of intrinsic GDP dissociation when K117 is 
mutated is due to disruption of side chain interactions with the base of the guanine 
84 
 
nucleotide.  Therefore, it is possible that monoubiquitination also activates the protein 
through a similar mechanism, since monoubiquitination captures the lysine side chain.  
We generated mUbRasK117 (Figure 3.4a) as previously described and measured changes 
in protein thermal stability and activity.  As shown in Figure 3.4b, monoubiquitination of 
Ras at K117 does not thermally destabilize the protein, unlike a mutation at the same site 
(Tm=52.5±0.5 oC).  However, the rate of intrinsic dissociation is 70-fold faster for 
mUbRasK117 compared to Ras (8.3±0.3x10-3 s-1) (Figure 3.4c), very similar to mutation at 
the same position.  This 70-fold increase in the rate of intrinsic hydrolysis would lead to 
increased activation in vivo.  As seen in Figure 3.4d, when Ras is monoubiquitinated it is 
still GAP-responsive.  The binding affinity between GAP and Ras decreases to 0.6±0.1 
μM, a smaller change than caused by mutation at the same site.  These data demonstrate 
that monoubiquitination at position 117 can directly alter Ras activity.  The greatest 
change in activation will be from the increased intrinsic nucleotide dissociation rates, but 
the decreased sensitivity to GAP-mediated hydrolysis will also contribute.  Taken 
together, these data suggest that in vivo, mUbRasK117 is likely more activated than 
unmodified Ras due to an increased rate of intrinsic nucleotide exchange.   
Pull Downs with Cell Lysate Support Isoform Specificity of Ras Monoubiquitination 
Our in vitro chemical ubiquitination system coupled with biochemical 
characterization studies indicate that monoubiquitination of H-Ras at K117 activates Ras 
through a mechanism distinct from monoubiquitination of K-Ras at K147.  In the original 
study by Sasaki et al., mass spectrometry data identified ubiquitination of H-Ras at either 
K117 or K147 (153).  Since the mechanisms of activation at these two lysines are 
distinct, we characterized H-Ras activity in cell lysates to determine if modification at 
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Figure 3.3.  Mutation of Ras at Lysine 117.  (a) Ribbon diagram highlighting the active 
site of Ras (PDB 1CRR) with nucleotide and Magnesium shown in various colors and 
red, respectively.  The sidechain of K117 is highlighted in purple. (b) Thermal stability of 
Ras and RasK117C in the presence of GTPγS measured by ABD–F incorporation as a 
function of temperature. The data were normalized using the maximum fluorescence 
intensity. Results are the mean ± s.d. (n=4).  (c) Intrinsic nucleotide dissociation rates for 
Ras and RasK117C loaded with MANT–GDP. Dissociation was monitored following the 
addition of unlabeled GDP by the decrease in fluorescence emission over time.  
Nucleotide dissociation was also measured in the presence of a 1:1 molar ratio of Ras to 
Soscat. Data were fit to an exponential dissociation curve, and the results are the mean ± 
s.d. (n=4).  (d) Intrinsic and GAP-mediated multi-turnover hydrolysis measured by the 
change in fluorescence of Flippi when bound to free phosphate.  Data were converted to a 
phosphate concentration using a standard curve. The rate of phosphate release was 
measured for 20 μM Ras in the presence of GAP concentrations from 0.0625 μM to 8 
μM.  Results are the mean ± s.d. (n=3).  Data were fit to a one site binding model in 
GraphPad Prism to calculate the apparent binding affinity between GAP and Ras. 
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Figure 3.4.  Monoubiquitination at Position 117.  (a) SDS-PAGE gel under non-reducing 
(NR) and reducing (R) conditions showing the formation of monoubiquitinated Ras 
(mUbRas) and Ubiquitin-Ubiquitin dimers (Ub-Ub) after dialysis.  (b) Thermal stability 
of Ras and mUbRasK117 in the presence of GTPγS measured as described for Figure 3.3b.  
(c) Intrinsic nucleotide dissociation rates for Ras and mUbRasK117 measured as described 
in in Figure 3.3c.  (d) Intrinsic and GAP-mediated multi-turnover hydrolysis for Ras and 
mUbRasK117 measured by the change in fluorescence of Flippi when bound to free 
phosphate as described in Figure 3.3d.   
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one lysine dominated over the other.  H-Ras was immunoprecipitated from HEK293T 
cells, and the populations of activated Ras and activated mUbRas were compared using 
Ras Binding Domain (RBD) pull downs.  We measured the activation state of H-Ras as 
well as its sensitivity to GEF- and GAP-mediated regulation in a cellular reconstitution 
system.  As seen in Figure 3.5a, GTP-bound mUbRas decreases more rapidly than 
unmodified GTP-bound H-Ras in the presence of excess GDP.  The increased loss of 
activated mUbRas in the presence of GDP indicates that the rate of nucleotide exchange 
is faster when H-Ras is monoubiquitinated.  This result is similar to what is observed in 
the RasK117N variant (Figure 3.5a), which is also known to increase the rate of intrinsic 
nucleotide exchange.  In vitro, an increased rate of nucleotide dissociation was observed 
when Ras was monoubiquitinated at K117, but not at K147.  Together, these data indicate 
that the observed increased rate of dissociation is due to a population of the Ras that is 
monoubiquitinated at K117.  We next determined whether the population of H-Ras that 
was monoubiquitinated in vivo was sensitive to GAP-mediated regulation.  As seen in 
Figure 3.5b, the amount of both Ras and mUbRas decreases as the concentration of 
recombinant GAP added to the cell lysate increases.  If H-Ras were monoubiquitinated at 
K147, it would not be sensitive to GAP-mediated hydrolysis as we previously showed 
with K-Ras (235).  Finally, the amount of activated Ras was measured in the presence of 
increasing concentrations of Sos.  While the population of GTP-bound unmodified Ras 
increases as the Sos concentration increases, mUbRas is either not sensitive to Sos-
mediated exchange or is already fully activated.  Taken together, these data indicate that  
H-Ras is primarily monoubiquitinated at K117 in HEK293T cells, which leads to its 
activation through a mechanism distinct from K-Ras ubiquitination.  
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Figure 3.5.  Assays of H-Ras in Cell Lysate Indicate H-Ras is Primarily Modified at 
K117.  (a)  Immunoblotting of GTP-bound Ras, GTP-bound mUbRas, and GTP-bound 
RasK117N in cell extract in the presence of increasing concentrations of GDP.  Anti–Flag 
and anti–HA antibodies reveal the relative fraction of total Ras and mUbRas, 
respectively, for all assays.  (b) Immunoblotting of GTP-bound Ras and GTP-bound 
mUbRas in cell extract in the presence of increasing concentrations of recombinant 
RasGAP.  (c)  Immunoblotting of GTP-bound Ras, GTP-bound mUbRas, and GTP-
bound RasK117N in cell extract in the presence of increasing concentrations of 
recombinant Sos.     
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Discussion 
It was established recently that both K-Ras and H-Ras are substrates for 
monoubiquitination in HEK293T cells and the sites of monoubiquitination were 
identified as K104, K117, and K147.  We established that the mechanism by which 
monoubiquitination of K-Ras at K147 promotes Ras activation is by rendering it 
insensitive to GAP-mediated GTP hydrolysis.  Here, we have shown that 
monoubiquitination of the second minor site on K-Ras, K104, does not alter the intrinsic 
or regulator-mediated activity of Ras.  Furthermore, H-Ras is primarily 
monoubiquitinated on K117, a site distinct from K-Ras ubiquitination, and 
monoubiquitination at K117 activates H-Ras by increasing the intrinsic rate of nucleotide 
dissociation.  Monoubiquitination of K-Ras also increases the affinity of the protein for 
select downstream effectors (153).  It remains to be seen if monoubiquitination of H-Ras 
at K117 also alters interactions with downstream effectors, perhaps in a manner distinct 
from K-Ras ubiquitination.   
Isoform specific ubiquitination may represent a new mechanism of dictating 
functional hierarchy of Ras isoforms (173).  It is likely that the differences in Ras 
ubiquitination, both in the studies described here as well as the previous studies of H-Ras 
ubiquitination, are due to differences in E3 ubiquitin ligase and deubiquitinating enzyme 
expression or localization (153).  It is these differences, as well as the differences in Ras 
localization, that contribute to differential modification of Ras isoforms by 
monoubiquitination, leading to translocation or activation of a particular Ras isoform in a 
particular tissue. 
90 
 
It is interesting to note that the secondary site of monoubiquitination (K104) does 
not alter Ras activity.  Because both of the primary sites of ubiquitination (K117 and 
K147) alter Ras activity, these data suggest that the change in Ras activity are an 
important component for how monoubiquitination is used to regulate Ras in HEK293T 
cells.  However, the identification of a site on Ras where monoubiquitination does not 
alter activity is also consistent with data from previous studies of Ras ubiquitination in 
CHOK-1 cells.  In these previous studies, trafficking to the endosome rather than Ras 
activation was the end result of H-Ras monoubiquitination.  The site of 
monoubiquitination in CHOK-1 cells was determined to be one of 8 surface exposed 
lysines, which include lysines 5, 42, 88, 101, and 147.  Consistent with ubiquitination at 
K104, we have already shown that ubiquitination at K88 or K101 does not impact GAP-
mediated regulation of GTP hydrolysis (235).  Therefore, it is likely that in this case, 
ubiquitination of H-Ras is primarily a trafficking signal. 
Lysine 104 is also a known site of other post-translational modifications; it was 
recently shown that Ras can be acetylated at this position (239).  Molecular dynamics 
simulations suggest that acetylation at this position alters the conformational stability of 
switch II due to a perturbation in electrostatic interactions, which is known to be 
important for GEF-mediated hydrolysis (239).  Furthermore, a conservative mutation at 
the same position (K140R) did not significantly impact GEF-mediated dissociation (239).  
We showed that a lysine to cysteine mutation, which also alters the charge at position 
104, similarly impaired GEF-mediated dissociation.  However, monoubiquitination at 
K104 did not alter GEF-mediated dissociation, likely because the modification does not 
alter charge at this position in the same manner as a mutation.  While the extent to which 
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both acetylation and monoubiquitination of K104 contribute to Ras-mediated regulation 
in vivo remains to be seen, it has not escaped our notice that monoubiquitination at K104, 
which does not affect Ras activation, would exclude the possibility of acetylation at the 
same position.  Therefore, there may be a role for K104 monoubiquitination in protection 
of Ras from other post-translational modifications. 
Taken together, these data have implications for studying the regulation of Ras by 
monoubiquitination.  This post-translational modification appears to be used in a site-
specific, isoform-specific, and cell-line specific manner.  This means that while 
monoubiquitination likely represents an essential component of Ras regulation in vivo, its 
effect on the protein is dependent on the lysine which is modified.  Our data indicate that 
the site of modification by monoubiquitination is essential to understanding the role this 
modification plays in the regulation of Ras in vivo.  Thus, it is crucial not only to identify 
when Ras is ubiquitinated, but to determine the primary sites of monoubiquitination.  It is 
possible that monoubiquitination is used in different ways in different tissue types or in 
various Ras-driven cancers.  Monoubiquitination of K-Ras at K147 has already been 
shown to play a role in Ras-driven tumorigenesis in a mouse model of cancer (153).  Ras 
regulates many key pathways within the cell, and its regulation of these diverse pathways 
is achieved through controlling spatial and temporal localization as well as through the 
use of distinct Ras isoforms. Monoubiquitination represents a new mechanism through 
which isoform-dependent Ras activity and signaling is distinguished.  
 
 
 
92 
 
Methods 
Protein Expression and Purification 
The Ras domains (1–166) of H–RasC118S, H–RasC118SK104C, H–RasC118SK117C were 
expressed in the pQlinkH vector (Addgene) with a histidine purification tag in E. coli 
BL21 (DE3) RIPL cells (Stratagene: La Jolla, CA). Proteins were purified following 
standard Qiagen nickel affinity purification procedures.  The His tag was cleaved 
overnight with Tobacco Etch Virus (TEV). Ras proteins were further purified by removal 
of uncleaved protein using Ni–NTA agarose beads (Qiagen). The final product was 
judged > 95% pure by SDS–PAGE. Proteins were stored in 20 mM HEPES, pH 8.0, 50 
mM NaCl, 500 μM TCEP, 50 μM GDP and 5 mM MgCl2.   
The standard Ras protocol was revised for purification of RasC118SK117C to 
accommodate for the instability of the protein as follows.  The cells were lysed by 
homogenization at 2000 psi (Nano DeBEE Laboratory Bench Homogenizer) and pelleted 
by centrifugation at 4°C (Beckman Coulter J2-HS Centrifuge). Proteins were purified 
using 2 mL of Ni-NTA (Qiagen) beads in a 15 mL conical equilibrated with Ras Buffer A 
(50 mM HEPES pH 7.75, 50 mM NaCl, 5 mM MgCl2, 80 mM Imidazole, 500 µM GDP, 
500µM TCEP, and 10% glycerol) at 4°C. The cell lysate was allowed to bind to the beads 
for 20 minutes. The beads were washed in succession with two washes with Buffer A, 
one wash with Buffer B (50 mM HEPES pH 7.75, 1 M NaCl, 5 mM MgCl2, 80 mM 
Imidazole, 500 µM GDP, 500µM TCEP, and 10% glycerol), and one more wash with 
Buffer A. Then, TEV protein was added in Ras Buffer D (20 mM HEPES pH 7.75, 50 
mM NaCl, 5 mM MgCl2, 500 µM GDP, 500 µM TCEP, and 10% glycerol) to cleave the 
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histidine tag overnight. The protein was determined pure by an SDS-PAGE gel and 
stored at 4oC to be used fresh within 3 days.  
Soscat (John Kuriyan; University of California, Berkeley) was purified as previously 
described(190). The catalytic domain of p120GAP (GAP–334) (138) was expressed in 
pQlinkH and purified as described for Ras. Purified proteins were stored in 20 mM 
HEPES, pH 8.0, 50 mM NaCl and 500 μM TCEP. Full length UbiquitinG76C was 
expressed in the pQlinkH vector system and purified as described for Ras. Proteins were 
stored in 20 mM HEPES, pH 8.0, 50 mM NaCl and 500 μM TCEP.  
Chemical Ubiquitination 
The chemical ligation strategy used to link H-RasK104C and H-RasK117C was 
performed as described in Baker et al. (235). Briefly, a ten–fold excess of UbiquitinG76C 
was added to RasK147C and dialyzed into 20 mM Tris, pH 8.0, 50 mM NaCl, 5 mM 
MgCl2, and 50 μM GDP at 4 oC overnight. The amount of disulfide complex formation 
was determined by non–reducing SDS–PAGE and considered complete by the absence of 
unmodified Ras.  The protocol was adapted for ubiquitination of RasK117C with the 
addition of 10 % glycerol.  
Thermal Stability of Ras 
The fast quantitative cysteine reactivity (fQCR) method (182) was employed to 
measure changes in Ras thermal stability. Briefly, 2 μM RasK104C, mUbRasK104, RasK117C, 
or mUbRasK117 was incubated with 1 mM 4–fluoro–7–aminosulfonylbenzofurazan 
(ABD–F, Anaspec) at pH 7.0 in the presence of 20 μM GDP and 2 mM MgCl2 at the 
desired temperature for three minutes. Fluorescent intensity was measured on a 
PHERAstar plate reader (BMG Labtech).  
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MANT-Nucleotide Dissociation Assay 
For the RasK104C and mUbRasK104variants, the assay was performed as previously 
published in Baker et al. (235).  The assay was adapted in the following way for RasK117C 
and mUbRasK117.  Protein was exchanged into Mant Nucleotide Exchange Buffer (50 
mM Tris pH 8.0, 50 mM NaCl, 5 mM MgCl2, and 100 µM DPTA). To a cuvette, 0.5 µM 
Mant-GDP was added to 1 µM of protein. The protein was determined to be fully loaded 
when the fluorescence of the spectra no longer increased, approximately 500s.  Unlabeled 
GDP (final concentration of 100 µM) was added to initiate dissociation. For Sos-
mediated measurements, 1:1 molar ratio of SOSCAT:H-Ras was also added. MANT–GDP 
dissociation was measured as a change in fluorescence intensity over time (excitation: 
360 nm, emission: 440 nm) (LS50B Perkin–Elmer Luminescence Spectrometer). 
Fluorescence data were fit in GraphPad Prism (GraphPad Software; San Diego, CA) to a 
one–phase exponential decay curve. Results are the mean ± s.d. (n=4). 
Single Turnover Nucleotide Hydrolysis 
Single turnover nucleotide hydrolysis assays were performed as described in 
Baker et al. (235).  The ratio of fluorescence emission was measured at 480 nm and 530 
nm with an excitation of 435 nm on a SpectraMax M5 (Molecular Devices). Fluorescence 
ratios were converted to phosphate concentrations using a standard curve. Hydrolysis 
curves were fit in GraphPad Prism (GraphPad Software; San Diego, CA) to a one–phase 
exponential association curve. Results are the mean ± s.d. (n=6).  
Multiple Turnover Nucleotide Hydrolysis 
 Due to limitations with the stability of RasK117C and mUbRasK117, we measured 
rates of hydrolysis in a multiple turnover nucleotide hydrolysis assay.  We also repeated 
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the assay under the same conditions with RasC118S for comparison.  The phosphate 
binding protein Flippi 5U (Addgene) was used to detect inorganic phosphate released 
upon GTP hydrolysis (185).  Ras was extensively exchanged into phosphate free buffer 
with 5mM EDTA and no magnesium.  For intrinsic hydrolysis, 20 μM Ras was mixed 
with 60 μM GTP and hydrolysis was initiated by the addition of Magnesium.  For GAP-
mediated hydrolysis, a range of GAP concentrations from 0.0625 μM to 8 μM were also 
added to the reaction.  Fluorescence ratios were converted to a phosphate concentration 
using a standard curve.  Data from the first 10 minutes of hydrolysis were fit in GraphPad 
Prism (GraphPad Software; San Diego, CA) to a linear regression and the results were 
plotted as a function of GAP concentration.  Results are the mean ± s.d. (n=3).     
Mapping GEF and GAP Binding Sites on Ras 
 Residues were considered to be part of the interaction surface if they were less 
than 6 Angstroms apart.  Interactions surfaces were determined from the crystals 
structures of Ras with Sos (PDB 1BKD) and Ras with RasGAP (PDB 1WQ1).  See 
Appendix A for a list of all residues that interact and the distance between the 
interactions. 
Assays in Cell Lysate 
Ras activation was measured as described previously (153). Flag–His–H–Ras or 
the mutant Flag–His–H–RasK117N were co–expressed with HA–Ubiquitin in HEK293T 
cells. The cells were rinsed with cold PBS and lysed with Buffer A (0.5% NP–40, 40 mM 
HEPES [pH 7.4], 150 mM NaCl, 10% glycerol, 1 mM DTT, 1 µg ml–1 leupeptin, 2 µg 
ml–1 aprotinin, 1 µg ml–1 pepstatin A, 100 µM AEBSF, Halt phosphatase inhibitor 
cocktail (Thermo Scientific), 10 mM iodoacetamide (IAA) and 5 mM N–ethylmaleimide 
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(NEM)). The soluble fraction from the cell lysates were isolated by centrifugation at 
13,000 rpm for 10 min, split, and subjected to anti–Flag agarose immunoprecipitation or 
incubated with 10 µg of GSH–Sepharose bound GST–Raf–RBD in the presence of 1 mg 
ml–1 BSA for 30 min as described previously. The immunoprecipitated proteins were 
washed three times with Buffer A and eluted by the addition of 8 M urea. To ensure 
detection of mUbRas, a secondary purification on Co2+ Talon metal affinity 
chromatography beads (Clontech) was performed. Flag–His–Ras was eluted with sample 
buffer containing 50 mM EDTA. For the Sos and GAP sensitivity assays, bacterially 
produced protein was incubated with the cell lysate for 20 min at room temperature and 
subjected to analysis using GST–Raf–RBD. 
  
  
CHAPTER IV 
 
THE HELICAL DOMAIN INFLUENCES THE ENZYMATIC ACTIVITY OF THE 
YEAST G ALPHA PROTEIN1 
 
Heterotrimeric G proteins transmit signals from cell surface receptors to 
intracellular effector proteins. Whereas G protein  subunits are largely interchangeable, 
the Ras-like domain of the G subunit confers effector binding specificity. It has recently 
become evident that the -helical domain of Gα subunits also plays a crucial role in G 
protein-mediated signaling.  In particular, biophysical characterization of Gα proteins has 
revealed large scale movements in the α-helical domain during receptor-mediated 
activation.  Furthermore, the dynamic properties of the helices within the α-helical 
domain have been shown to influence Gα enzymatic activity. Here, we examine the 
function of the G protein  subunit in yeast, Gpa1. By site-directed mutagenesis we show 
that the α-helical domain dictates the thermal stability and intrinsic activity of the protein. 
Apart from the canonical Ras-like and α-helical domains, Gpa1 also contains a 
ubiquitination domain, a unique 109 amino acid insert within the α-helical domain, that is 
post-translationally modified by phosphorylation and ubiquitination.  We show that the 
ubiquitination domain, while known to be important for Gpa1 trafficking to the 
endosome, does not impact catalytic function. These data suggest that while the α-helical 
                                                 
1 All figures contributed by Rachael Baker 
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domain modulates Gα activity, the ubiquitination domain promotes Gpa1 trafficking 
without affecting enzymatic activity.  More broadly, these data support recent evidence of 
the importance of the α-helical domain in Gα signaling but also establish a distinct 
function for the ubiquitination domain in vivo. 
 
Introduction 
Gα proteins are enzymatic switches that are part of a multi-component signaling 
complex at the cell membrane (240).  The complex typically consists of a seven 
transmembrane spanning G protein coupled receptor (GPCR), a guanine nucleotide 
binding protein (Gα) and an associated dimer consisting of β and γ subunits (Gβγ) (241).  
Signaling is turned on and off based on the nucleotide-bound state of the Gα protein.  
When the Gα is GDP-bound, Gβγ is sequestered and signaling pathways are off (145).  
When the Gα releases GDP and binds GTP in response to GPCR activation, Gβγ 
dissociates and the signaling pathways are turned on (242).  For the pathway to be turned 
off, the Gα must hydrolyze GTP back to GDP.  GTP hydrolysis is facilitated by 
regulators of G protein signaling (RGS proteins) (145, 243, 244).  
Small G proteins are fully functioning enzymes with only the Ras-like domain.  
Large Gα proteins contain a Ras-like domain as well as an independently folded α-helical 
domain (116, 245).  Within this group of proteins there is a well-established role for the 
Ras-like domain in specifying interactions with Gβγ, effectors and RGS proteins (145). 
Furthermore, crystal structures of Gα showed that nucleotide binding was mediated by 
residues in the Ras-like domain (144).  Therefore, historically, the Ras-like domain of Gα 
proteins was assumed to be responsible for guanine nucleotide binding and hydrolysis 
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activity (116).  However, recent evidence has shown that the α-helical domain is also 
important for modulating signaling (246).  For example, crystal structure determinations 
have revealed differences in the α-helical domain of Gαi when bound to GDP and GTPγS 
(132).  Similarly, structure-based analysis of Gα bound to a GPCR revealed that upon 
receptor activation, the Ras-like and α-helical domains separate, which exposes the 
nucleotide binding pocket (141). Significant α-helical domain displacement was also 
observed using electron-electron resonance spectroscopy (247) and electron microscopy 
(141). Finally, the Gα protein in A. thaliana, AtGpa1, requires no receptor for activation, 
displaying a rate of nucleotide exchange two-orders of magnitude faster than its 
mammalian counterparts (248, 249).  Crystal structure analysis and molecular dynamic 
simulations revealed that AtGpa1 possesses a more dynamic and flexible α-helical 
domain than that of other Gα proteins (249, 250).  Furthermore, the difference in the 
dynamics of two helices within the α-helical domain (the A/B helix) accounts for the 
change in observed nucleotide exchange rate (249). Together, these data suggest that the 
-helical domain is a more important component of Gα-mediated signaling than was 
previously assumed.   
Another potential role for the -helical domain is in proper protein localization. 
Gα subunits are known to exist at the plasma membrane (251-255), the Golgi (256), 
endoplasmic reticulum (251), endosomes (257), and the nucleus (258).  While it is not 
clear if the Gα signals from all these locations, investigators have observed stimulus-
dependent movement of Gα and Gβγ to various endomembrane compartments (259).  
Direct evidence of intracellular signaling comes from work in S. cerevisiae, where the 
G Gpa1 was shown to transmit a signal from the endosome, and to do so by binding and 
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activating the phosphatidylinositol-3-kinase (PI3K) Vps15/Vps34 (260, 261). More 
recently, work by Irannejad et al. demonstrated that mammalian Gαs is also present at, 
and can signal from, endosomes (262). 
While there are several possible functions for the α-helical domain, there are few 
examples of known binding partners. The α-helical domains of some Gα proteins are 
known to be phosphorylated or ubiquitinated. Thus at a minimum, the α-helical domain 
participates in binding to the appropriate ubiquitin ligases and protein kinases (as well as 
phosphatases and deubiquitinating enzymes) (263-265). Furthermore, it is known that α-
helical domain contacts are formed between particular Gα proteins and their cognate 
RGS proteins (266-272). 
Here we focus on the -helical domain of the yeast G protein Gpa1 (Figure 4.1). 
Due to the complex nature of G protein mediated signaling in mammalian systems, model 
systems like S. cerevisiae are a valuable resource for studying and understanding these 
pathways.  The key features of yeast that make it a useful model organism are (a) the 
ability to perform genetic manipulations including gene replacement (b) the ability to 
exist stably as a haploid or diploid, (c) the availability of powerful genetic tools such as 
libraries of knockouts or tagged proteins (273, 274), and (d) the strong similarities 
between yeast and mammalian signaling pathways (275).  Indeed the founding members 
of many protein families were discovered in yeast, including the first regulator of G 
protein signaling (276).  
While the Ras-like and α-helical domains of Gpa1 are highly conserved with their 
mammalian counterparts, Gpa1 also possesses a unique 109 amino acid insert within the 
α-helical domain (277).  This insert contains the known sites of phosphorylation, 
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monoubiquitination, and polyubiquitination; both forms of ubiquitination occur at the 
same site in the ubiquitination domain, K165 (278-280). Given that the α-helical domain 
of Gα proteins modulates Gα activity it is therefore possible that the ubiquitination 
domain, or ubiquitination thereof, could influence Gpa1 activity. Here we show that 
mutations within the α-helical domain of Gpa1 influence the activity and thermal stability 
of the protein. In contrast, complete deletion of the ubiquitination domain is without 
consequence for GTP binding or hydrolysis. Thus the ubiquitination domain does not 
contribute to the overall enzymatic activity of Gpa1.  These findings suggest that the G 
protein in yeast has acquired this unique domain to regulates delivery to the endosome, 
vacuole, or proteasome. 
 
Results 
Optimizing Gpa1 Growth and Purification for Biophysical Studies 
While Gpa1 has been extensively characterized using genetics and molecular 
biology, few studies have been done on the biophysical properties of this substrate.  A 
better knowledge of Gpa1 structure and biophysical properties would allow us to generate 
hypotheses based on structural and biochemical analysis of Gpa1 in vitro and test their 
importance on Gα signaling and regulation in vivo.  In particular, we are interested in 
characterizing the role of the α-helical domain and ubiquitination in Gα-mediated 
signaling.  Biophysical analysis and chemical ubiquitination approaches require large 
quantities of protein.  Generating high quantities of pure Gpa1 in E.coli to complete these 
studies has been a barrier to progress in this area.  To overcome this problem, we used a 
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Figure 4.1.  Gpa1 Activity at the Plasma Membrane and Endosome.  Yeast mating 
response pathway is controlled by a G protein coupled system.  Pheromone binding to the 
receptor initiates exchange of GTP for GDP on Gpa1 and dissociation of Gβγ.  Gβγ 
activates a canonical MAP Kinase cascade.  Gpa1 can also be monoubiquitinated and 
trafficked to the endosome, where it activates PI3K.  When phosphorylated, Gpa1 is also 
a substrate of polyubiquitination. 
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number of approaches to optimize Gpa1 expression and purification.  The two primary 
problems with the standard purification were low protein yield and impurities in the final 
product, which required additional purification steps.  The low protein yield arose both 
from inefficient expression and the stability of the final product.  The impurities in the 
purification were likely due both to the inefficient expression of Gpa1 as well as the 
purification process.  Because Gpa1 is a yeast protein which we expressed in E. coli, the 
first step we took to overcome the inefficient expression of Gpa1 was to asses rare codon 
usage (281).  We found that 46% of the codons in Gpa1 were rare E. coli codons, which 
can significantly reduce the efficiency of expression (Figure 4.2a) (281).  To increase the 
expression of the protein in E. coli, we synthesized a Gpa1 construct that only uses 
common E. coli codons (Figure 4.2b-c).  We found that by removing rare codons, we 
increased the final protein yield 12-15 fold.  It is of note that we have also had success 
increasing our efficiency in expression through the use of auto-induction media (282).   
To increase the purity and stability of our final protein product, we optimized the 
construct length, buffers for purification, and purification method.  We chose to use a 
modified Gpa1 construct, Gpa1ΔN, which lacks the first 38 amino acids of the N-terminus.  
This construct was designed based on the crystal structure of Gαi, which shows that the 
analogous stretch of N-terminal amino acids are unstructured (144).  While removing 
these amino acids did not have a significant impact on protein expression levels, it did 
improve the lifetime and stability of the protein once purified, as assessed by decreased 
degradation and aggregation over time.  We optimized the buffers for purification by 
using a simple phosphate buffer system with high concentrations of TCEP (reducing 
agent) and GDP.  To speed up the process of purification and reduce expenses, Gpa1 was 
104 
 
 
 
Figure 4.2.  Optimization and Purification of Gpa1.  (a) Instances of rare codons in the 
sequence of yeast Gpa1 (scGpa1).  The x-axis is the codon window, a sliding window 
that averages 18 codons of the protein at a time.  The y-axis is a measure of the frequency 
of the codon usage in E. coli.  The higher the value, the more frequently the codon is 
used.  Negative values (shown in red), represent instances of rare codons.  (b)  Instances 
of rare codons in the sequence of Gpa1 codon optimized for expression in E. coli 
(coGpa1).  The x and y axes are the same as described in part (a)  (c)  Quantification of 
codons and their frequency of use for scGpa1 and coGpa1.  (d)  SDS-PAGE gel showing 
the result of the optimized purification of coGpa1ΔN. 
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purified using a batch purification protocol.  Finally, to improve both purity and protein 
stability, we cloned Gpa1 into the expression vector pQlinkH, which has a Tobacco Etch 
Virus (TEV)-cleavable His tag.  Instead of eluting the protein from the nickel beads at the 
end of purification, which would require imidazole as well as overnight dialysis to 
remove the imidazole, we added His-TEV to the beads for overnight cleavage.  While 
this method decreased the overall efficiency of the purification (only about half of the 
Gpa1 is cleaved from the beads), this loss in efficiency is compensated for by obtaining 
pure protein that does not require further dialysis or purification (Figure 4.2d).  Overall, 
our approach increased pure Gpa1 yield from 1.5 mg/L to 12 mg/L, which is sufficient 
for biochemical and structural studies.   
The Insert Domain of Gpa1 Does Not Alter Gpa1 Activity 
The site of ubiquitination on Gpa1 is on an insert, the ubiquitination domain, that 
is not found in other Gα proteins (279).   Based on sequence alignment with Gα proteins 
of the same subtype, the ubiquitination domain of Gpa1 is likely at the end of the A/B 
helix in the α-helical domain, as highlighted in Figure 4.3a.  The A/B helix is the region 
of the α-helical domain whose dynamics were previously shown to be important for 
modulating AtGpa1 activity (250).  Therefore, it is possible that the ubiquitination 
domain could play a role in regulating the activity of Gpa1.  To test this hypothesis, we 
removed the ubiquitination domain (Gpa1ΔNΔUD) determined whether the loss of this 
domain affected Gpa1 thermal stability and enzymatic activity.  As shown in Figure 
4.3b, removing the ubiquitination domain did not alter Gpa1 thermal stability, despite the 
loss of 109 amino acids.  Since the structure of Gpa1 has not been solved, it is not known 
if the ubiquitination domain contains secondary structure or is unstructured.  We 
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therefore used circular dichroism (CD) to determine if any secondary structure content 
was lost when the ubiquitination domain was removed.  The CD signature of Gpa1 was 
the same in presence and absence of the ubiquitination domain (Figure 4.3c), suggesting 
that the insert domain does not significantly contribute to the secondary structure content 
of the protein and is likely unstructured. 
While the thermal stability and secondary structure content of Gpa1 are the same 
in the absence of the ubiquitination domain, it is possible that the ubiquitination domain 
modulates Gpa1 activity due to its location adjacent to the A/B helix.  Therefore, we 
measured the ability of Gpa1 to bind, exchange, and hydrolyze nucleotide in the presence 
and absence of the ubiquitination domain.  As shown in Figure 4.3d, the rate of 
nucleotide dissociation was not altered by the absence of the ubiquitination domain.  
Furthermore, similar rates of nucleotide binding were obtained in the presence and 
absence of the ubiquitination domain (Figure 4.3e).  The assay used to measure 
nucleotide hydrolysis takes advantage of a nucleotide-dependent change in the intrinsic 
fluorescence of Gpa1 (283).  Although the overall intrinsic fluorescence of Gpa1 was 
reduced upon loss of the insert, the fluorescence changes associated with nucleotide 
dependent binding was retained.  Finally, the observed rate of GTP hydrolysis in 
Gpa1ΔNΔUD was identical to full length Gpa1ΔN (Figure 4.3f).  Together, these data 
suggest that the insert has evolved so its presence does not alter the enzymatic activity of 
Gpa1. Rather, we speculate that it functions as a site of post-translational modification for 
the purpose of trafficking to the vacuole (by monoubiquitination) or the proteasome (by 
phosphorylation and polyubiquitination). 
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Does Ubiquitination Alter Gpa1 Activity? 
 Because the ubiquitination domain does not influence Gpa1 activity, it is likely 
that monoubiquitination does not alter Gpa1 activity.  To address this question, it is 
necessary to obtain enough ubiquitinated protein for biochemical analyses.  We have 
already shown we can overcome challenges in obtaining adequate quantities of pure 
Gpa1.  We also have the ability to generate large quantities of monoubiquitinated 
substrate using our previously developed chemical ubiquitination approach (235).  This 
chemical ubiquitination approach requires mutation of the ubiquitination site on Gpa1 to 
a cysteine (K165C) and the use of Ubiquitin with a cysteine at the c-terminus (UbG76C).  
Gpa1 has seven native cysteines: two in the Ras-like domain, four in the α-helical 
domain, and one in the ubiquitination domain.  Our first attempts at ubiquitination 
employed Gpa1ΔN with a single background cysteine mutation (C208S).  We chose to 
mutate cysteine 208 because it is the only cysteine in the ubiquitination domain.  Since 
our previous data suggested that the ubiquitination domain lacks significant secondary 
structure, this cysteine is likely to be reactive.  We first used the published ubiquitination 
reaction conditions, which include overnight dialysis of the protein in the absence of 
reducing agent at pH 8.5 (235).  Chemical ubiquitination is performed at this pH because 
cysteines are most reactive above pH 8.0, where they are predominately in the thiolate 
species.  Unfortunately, the pI of Gpa1ΔN is close to 8.5, which leads to its destabilization 
under standard chemical ubiquitination conditions.  We tried a number of approaches to 
ubiquitinate Gpa1 at a lower pH including additives that might activate the cysteine 
(glutathione, copper).  We also tried ubiquitination reactions for shorter time periods at 
high pH.  After one hour of dialysis at pH 8.0 we obtained 10 % monoubiquitinated 
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Gpa1.  We tried to separate this small population of monoubiquitinated Gpa1 using gel 
filtration, ion chromatography, or affinity chromatography using a His-tag on Ubiquitin.  
Unfortunately, the yield from gel filtration or ion chromatography was not sufficient for 
biochemical analysis.  Ubiquitination of Gpa1 with His-Ubiquitin was also not successful 
because His-Ubiquitin aggregates above pH 8, making the ubiquitination reaction 
significantly less efficient. We therefore decided to return to the full-length Gpa1 
construct, which has a predicted pI of 7.5, suggesting it is much more likely to be stable 
at a pH above 8.0.  For the first experiments, we used Gpa1WT with no background 
mutations and Gpa1K165C.  Over four hours of dialysis in the absence of reducing agent, 
we observed a significant loss of Gpa1WT, but less loss of Gpa1K165C, suggesting that a 
modification at that site may be stabilizing the protein (Figure 4.4).  However, we were 
unable to clearly observe modification by ubiquitination in the presence of K165C.  
Finally, we could not find conditions under which Gpa1 remained stable and adequate 
ubiquitination occurred. 
Changes in the α-Helical Domain of Gpa1 Influence its GTPase Activity 
 It has recently come to light that the α-helical domain influences the activity of 
Gα proteins (140, 250).  Direct evidence has shown that the activity of the Gα proteins in 
mammals and plants are influenced by dynamics of the α-helical regions (250).  While 
Gpa1 has a ubiquitination domain inserted into the α-helical domain, we have already 
established that the presence of this domain does not alter Gpa1 activity.  Therefore, we 
considered whether changes to the adjoining α-helical domain of Gpa1 could alter the 
function of the Ras domain, similar to mammalian Gα proteins.  To test this hypothesis, 
we made point mutations in the α-helical domain of Gpa1 and measured the effect on 
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Gpa1 stability and activity.  We chose to mutate the five cysteines in the α-helical domain 
since they represent a spread of the types of residues important in Gpa1 (Figure 4.5a).  
Two of these cysteines are buried and conserved within other Gα proteins in the same 
family as Gpa1, two cysteines are near the A/B helix whose dynamics were shown to be 
important in modulating the activity of plant and mammalian Gα activity, and one 
cysteine is proximal to the site of ubiquitination.  We made a single mutation at the 
cysteine in the ubiquitination domain (Gpa1ΔNC208S) as well as a mutant that has all five 
cysteines replaced with serines in the α-helical domain (Gpa1ΔNCαS).  In both constructs, 
no changes made to the two cysteines present in the Ras-like domain.  We first used 
fQCR to measure the thermal stability of Gpa1ΔNC208S and Gpa1ΔNCαS.  As seen in Figure 
4.5b, we found that while mutation of the single cysteine near the site of ubiquitination 
did not have a significant effect on protein stability, simultaneous mutation of all five 
cysteines in the α-helical domain significantly destabilized the protein.  Furthermore, in 
the presence of the α-helical domain mutations, Gpa1ΔNCαS is no longer thermally 
stabilized by the addition of GTPγS (Figure 4.5c).  This suggests a possible change in the 
affinity of Gpa1 for nucleotide.  We next used intrinsic fluorescence to measure rates of 
GTPγS binding and GTP hydrolysis.  While mutation of the cysteine within the 
ubiquitination domain alone does not alter Gpa1 activity, we observed a significant 
decrease in the rate of GTP hydrolysis in Gpa1ΔNCαS (Figure 4.5d).  Thus, changes in the 
α-helical domain can influence the stability and enzymatic activity of Gpa1.  Taken 
together, these data show that changes to the α-helical domain of Gpa1 can alter the 
function of the Ras-like domain of the protein. 
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Figure 4.3.  The Insert Domain of Gpa1 Does Not Alter Gpa1 Activity.  (a) Structure of 
Gαi showing the location of the ubiquitination domain based on sequence alignment, in 
magenta.  The Ras-like domain is shown in green and the α-helical domain is shown in 
blue.  (b) Thermal stability curves showing no difference between Gpa1ΔN and 
Gpa1ΔNΔUD.  (c) Secondary structure content of Gpa1ΔN and Gpa1ΔNΔUD measured by 
circular dichroism. (d) Mant-GDP dissociation curves for Gpa1ΔN and Gpa1ΔNΔUD. 
Dissociation was monitored following the decrease in fluorescence emission over time 
following the addition of unlabeled GDP. Data were fit to an exponential dissociation 
curve, and the results are the mean ± s.d. (n=4).  (e) Mant-GDP association curves for 
Gpa1ΔN and Gpa1ΔNΔUD. Data were fit to an exponential association curve. The results are 
the mean ± s.d. (n=4).  (f) Intrinsic hydrolysis data for Gpa1ΔN and Gpa1ΔNΔUD. 
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Figure 4.4.  Time Course of Gpa1 Ubiquitination.  SDS-PAGE gel of Gpa1WT and 
Gpa1K165C in the presence of Ubiquitin over a 4 hour time frame under (a) non-reducing 
and (b) reducing conditions.    
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Figure 4.5.  Changes in the α-Helical Domain of Gpa1 Influence its Enzymatic Activity.  
(a) Structure of Gαi, showing the location of the cysteines in Gpa1 based on structural 
alignment.  Cysteines in orange are conserved between Gα proteins, while cysteines in 
yellow are present in Gpa1 but not Gαi .  (b) Thermal stability of Gpa1ΔN, Gpa1ΔNC208S, 
and Gpa1ΔNCαS measured by 4 –Fluoro–7–aminosulfonylbenzofurazan (ABD–F) 
incorporation as a function of temperature in the presence of GTPγS. The data were 
normalized using the maximum fluorescence intensity. Results are the mean ± s.d. (n=4). 
(c)  Thermal stability of Gpa1ΔNCαS in the presence of GDP and GTPγS.  (d) Intrinsic 
fluorescence was used to measure GTPγS binding and GTP hydrolysis in Gpa1ΔN, 
Gpa1ΔNC208S, and Gpa1ΔNCαS.  Data were normalized to the maximum signal achieved in 
each experiment upon completion of GTPγS binding. 
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Discussion 
It has long been known that G protein signaling is highly dynamic and tightly 
regulated.  Recent findings indicate that these properties are not confined to the G Ras-
like domain, but may extend to the α-helical domain as well.  In addition, Gpa1 has a 
unique domain that is subject to phosphorylation and ubiquitination.  Here we used 
biochemical and biophysical approaches to demonstrate that the ubiquitination domain of 
Gpa1 functions independently of its enzymatic activity. Most strikingly, we were able to 
remove the ubiquitination domain without affecting nucleotide binding or hydrolysis. 
These results are particularly striking given that (a) the ubiquitination domain is located 
near a key dynamic region of the α-helical domain, (b) the ubiquitination domain is 
essential for transport to the endosome (260), and (c) there are a number of unique 
binding partners that specifically regulate post-translational modification of the 
ubiquitination domain.  We conclude that the ubiquitination domain evolved to serve a 
unique trafficking function, and that this function is wholly separate from the regulation 
of G protein catalytic activity. 
The ubiquitination domain is phosphorylated, polyubiquitinated, and 
monoubiquitinated. Recent work from our lab has identified the enzymes that add and 
remove these post-translational modifications (280, 284).  One kinase responsible for 
phosphorylation of Gpa1 is Elm1, which had been identified by screening a panel of 
yeast kinase deletion strains for those necessary for proper Gpa1 phosphorylation (285). 
We have since shown that Elm1 and two related kinases, Sak1 and Tos3, also 
phosphorylate Gpa1 under glucose-starved conditions. Conversely, the Reg1/Glc7 
phosphatase complex is needed to dephosphorylate Gpa1 (Clement, manuscript under 
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review). Finally, we have shown that the ubiquitin ligase SCF-Cdc4 is necessary and 
sufficient for polyubiquitination of Gpa1 (280), while the HECT ubiquitin ligase Rsp5 is 
responsible for monoubiquitination of Gpa1 (284). This list of binding partners includes 
only those that are known to form an interaction with the ubiquitination domain.  
However, we anticipate that monoubiquitination acts to regulate the binding of additional 
proteins that deliver Gpa1 to the endosome and vacuole.   
Once at the endosome, Gpa1 transmits a signal via two subunits of 
phosphatidylinositol 3-kinase (Vps15 and Vps34). Thus it will be interesting to determine 
if these proteins also bind to the ubiquitination domain of Gpa1. In comparison, it seems 
unlikely that proteins involved in Gpa1 signaling at the plasma membrane, including the 
pheromone receptor Ste2 (286), Gβγ subunit Ste4/Ste18 (287), GTPase accelerating 
protein Sst2 (288), and non-receptor exchange factor (Get3), would be affected by Gpa1 
monoubiquitination. 
Given that the ubiquitination domain is found exclusively in Gpa1, information 
concerning its activities may not be directly relevant to other Gα proteins. Nevertheless 
our investigation has the potential to reveal structural determinants that promote protein 
ubiquitination. In particular, little is known about what makes a protein a good substrate 
for monoubiquitination vs. polyubiquitination. Gpa1 is a substrate of both types of 
ubiquitination, and these modifications are mediated through two distinct ubiquitination 
ligases.  One distinguishing feature of polyubiquitination is that phosphorylation of the 
ubiquitination domain is required for SCF-Cdc4 to bind to Gpa1 (285). Conversely, it is 
likely that monoubiquitinated Gpa1 will not be recognized as a substrate for 
polyubiquitination.  Structural analysis of the Gpa1 ubiquitination domain, before and 
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after phosphorylation, monoubiquitination and polyubiquitination, could reveal 
distinguishing features of the two processes. 
Our analysis may also lead to insights into the function of unique domains in 
other GTPases.  While no mammalian Gα proteins contain an insert similar to Gpa1, 
there are other families of small GTPases that are known to contain inserts within their 
highly conserved Ras-like domains.  For example, members of the Rho family of small 
GTPases have a unique insert, called the Rho insert, that is not present in other small 
GTPases (289).  The presence or absence of the Rho insert does not alter the intrinsic 
activity of these small GTPases (290) .  When the insert is absent however, Rho can bind, 
but no longer activate, its downstream effector Rho kinase (290).  There is additional 
evidence showing that the Rho insert participates in other effector-mediated functions 
such as cytoskeletal remodeling and Nox regulation (291).  However, the mechanism 
through which the insert domain contributes to regulation is not known.  Finally, the Rho 
insert in Rac1 was recently shown to be monoubiquitinated (157).  While no function has 
yet been assigned to monoubiquitination of Rac1, it is possible that this modification 
could be involved in the mechanism by which Rho interacts with downstream effectors, 
similar to our proposal that Gpa1 monoubiquitination in the ubiquitination domain alters 
interactions with select protein binding partners. 
Our understanding of the signaling and regulation of Gα proteins continues to 
evolve despite several decades of intensive investigation. Here, we present evidence that 
the α-helical domain regulates the stability as well as the enzymatic activity of the 
protein, and does so independently of the ubiquitination domain. More broadly our work 
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in vitro points to a number of potential experiments using the yeast model system to 
understand the impact of the α-helical domain on Gα signaling in vivo. 
 
Methods 
Protein Expression and Purification 
Gpa1 containing a cleavable (Tobacco Etch Virus (TEV)) N-terminal His tag was 
expressed in the pQlinkH vector (Addgene) in E. coli BL21 (DE3) RIPL cells 
(Stratagene: La Jolla, CA).  Cells were lysed by homogenization (NanDeBee) at 1000 psi 
in 25 mM potassium phosphate buffer with 300 mM KCl and 250 μM TCEP.  After 
clarification by centrifugation, the lysate from 500 ml of cells was bound to 1 ml Ni-NTA 
agarose bead slurry (Qiagen) for 20 min at 4oC.  The beads were washed three times with 
lysis buffer, then three times with 25 mM phosphate buffer, pH 7.0, 100 mM KCl, 100 
μM GDP, and 500 μM TCEP.  Gpa1 was cleaved from the beads overnight by incubation 
with TEV.  The final product was judged > 95% pure by SDS–PAGE.  UbiquitinG76C was 
expressed in the pQlinkH vector system and purified following standard Qiagen nickel 
affinity purification procedures. The His tag was cleaved overnight with TEV. Ubiquitin 
was further purified by removal of uncleaved protein using Ni–NTA agarose beads 
(Qiagen). The final product was judged > 95% pure by SDS–PAGE. Proteins were stored 
in 20 mM HEPES, pH 8.0, 50 mM NaCl and 500 μM TCEP.  
Thermal Stability of Gpa1 
The fast quantitative cysteine reactivity (fQCR) method (182) was employed to 
measure changes in Gpa1 thermal stability. Briefly, 2 μM protein was incubated with 1 
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mM 4-fluoro-7-aminosulfonylbenzoflurazan (ABD–F, Anaspec) at pH 7.0 in the 
presence of 20 μM GDP or GTpγS and 2 mM MgCl2 at the desired temperature for three 
minutes.  The reaction was quenched with HCl and ABD-F fluorescence was measured 
on a PHERAstar plate reader (BMG Labtech, excitation at 400 nm and emission at 500 
nm). The data were normalized and fit to determine the temperature at which half the 
protein was unfolded, representing the melting temperature (Tm).  
Circular Dichroism 
Circular Dichroism (CD) experiments were performed from 190 nm – 260 nm on 
a Chirascan plus CD spectrometer.  Spectra of 5 μM protein were recorded in 25 mM 
Potassium Phosphate buffer, pH 7.0, 100 mM KCl, 50μM GDP, 50 μM MgCl2, and 550 
μM TCEP at 25oC using a 1 mm quartz cell.  Buffer background was subtracted from the 
spectra. 
MANT-Nucleotide Association and Dissociation Assay 
Gpa1 was exchanged into 25 mM potassium phosphate buffer, pH 7.0, 100 mM 
KCl, 50 μM MgCl2, and 100 μM GDP. To initiate association, 1 μM Mant-GDP was 
added to 1 µM protein. Gpa1 was determined to be fully loaded when the fluorescence 
intensity reaches a maximum at approximately 250 sec.  Association was measured as a 
change in fluorescence intensity over time (excitation: 360 nm, emission: 440 nm) 
(LS50B Perkin–Elmer Luminescence Spectrometer).  MANT-GDP dissociation was 
initiated by the addition of 500 μM unlabeled GDP.  Fluorescence data were fit in 
GraphPad Prism (GraphPad Software; San Diego, CA) to a one–phase exponential 
association or decay curve. Results are the mean ± s.d. (n=4). 
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Intrinsic GTP Binding and Hydrolysis 
Purified Gpa1 (200 nM) was equilibrated in a cuvette with 25 mM phosphate 
buffer, pH 7.0, 100 mM KCl, and 50 μM MgCl2.  GTP or GTPγS at a final concentration 
of 200 nM was added to the cuvette, and either GTPγS binding or GTP hydrolysis was 
monitored by the change in intrinsic fluorescence of Gpa1 that occurs upon 
rearrangement of the tryptophan near the nucleotide binding region (excitation at 284 nm 
and emission at 340 nm).  Data was collected on a Perkin Elmer Luminescence 
Spectrometer and analyzed using GraphPad Prism (GraphPad Software; San Diego, CA). 
Chemical Ubiquitination 
The chemical ligation strategy used to link Gpa1 to UbiquitinG76C was adapted 
from Baker et al (235). Briefly, a ten–fold excess of UbiquitinG76C was added to 
Gpa1K165C and dialyzed into 20 mM Tris, pH 8.0, 50 mM NaCl, 5 mM MgCl2, and 50 μM 
GDP at 4 oC for 4 hours. The amount of disulfide complex formation was determined by 
non–reducing SDS–PAGE.  
  
  
CHAPTER V 
 
CONCLUSIONS AND FUTURE DIRECTIONS1 
 
The regulation of cell signaling is essential for maintaining normal, healthy cells.  
Key to the proper function and specificity of signaling pathways is the use of post-
translational modifications to regulate protein abundance, localization, and activity.  
Monoubiquitination is one dynamic and reversible post-translational modification that is 
emerging as an important regulator of signaling pathways.  Regulation by 
monoubiquitination acts on the level of protein trafficking, gene expression, and in some 
cases protein activity.  Because the diverse roles of monoubiquitination in cell signaling 
have only recently been recognized, very little work has been done to pursue the 
mechanisms by which monoubiquitination regulates substrates.  However, preliminary 
data suggest that biochemical and biophysical approaches, when coupled with in vivo 
data, can be a powerful tool for understanding how monoubiquitination fine-tunes cell 
maintenance and signaling.     
In this dissertation, we report the development of a validated chemical approach 
to study monoubiquitinated substrates.  This approach was optimized not only to 
completely modify the substrate of interest, eliminating the need for additional 
purification steps, but also to be a simple and accessible tool for use by scientists who 
                                                 
1 All figures contributed by Rachael Baker 
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already study monoubiquitination by other methods.  We used our chemical 
ubiquitination system to study the mechanism by which monoubiquitination regulates 
multiple isoforms of the small GTPase Ras.  We showed that monoubiquitination at K147 
activates K-Ras by impeding GAP-mediated GTP hydrolysis and that monoubiquitination 
at K117 activates H-Ras by increasing the rate of intrinsic nucleotide exchange.  These 
studies demonstrated not only that the effects of ubiquitination on a substrate can be site-
specific, but that two isoforms of Ras are differentially monoubiquitinated within the 
same cell.  Therefore, monoubiquitination represents both a new mechanism of Ras 
signaling regulation as well a new mechanism by which Ras isoforms are potentially 
differentiated.  Finally, we turn our attention to a heterotrimeric GTPase, Gpa1, which is 
a substrate of both polyubiquitination and monoubiquitination.  Using biochemical 
approaches, we show that this protein has uniquely evolved a domain for post-
translational modification by ubiquitination, and that this domain does not interfere with 
α-helical domain modulation of Gpa1 activity.  Here, monoubiquitination is likely 
important for trafficking but not the direct regulation of Gpa1 activity.   
The studies described in this dissertation highlight three unique cases in which a 
GTPase is regulated in a unique manner by monoubiquitination.  Furthermore, this work 
highlights the importance of using multiple approaches to understand the role of post-
translational modifications in protein regulation. In this last chapter, I will relate the work 
in this dissertation to what is already known about the regulation of both Ras and Gpa1 
and discuss its implications.  I will also present some preliminary studies that highlight 
the future directions the research on each of these proteins may take.  Finally, I will 
discuss possibilities for the future direction of monoubiquitination research in general. 
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Chemical Ubiquitination 
One of the challenges of studying monoubiquitinated substrates is that it requires 
modifying a protein with a second protein.  This makes the study of ubiquitination 
difficult for two reasons.  First, the native ubiquitination process, involving multiple 
enzymatic steps, is challenging to reconstitute in vitro and is often much less efficient and 
site-specific than it would be in vivo. This could potentially complicate the results of 
biochemical and biophysical studies since site-specificity is often important for the 
mechanism of regulation by ubiquitination.  Furthermore, biochemical studies require 
significant amounts of protein, which is difficult to generate through native ubiquitination 
approaches.  Second, there are a number of biophysical approaches, like CD, that give 
readouts of the total protein population and these approaches cannot be used to 
specifically observe the effects of monoubiquitination on the substrate itself.  Other 
approaches, like NMR and crystallography, allow specific observation of the substrate 
separate from the Ubiquitin modifier, but if the ubiquitination reaction is inefficient, the 
costs of generating enough pure, properly labeled (NMR) substrate may be prohibitive. 
Chemical ubiquitination is a powerful approach to study ubiquitinated substrates 
and can overcome a number of the challenges described in the previous paragraph.  The 
chemical ubiquitination reaction is site-specific since it occurs at a site modified through 
mutagenesis (235).  The reaction is also very efficient, in some cases leading to complete 
substrate modification.  This approach decreases the cost of generating 
monoubiquitinated substrates and makes it feasible to do experiments that require large 
quantities of protein.   
122 
 
In the work described here, we took advantage of a chemical ubiquitination 
approach coupled with powerful methods to study ubiquitinated substrates.  For example, 
we selectively 15N-labeled Ras and monoubiquitinated it with unlabeled Ubiquitin as well 
as 15N- enriched Ubiquitin and used it to monoubiquitinate unlabeled Ras.  These 
approaches allowed us to observe the effects of monoubiquitination on the structure and 
dynamics of Ubiquitin and Ras individually.  We also took advantage of the unique 
properties of fast quantitative cysteine reactivity (fQCR) to measure substrate thermal 
stability.  The fQCR assay gives information about protein thermal stability by labeling 
accessible cysteines as a function of temperature.  Because Ubiquitin does not have any 
cysteines (except the one we introduced to form the disulfide bond in our chemical 
ubiquitination system), this assay specifically measures the thermal stability of the 
substrate itself.  A chemical ubiquitination approach coupled with these types of 
biochemical and biophysical experiments make it possible to elucidate mechanisms by 
which substrates are regulated by monoubiquitination. 
Chemical Ubiquitination Strategies 
There are numerous published approaches to chemically ubiquitinating a 
substrate.  Here I will discuss three primary strategies used as well as their disadvantages 
and advantages.  For a comprehensive review of the chemistry behind each approach, see 
one of the following reviews (106, 292).  There are: chemical approaches for generating 
an isopeptide bond linkage, synthesis or semi-synthesis of ubiquitinated substrates, and 
the use of isopeptide bond surrogates.  For a summary of the types of linkages generated 
in these various approaches, see Figure 5.1.  First, there are numerous examples of using 
synthetic and organic chemistry to generate the same isopeptide bond that is formed in 
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enzymatic ubiquitination (Figure 5.1a).  Many of these approaches require the use of 
non-natural amino acids coupled with intein-activated ubiquitin (293, 294) to protect the 
site of ubiquitination.  In other approaches, native protein is used, and the lysine is 
chemically modified after protein expression (295-297).  These novel approaches have all 
been developed recently and have the advantage of precisely mimicking enzymatic 
ubiquitination (298-300).  However, the disadvantage of these approaches is that the 
chemistry is very slow, in some cases taking a week to complete (106).  Furthermore, the 
multiple steps in many of the chemical synthesis approaches leads to low yields of 
modified substrate (292). 
The second approach to generating monoubiquitinated substrate involves either 
the synthesis or semi-synthesis of the final modified protein.  A number of the 
biophysical studies of ubiquitinated substrates discussed in the introduction were done 
through these methods, including studies of monoubiquitination of histone H2B (107, 
108), PCNA (109, 110), and α-synuclein (114).  In these approaches, the simplest 
strategy is to express the substrate in two separate pieces, with one piece being expressed 
tandem to Ubiquitin (Figure 5.1b).  In more complex approaches, expression of the split 
substrate is coupled with the organic synthesis approaches above to generate the final 
ubiquitinated substrate (106).  This approach generates large quantities of stable substrate 
for study by biochemical approaches.  However, it is a viable approach for only a limited 
number of substrates.  For this approach to work, substrate structure must be known, the 
substrates must be amenable to expression in two separate pieces, and methods to 
validate the correct reassembly of the monoubiquitinated substrate are necessary.  
Furthermore, additional studies with histone H2B showed that not all semi-synthesis 
124 
 
approaches are successful.  While one approach did lead to generation of 
monoubiquitinated H2B that accurately mimicked natively modified protein, this 
approach was very inefficient and time consuming (107, 108).  When the authors tried to 
adopt more efficient strategies to generate monoubiquitinated H2B, the native structure of 
the protein was compromised (293, 301).    
The third strategy for generating monoubiquitinated substrate is to use isopeptide 
bond surrogates.  The primary goal of these types of strategies is to simplify highly 
technical synthesis approaches while still producing stable monoubiquitinated substrate.  
In some cases, a non- natural amino acid is used, often a pyrrolysine analog, on the 
substrate, and the Ubiquitin is linked through intein-based approaches or another 
genetically encoded non-natural amino acid (Figure 5.1c)  (301-303).  However, this 
approach does not always successfully recapitulate the in vivo effects of ubiquitination 
(301).  In other cases, chemical synthesis of the lysine or cysteine after protein expression 
is used to link the protein to processed Ubiquitin (Figure 5.1d) (304).  One common 
form of this approach is called click chemistry and requires an alkylated cysteine residue 
and intein-Ubiquitin that has been processed with aminolysis (Figure 5.1e) (305).  One 
of the simplest approaches, however, is to use a disulfide bond as a replacement for the 
chemical bond (Figure 5.1f) (109, 301, 306).  In many of these examples, the Ubiquitin 
is expressed through an intein based approach and organic molecules are used to make 
the linker closer in length to the enzymatic linker (Figure 5.1g) (307).  The advantage of 
these types of approaches, especially the disulfide chemistry, is that they are faster and 
easier than chemically synthesizing the enzymatic linkage.  However, little work has been  
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Figure 5.1.  Native and Chemical Ubiquitination Linkages.  (a) Ubiquitin (Ub) substrate 
linkage generated through enzymatic ubiquitination or a chemical method for 
constructing an isopeptide bond.  (b) An example of one straightforward strategy for the 
semi-synthesis of monoubiquitinated substrate.  (c) Isopeptide bond surrogate obtained 
from a genetically encoded pyrrolysine analog on the substrate and intein-Ubiquitin.  (d) 
Isopeptide bond surrogate obtained from chemical synthesis of the substrate.  (e) 
Isopeptide bond surrogate obtained from substrate with an alkylated cysteine and intein-
Ubiquitin that has undergone aminolysis.  (f)  Isopeptide bond surrogate generated from 
cysteine mutation on the substrate and Ubiquitin.  (g) Isopeptide bond surrogate obtained 
from a cystine mutation on the substrate processed with dichloroacetone and intein-
Ubiquitin. 
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done to validate how successfully these individual approaches mimic the behavior of 
substrate modified by the native ubiquitination linkage. 
While each approach for chemical ubiquitination has advantages and 
disadvantages, the most successful approaches will likely involve the isopeptide bond 
surrogates.  This ubiquitination approach does not require the advanced chemical 
knowledge of the more involved synthetic approaches and provides higher substrate 
yields than possible through the synthesis of an isopeptide bond.  Isopeptide bond 
surrogates are also more likely than the semi-synthesis approaches to work on a broad 
array of substrates.  We were particularly interested in the disulfide chemistry approaches 
because they represented the simplest and fastest way to generate monoubiquitinated 
substrate (Figure 5.1f).  However, even within this disulfide approach there are 
discrepancies in the methods used and the final outcome.  Representative studies that use 
a basic disulfide approach are described in Table 5.1 (174, 177, 235, 308).  As 
summarized in the table, we improved on existing methods by eliminating the need for 
additives like copper and driving substrate modification to 100% using excess Ubiquitin 
and a pH of 8.5, which fully activated the cysteines.  This simple and efficient approach 
is accessible to anyone who has the ability to purify proteins.  Furthermore, as described 
in Chapter II, using assays in cell lysate as well as computational modeling, we validated 
that the differences in linkage length and rotational preferences did not have a significant 
effect on the biochemistry of monoubiquitination (235). 
However, as evidenced by the work with Gpa1 in Chapter IV, there are 
limitations to this method.  There were two main reasons why our chemical 
ubiquitination approach was not successful for Gpa1.  The problems were [1] that Gpa1 
  
Substrate Disulfide Bond Strategy Buffer pH 
Additional 
Notes 
Amount 
Modified Publication 
Ubc1 
Cys mutation 
on substrate and 
Ubiquitin 
100 mM 
HPO4 
100 mM NaCl 
10 μM CuCl2 
 
7.5 
Substrate pre-
reduced with 
TCEP 
100% 
Merkley et al. (2005) Ubiquitin 
Manipulation by an E2 Conjugating 
Enzyme Using a Novel Covalent 
Intermediate, J Biol Chem 280, 31732-
31738. 
UbcH7 
Cys mutation 
on substrate and 
Ubiquitin 
100 mM 
HPO4 
100 mM NaCl 
10 μM CuSO4 
 
8.0 
Substrate pre-
reduced with 
βME 
> 50% 
Purbeck et al. (2009) Kinetics of the 
Transfer of Ubiquitin from UbcH7 to 
E6AP, Biochemistry 49, 1361-1363. 
PCNA 
Cys mutation 
on substrate and 
Ubiquitin, 
linked with 1,3-
Dichloroacetone 
200 mM 
sodium borate 
 
8.6 
Substrate pre-
reduced with 
βME 
60%-70% 
Carlile et al. (2009) Synthesis of Free 
and Proliferating Cell Nuclear Antigen-
bound Polyubiquitin Chains by the 
RING E3 Ubiquitin Ligase Rad5, 
Journal of Biological Chemistry 284, 
29326-29334. 
Ras 
Cys mutation 
on substrate and 
Ubiquitin 
20 mM Tris 
50 mM NaCl 
 
8.5 
Substrate pre-
reduced with 
TCEP 
10-fold excess 
Ubiquitin 
100% 
Baker et al. (2013) Site-specific 
monoubiquitination activates Ras by 
impeding GTPase-activating protein 
function, Nature Structural and 
Molecular Biology 20, 46-52. 
 
Table 5.1.  Summary of Disulfide Chemical Ubiquitination Approaches.  First column describes the substrate modified.  
Second column summarizes the strategy used to generate the disulfide bond.  Third column has the buffer components under 
which the disulfide formation reaction was performed, with the pH listed in column four.  The fifth column describes any other 
key differences between the ubiquitination approaches.  The efficiency of the reaction is summarized in column six, and 
column seven contains the original publication in which the experiment was performed. 
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had a number of cysteines, and mutation of a significant number of cysteines altered the 
biochemical activity of the protein and [2] due to its predicted pI of pH 8.5 Gpa1 was not 
stable at pH 8-8.5, where cysteines are most reactive.  Further plans for modifying Gpa1 
will be discussed in the section specifically dedicated to Gpa1.  It is important to note, 
however, that the reasons that Gpa1 was not amenable to our chemical ubiquitination 
approach would also make it a poor candidate for many of the other chemical methods 
described above.  This result highlights that while chemical ubiquitination will likely be a 
widely successful approach for studying monoubiquitinated substrates, it is not a 
universal solution to the challenge of studying these substrates in vitro. 
 
Regulation of Ras by Monoubiquitination 
In Chapters II and III, we used a combination of computational, structural, and 
biochemical approaches to show that when K-Ras is monoubiquitinated at K147, but not 
K104, it is activated by impairing GAP-mediated hydrolysis (235).  Furthermore, when 
H-Ras is monoubiquitinated at K117, it is activated due to an increased rate of intrinsic 
nucleotide dissociation, distinct from the mechanism of K-Ras activation.  Together, 
these data describe a new mechanism for the regulation of Ras activity through reversible 
post-translational modification by monoubiquitination.  This mechanism is distinct for 
two Ras isoforms, H-Ras and K-Ras, which may contribute to the differences between 
these isoforms in vivo.  We also showed that the mechanism of activation is site-specific, 
similar to the ubiquitination of α-synuclein (114) but distinct from ubiquitination of 
PCNA (110).  Finally, our use of NMR as well as PDZ modification of Ras showed that 
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the effects of monoubiquitination at K147 are mediated by low-affinity, non-specific 
interactions between Ras and Ubiquitin rather than a specific, high-affinity interaction. 
Future Questions and Experiments for K-Ras Ubiquitination at K147 
 There are four questions that directly arise from the studies of K-Ras 
monoubiquitination at K147.  First, the mechanism by which Ubiquitin regulates Ras 
through non-specific interactions is not clear.  There may be a surface on Ras where 
Ubiquitin spends a significant amount of time.  Second, while we demonstrated that 
monoubiquitination alters the dynamics of Ras in the GDP-bound state, we do not know 
if it also alters switch dynamics in GTP-bound state and how that difference might 
contribute to its mechanism of activation.  Third, we do not know the mechanism by 
which GAP-mediated catalysis is impaired.  We showed that GAP still binds to Ras, but 
we do not know if the binding affinity is reduced or if the GAP binds Ras in the proper 
orientation.  Furthermore, the same GAP deficiency is not observed with the shorter and 
stiffer PDZ linker.  Finally, we have not explored how monoubiquitination of Ras at 
K147 increases the affinity of GTP-bound mUbRas for select downstream effectors.   
To answer the first question about how Ubiquitin regulates Ras through non-
specific interactions, we need to know more about how Ubiquitin dynamically samples 
conformational space surrounding Ras.  We also need to further quantify the observed 
changes in the switch region dynamics.  Our evidence that Ras does not form specific 
interactions with Ubiquitin comes from the work we did with NMR showing no specific 
shifts are observed when Ras is monoubiquitinated as well as the data showing that 
ligation of PDZUL to Ras can recapitulate the effects of monoubiquitination in terms of 
impairing GAP-mediated hydrolysis.  The first step to address these questions would be 
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to more extensively characterize GDP-bound mUbRas by NMR.  The types of 
experiments that would help us understand the behavior of Ubiquitin relative to Ras 
include hydrogen exchange (308) and Cleanex (309), relaxation experiments (310), and 
cross correlation relaxation experiments (311-313).  The information we could obtain 
from each of these experiments individually is summarized in Table 5.2.  Overall, these 
experiments will provide information about the specific surface on Ras that can come in 
contact with Ubiquitin and about whether Ubiquitin and Ras act as a single unit or move 
independently of one another.   
Pursuing the differences between Ubiquitin and PDZ ligation will also aid in 
understanding regulation of Ras by monoubiquitination.  Specifically, we would like 
repeat our HSQC NMR experiments with Ras ubiquitinated with Ubiquitin with the PDZ 
linker and Ras modified with PDZ with the native linker to determine if we still observe 
altered switch region dynamics.  If switch region dynamics change similar to mUbRas, it 
would suggest that this is a side effect, rather than the central mechanism, through which 
monoubiquitination regulates Ras.  If we do not observe changes in switch region 
dynamics, it would suggest that even though Ubiquitin and Ras do not form high affinity 
binding interactions, the ability of Ubiquitin to physically access a specific surface on 
Ras is necessary for its modulation of switch region dynamics in the GDP-bound state of 
the protein. 
In conjunction with our experimental approaches, we are also pursuing molecular 
dynamic simulations of mUbRas in collaboration with Brenda Temple at UNC.  While 
we have only done preliminary 20 ns and 200 ns simulations of mUbRas (without 
constraints), we observed that Ubiquitin spends a significant amount of time near the 
  
NMR Approach Information Obtained Contribution to Mechanistic Knowledge 
Hydrogen Exchange 
determine which amide resonances 
show enhanced protection when Ras 
is ubiquitinated 
may indicate interaction sites within or outside of the 
switch regions that become less accessible to the 
solvent in mUbRas, indicating a region where 
Ubiquitin spends a significant amount of time 
Cleanex 
measure exchange rates for residues 
that may be too fast to be detected by 
hydrogen exchange 
same information as obtained from hydrogen exchange 
Relaxation 
(a) overall rotational tumbling time  
(b) the order parameter (a measure of 
rigidity) 
(c) internal motion for each 
observable backbone amide 
resonance  
The rotational correlation time of Ras with and without 
ubiquitination will be used to determine if the two 
proteins tumble as independent domains or if their 
motions are correlated.   
Comparing relaxation parameters will provide 
additional quantification of differences in the backbone 
dynamics when Ras is ubiquitinated on the 
picosecond/nanosecond as well as milisecond 
timescales.   
Cross Correlation Relaxation torsion angle restraints at the site of Ubiquitin linkage to Ras 
Parameters to be used for computational modeling of 
mUbRas 
 
 
Table 5.2.  Proposed NMR Experiments for the Study of mUbRas.  All experiments would be done with 15N-Ras and 15N-Ras 
ubiquitinated with unlabeled Ubiquitin.  First column lists the type of experiment (references provided in main text).  Second 
column described the information that can be obtained from doing the experiment with unmodified and monoubiquitinated.  
The final column describes how the information obtained will contribute to our understanding of how Ras is regulated by 
monoubiquitination.  
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surface of Ras (Figure 5.2).Sometimes Ubiquitin is found interacting with the switch I 
region of Ras and sometimes with residues opposite the switch regions.  These 
preliminary findings that Ubiquitin forms transient interactions with Ras are consistent 
with the broadening we observed near the site of ubiquitination and on the surface of 
Ubiquitin itself through NMR.  Furthermore, in our preliminary studies of 15N-enriched 
Ubiquitin, we observed that few Ubiquitin backbone amides were altered by 
monoubiquitination, which suggests that Ubiquitin undergoes only local perturbations 
upon ligation.  The same residues that were broadened on Ubiquitin by NMR are the 
residues that make contact with the surface of Ras during the MD simulations.  These 
data suggest that these MD simulations may aid in understanding how the experimental 
constraints determined by our proposed NMR experiments contribute the behavior of 
Ubiquitin on Ras. 
The second question relates to whether monoubiquitination alters the dynamics of 
the switch regions of Ras in the GTP-bound state of the protein.  When Ras binds GTP, it 
restricts conformational sampling of the diverse possible positions of the switch regions 
(118, 139).  If ubiquitination limits dynamics of the switch regions in the GDP-bound 
state, it does not mean that the same changes will be observed in the less 
conformationally dynamic GTP-bound state of the protein.  NMR is again an ideal 
method to use for this characterization because it provides site-specific dynamic and 
structural information. We have optimized a procedure to load mUbRas with a non-
hydrolyzable GTP analog (GMPPNP) so that we can characterize the GTP-bound state of 
mUbRas by NMR.  We will use the same types of approaches described above 
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Figure 5.2.  Preliminary Molecular Dynamics Simulations of mUbRas.  Summary of 200 
ns MD simulation for GDP-bound Ras chemically ligated to Ubiquitin.  (a)  Ras is shown 
in green with a cartoon of the secondary structure overlaid in light gray.  Ubiquitin is 
shown in dark gray.  The switch regions are shown in blue (Switch I) and purple (Switch 
II).  Residues shown in red make contact with Ubiquitin when it comes close to the 
surface of Ras.  (b) 180 degree rotation around the vertical axis of the image shown in 
(a). 
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and in Chapter II to determine if monoubiquitination alters the dynamics of switch 
regions in the GTP-bound state of Ras.  These approaches will also provide information 
about whether the interaction surface of Ubiquitin is altered when Ras is bound to GTP.  
If we have trouble visualizing the switch regions, another NMR approach to consider is 
31P-NMR.  There are a number of studies of Ras that observe resonances on the 
phosphates of GTP analogs by 31P-NMR (314, 315).  In these studies, the authors 
demonstrate that even in the less conformationally dynamic GTP-bound state of Ras, 
there are multiple conformations that the switch regions can adopt that give distinct peaks 
by 31P NMR (316).  Interestingly, only one conformation of the switch regions that is 
detected in these NMR studies is recognized efficiently by downstream effectors (316).  
We could use 31P-NMR to determine if monoubiquitination of Ras alters the population 
of the protein into the active or inactive GTP-bound switch region conformations.  These 
data would provide insight not only into switch regions dynamics, but also potentially 
into how monoubiquitination alters interactions of Ras with downstream effectors.  
Finally, knowing whether dynamics in the GTP-bound state of Ras change or not will 
contribute to answering the next two questions about the mechanisms of mUbRas 
interactions with GAPs and downstream effectors. 
 The third question to address is the mechanism by which GAP-mediated 
hydrolysis is impaired when Ras is ubiquitinated.  While our modeling and gel filtration 
data suggest that ubiquitination does not impair the ability of GAP to bind to Ras, it does 
not mean that the GAP is adopting the proper conformation to allow catalysis of 
hydrolysis to occur.  Furthermore, the gel filtration studies were done with AlF3, which is 
transition state mimetic and may be different than studying the initial ability of GAP to 
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bind to Ras-GTP (138, 197).  GAP-mediated hydrolysis is known to proceed through two 
steps (317).  In the first step, the switch I region of Ras transitions from an ordered off 
state to an ordered on state due to GAP binding, which is essential for both GAP-
mediated and intrinsic hydrolysis (130).  The second step of hydrolysis involves the 
movement of the arginine finger of the GAP into the proper catalytic position (118).  The 
arginine finger interacts with a water molecule at the active site and stabilizes the 
transition state of GTP for phosphate cleavage (318).  It is possible that these structural 
rearrangements that must occur after GAP binds are not possible when Ras is 
monoubiquitinated.  Furthermore, it is possible that the switch regions do not adopt the 
proper positions when bound to GAP due to altered dynamics when Ras is 
monoubiquitinated.   
 We would first like to quantify any changes in binding affinity between Ras and 
GAP when Ras is monoubiquitinated.  One promising approach to address this question 
is the Homogenous Time-Resolved Fluorescence (HTRF) assay (319). For this assay, we 
will load His-Ras (1-166) with GTPγS and add Flag-RasGAP334. After addition of His-d2 
and Flag-Eu antibodies, the FRET signal will be measured. By varying the amount of Ras 
or RasGAP, the binding affinity can be derived from changes in the FRET signal.  These 
data will allow us to quantify how much monoubiquitination impairs the ability of GAP 
to bind to Ras. 
 Measuring the binding affinity of GAP for mUbRas does not provide information 
about whether the GAP is bound in the proper conformation.  An ideal method to 
determine how GAP binds to mUbRas is crystallography.  In Chapter II we have already 
shown that we can isolate the GAP-mUbRas complex, and we could use this complex to 
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set up crystallization trials.  Another approach to visualize differences in binding when 
Ras is monoubiquitinated is through NMR.  We will use Ras bound to a non-
hydrolyzable GTP analog to look for differences in the interaction surface formed when 
mUbRas binds GAP as compared to unmodified Ras.  This approach would provide 
information about whether the GAP bound to the proper surface on mUbRas.  We could 
also 15N-enrich the GAP itself and see if the surface altered upon interaction with Ras 
changes when Ras is monoubiquitinated.  Furthermore, we could 15N-enrich Ubiquitin, 
ligate it to Ras, and use NMR to see if there were any major shifts in the presence of 
GAP, which would indicate a change in the way Ubiquitin interacted with either GAP or 
Ras.  For these experiments, further use of the Rosetta models described in Chapter II 
may aid in understanding how interactions between the two proteins are altered when Ras 
is monoubiquitinated.  We could incorporate the constraints derived from the NMR 
studies described earlier and determine if the constraints lead to an occlusion of the GAP 
binding site on Ras.  Rosetta modeling data used in conjunction with our experimental 
approaches should provide insight into the mechanism by which GAP-mediated 
hydrolysis is impaired.  For example, if monoubiquitination of Ras appears to weaken 
GAP binding affinity and the Rosetta models suggest partial occlusion of the GAP 
binding site, we would expect the NMR data to show that GAP is not adopting the proper 
position on Ras to make the structural changes necessary for GAP-mediated hydrolysis.  
In this case, we would predict that if we ubiquitinated Ras with Ubiquitin that had the 
shorter, stiffer PDZ linker, it would remove the interference of Ubiquitin with GAP 
binding and restore GAP-mediated hydrolysis. 
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Our final question is related to how monoubiquitination increases the affinity of 
activated Ras for select downstream effectors.  Sasaki et al. showed that 
monoubiquitination of Ras enhances its affinity for the downstream effectors Raf, PI3K, 
and RalGDS (320).  Each of these effectors contains a Ras Binding Domain (RBD) or 
Ras Association (RA) domain that possess a ubiquitin-like fold and forms an extended 
beta sheet network with the switch I region of Ras-GTP (321).  Binding of Ras to one of 
these domains locks the dynamic switch regions of Ras into a conformation that 
facilitates detection of the switch resonances (316). It is therefore possible that since 
monoubiquitination alters the dynamics of the switch regions, effector binding could be 
altered as well (316).  Binding affinity between the RBD or RA domains of downstream 
effectors and mUbRas can also be measured using the HTFR assay described above for 
the measurement of GAP binding.  However, particularly in the case of Raf, increased 
binding affinity for mUbRas was only observed if the cysteine rich domain (CRD) of 
Ras, which is adjacent to the RBD domain, was present (153).  It is therefore possible 
that the increased affinity for select downstream effectors could be due to an additional 
binding interaction between Ras and the effector in the presence of Ubiquitin rather than 
changes in the switch region dynamics of Ras, which we have not yet characterized in the 
GTP-bound state of the protein.  Measuring the binding affinity in the presence and 
absence of the CRD for both Ras and mUbRas will clarify if this is the case.  If the CRD 
is important for the increased binding affinity, NMR can be used to determine in the 
additional interaction is formed between the CRD and Ras itself or the CRD and 
Ubiquitin.  
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Future Questions and Experiments for H-Ras Ubiquitination at K117 
 While many of our future mechanistic studies are focused on modification of K-
Ras at K147, there are additional questions raised by the studies performed with H-Ras 
showing distinct, site-specific mechanisms of regulation.  Primarily, it will be important 
to determine whether monoubiquitination of H-Ras at K117 also alters (either positively 
or negatively) the interactions of downstream effectors with mUbRas.  To answer this 
question, the most successful approach would be to use our collaboration with Sasaki et 
al. to repeat the in vivo effector interaction assays with H-Ras.  We will also repeat the 
assays described above for measuring interactions of effectors in vitro with mUbRasK117.  
If monoubiquitination at K117 alters interactions with downstream effectors, particularly 
if it is in a manner distinct from monoubiquitination at K147, it would further support our 
hypothesis that monoubiquitination is one of the mechanisms by which Ras isoforms are 
distinguished in vivo. 
 It is interesting to note that modification of K104 does not lead to changes in 
intrinsic or regulator-mediated Ras activity.  Besides our example of monoubiquitination 
at K104, we also have data that monoubiquitination at K88 or K101 has no effect on 
GAP-mediated Ras activity (235).  These are two of the five lysines that had to be 
removed in the core domain of Ras in the previous studies of H-Ras ubiquitination 
leading to endosomal trafficking (173).  This observation is consistent with our 
hypothesis discussed in Chapter III that in CHOK-1 cells, ubiquitination is primarily as a 
marker for transport rather than a direct regulator of Ras activity.  Furthermore, this data 
raises the question of why specific sites on Ras lead to changes in activity when 
monoubiquitination occurs while others do not.  One hypothesis is that access to the 
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switch regions, in particular switch I, which is most important for hydrolysis and effector 
recognition, is essential for the mechanism by which monoubiquitination regulates Ras 
activity.  If that is the case, of the lysines studied only K147 and K117 appear to be close 
enough to this region, as seen in Figure 5.3.  To test this hypothesis, we could use 
Rosetta modeling to find residues on Ras (not necessarily lysines) that provide varying 
degrees of access to the switch I region of the protein.  We could then make the 
appropriate cysteine mutations and determine the extent to which ubiquitination altered 
the activity of the protein from each of these chosen locations.  If the ability of 
monoubiquitination to alter Ras activity was correlated to proximity to Switch I, it would 
support our hypothesis, as well as our preliminary MD simulations and PDZ ligation data 
that it is access to Switch I that drives the mechanism by which monoubiquitination 
activates Ras.  
Finally, our experiments with monoubiquitination at K104 also highlight an 
interesting phenomenon; monoubiquitination of Ras does not always have the same effect 
as mutation at the same site.  Mutation at K147 increased intrinsic exchange slightly, but 
monoubiquitination did not.  Mutation at K117 thermally destabilized the protein, but 
monoubiquitination did not.  Mutation of K104 decreased sensitivity to Sos-mediated 
dissociation, but monoubiquitination did not.  The explanations for the differences 
between mutations and monoubiquitination at K147 and K117 are likely connected to the 
mechanisms by which monoubiquitination modulate or possibly stabilize switch 
dynamics.  However, ubiquitination at K104 does not provide the same access to the 
switch regions as K147 and K117.  While K104 does not have the same proximity to the 
switch regions, it is in proximity to but not on the Sos binding interface.  As seen in 
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Figure 5.4, the residue sits at the edge of the Sos binding interface. Molecular dynamics 
simulations of acetylation at K104 suggested that acetylation at this position alters the 
conformational stability of the switch II region due to a perturbation in electrostatic 
interactions, which is known to be important for GEF-mediated hydrolysis (239).  In 
Chapter III, the only mutation we made at this site was a K104C mutation.  It is possible 
that the properties of the cysteine side chain adversely effected Sos-mediated dissociation 
in a way that removing the side chain (ubiquitination) does not.  To test this hypothesis, 
we should repeat our experiments with a K104G mutation, which would more closely 
mimic removal of the lysine sidechain, similar to monoubiquitination.  If our hypothesis 
is correct, this mutation will not lead to the same disruption of Sos-mediated dissociation.  
Together, these examples show the importance of measuring the effect of 
monoubiquitination on a substrate.  The outcome cannot always be accurately predicted 
from knowing the effect of a mutation at the same site   
Future Directions for the Study of Ras Monoubiquitination 
These studies of the regulation of Ras by monoubiquitination have also raised 
larger questions about how this mechanism contributes to the role of Ras in normal cell 
maintenance and tumorigenesis.  Monoubiquitination of K-Ras was shown to be 
important for Ras-driven tumorigenesis, but that does not mean that it is only important 
in cancer progression.  In cancer, cells pervert normal signaling pathways.  By observing 
what is misregulated in cancer, we see an exaggerated picture of pathways that are 
important in normal cell maintenance.  Therefore, even though the easiest role to detect 
for monoubiquitination of K-Ras is in tumorigenesis, it is very likely that it also plays an 
important role in normal cell maintenance.  For example, it is possible that   
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Figure 5.3.  Proximity of Ubiquitination Sites to Switch I.  Ribbon diagram of Ras shown 
in grey (PDB 5P21) with the switch regions highlighted in light green (GDP-bound) and 
dark green (GTP-bound).  Mg2+ represented as a sphere in brown, and GDP is shown in 
multiple colors.  Sidechains of lysines that have been chemically ubiquitinated are shown 
as spheres in various colors: pink (K147), purple (K117), yellow (K88), cyan (K101), and 
dark blue (K104).  Distances are measured from the sidechain to the nearest point on 
switch I and are: 9.6 Angstroms (K147), 10.3 Angstroms (K117), 16.2 Angstroms (K88), 
26.9 Angstroms (K101) and 23.7 Angstroms (K104).  Note that proximity to the p-loop 
(shown in purple) is not a predictor of which residues will alter intrinsic or regulator-
mediated Ras activity. 
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Figure 5.4.  Proximity of K104 to Surface of Sos Interface with Ras.  Crystal structure of 
Ras bound to Sos (PDB 1BKD) with Ras represented as a ribbon diagram in grey and Sos 
represented as a surface colored by the properties of the amino acid sidechain.  The 
Lysine 104 sidechain is shown in spheres. 
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monoubiquitination is one of the mechanisms that lead to specificity in the interactions of 
particular Ras isoforms with distinct downstream effectors. 
Future studies are required to address: [1] the role of K-Ras monoubiquitination in 
normal cell proliferation.  In this case, a good initial approach may be to use mice models 
lacking the site of ubiquitination.  [2] The role of monoubiquitination in mutant K-Ras 
effector signaling and cancer growth.  This effect may depend on the type of cancer being 
considered.  For example, in some cancers, mutant K-Ras (G12D and G12C) is fully 
activated, therefore any role of monoubiquitination would likely be due to altered 
interactions with downstream effectors (322, 323).  However, in other cancers, like 
colorectal cancer, the mutant K-Ras (G13 and A146) is not fully activated, and in this 
case the increase in GTP-bound Ras when Ras is monoubiquitinated may be important 
(323).  [3] The role of monoubiquitination in tumor growth for mutant H-Ras and N-Ras.  
Our data show differences in regulation of Ras by monoubiquitination between cell lines, 
suggesting that it may also be tumor-type dependent.  The best place to begin these 
studies would be common tumor types for each isoform, which are bladder carcinomas 
(H-Ras) and melanoma (N-Ras) (322, 324).   
Currently, no effective inhibitors that directly target mutant Ras proteins have 
successfully been developed.  The first approach to developing a Ras inhibitor was to 
target mutant Ras that is persistently GTP-bound.  However, Ras binds GTP with a high 
affinity (60 pM), which makes it difficult to develop competitive inhibitors that would be 
analagous to protein kinase competitive inhibitors of ATP binding (low μM binding 
affinity) (325).  Because of its high affinity binding to GTP, Ras is considered 
“undruggable”, and most current efforts have sought to indirectly target Ras, either 
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through inhibiting membrane association or downstream effector signaling (326).  While 
there are over 40 inhibitors currently under clinical evaluation, none have shown 
significant anti-tumor activity against K-Ras mutant driven cancers (326).  The recent 
findings that monoubiquitination contributes to driving oncogenesis may represent a new 
set of targets for developing Ras inhibitors. 
 
Gpa1 as a Substrate for Monoubiquitination 
In Chapter IV, we used biochemical approaches to study the yeast Gα protein 
Gpa1.  Key for our ability to study this protein was the preliminary work we did 
optimizing the DNA sequence, expression, and purification of Gpa1.  By removing the 
ubiquitination domain of the protein, we showed that this domain has most likely evolved 
for post-translational modification without influencing the biochemical or enzymatic 
properties of Gpa1.  This finding is important because the ubiquitination domain is not 
present in other Gα proteins.  However, its lack of influence on enzymatic activity 
suggests that Gpa1 may still serve as a model for the study of Gα proteins.  Toward this 
end, we showed that mutations to the α-helical domain of Gpa1 altered the enzymatic 
activity of the protein, similar to what is now known for mammalian and plant Gα 
proteins as well. 
 The advantages of studying Gpa1 lie in the fact that it is a yeast protein. Thus, it is 
possible to couple our biochemical and biophysical studies with genetic and molecular 
biology studies. By this integrated approach we can better understand how the changes 
we observe in the protein in vitro contribute to its mechanisms of activity and regulation 
in vivo.  There are two primary avenues of research that we would like to pursue with 
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Gpa1.  The first relates to the study of Gpa1 as a substrate of monoubiquitination.  It is 
intriguing that this protein possesses a domain that appears to be present only for 
modification by ubiquitination.  We would like to know more about how this 
ubiquitination domain may interact with the rest of the protein, whether ubiquitination 
influences the biochemical properties of Gpa1, and if there are any known binding 
partners of Gpa1 that interact with the ubiquitination domain.  The second avenue of 
research we would like to pursue relates to using Gpa1 as a model system to understand 
the contributions the α-helical domain makes to Gα signaling.  Using the powerful 
genetics of yeast coupled with our biochemical and biophysical approaches, we are in a 
unique position to alter Gpa1 activity through mutation in vitro and then measure the 
effects these changes have on Gpa1 signaling in vivo.  Our proposed experiments are 
described below. 
 First, we would like to learn more about how the ubiquitination domain may 
interact with the rest of the protein.  Based on the preliminary data in Chapter IV showing 
that there is no change in Gpa1 when the ubiquitination domain is removed, we expect 
that it does not form significant interactions with the rest of Gpa1.  It is not known, 
however, whether the domain itself contains any protected sites or possible secondary 
structure features.  The two experimental approaches we would like to use are limited 
proteolysis and NMR.  The use of limited proteolysis would give us information about 
whether there are any regions of the insert that are structure, and therefore protected, or 
whether the insert is primarily unstructured, making all residues available for proteolysis.  
We would also like to use NMR to observe the ubiquitination domain of Gpa1.  Because 
Gpa1 is a large protein that is not amenable to long, three dimensional NMR experiments, 
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we propose to do a 15N-HSQC in the absence and presence of the ubiquitination domain 
and compare the spectra.  These experiments will provide information about whether the 
resonances that appear in the presence of the ubiquitination domain are primarily in the 
unstructured region of the spectra. They would also reveal whether there are any 
significant changes in the rest of the NMR spectra in the presence of the ubiquitination 
domain, which would suggest that the ubiquitination domain did form interactions with 
other regions of Gpa1.   
We have already done significant work to optimize the conditions for NMR of 
Gpa1 without the ubiquitination domain.  The thermal stability of Gpa1 is pH dependent 
and a significant increase in thermal stability of the GTP-bound state of the protein is 
observed at pH 6.0 as compared to pH 7.0 (Figure 5.5a).  Decreasing the pH below pH 
6.0 did not significantly increase thermal stability (data not shown).  Using fQCR, we 
also showed that not all GTP analogs lead to the same increase in the thermal stability of 
Gpa1.  AlF3, although it has successfully been used for NMR studies of mammalian Gα 
(327), is not as thermally stabilizing as GTPγS (Figure 5.5b).  In Figure 5.5c-d, the 
spectra obtained at pH 7.0 and pH 6.0 are shown.  We can detect over 200 resonances in 
the Gpa1 spectrum lacking the ubiquitination domain at pH 6.0.  These data suggest it 
will be feasible to observe changes in Gpa1 when the ubiquitination domain is present. 
Next, we would like to determine if ubiquitination alters the biochemical activity 
of Gpa1.  This requires obtaining enough monoubiquitinated Gpa1 to perform the 
necessary assays.  In Chapter IV, we describe a number of approaches that we tried to 
make Gpa1ΔN amenable to chemical ubiquitination.  As described earlier in this chapter, 
there are limitations in the protein itself that made these attempts at optimization  
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Figure 5.5.  Optimization of Parameters for NMR of Gpa1.  (a)  The thermal stability of 
Gpa1 in the presence of GDP and GTPγS was measured by fQCR at pH 7.0 and pH 6.0.  
Results are plotted as the change in thermal stability between the GTPγS and GDP bound 
states at each pH for GpaΔN and Gpa1ΔNΔL.  (b) Thermal stability of Gpa1 at pH 6.0 in the 
presence of GDP, GDP-AlF4, and GTPγS.  (c) HSQC spectrum of 15N-Gpa1ΔNΔL at pH 
7.0 in the presence of GTPγS.  (d) HSQC spectrum of 15N-Gpa1ΔNΔL at pH 6.0 in the 
presence of GTPγS.  
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unsuccessful.  We have a few options to generate monoubiquitinated substrate in the 
future.  First, it is possible that ubiquitination may still work in Gpa1WT if the proper 
background cysteine mutations are made to stabilize the protein in the absence of 
reducing agent.  Second, the protein could be ubiquitinated using the native 
ubiquitination complex, which has been previously reconstituted in the Dohlman lab 
(284).  The problem with this approach is that the protein will not be fully modified and 
additional purification steps would be required to separate the modified and unmodified 
forms of the protein.  Furthermore, Ubiquitin ligase complexes are not as specific in vitro 
as they are in vivo, which means Gpa1 may be monoubiquitinated at more than one 
lysine.  Finally, there are alternative chemical ubiquitination approaches that may be 
successful for ubiquitinating Gpa1.   One approach is to use non-natural amino acids.  
Recent advances in the optimization of the click chemistry approach described above 
have created a system where, once the proteins are expressed and purified, modification 
can occur in as little time as one hour in the presence of reducing agent (328).  
Third, we would like to determine if there are binding partners of Gpa1 that 
recognize the ubiquitination domain.  While Gpa1 may not be an ideal model for the 
study of Gα ubiquitination, since ubiquitination occurs on a unique insert, it is still a very 
interesting substrate of ubiquitination.  The information obtained about this domain is 
relevant beyond the study of Gpa1 and G proteins.  Therefore, we would like to ask not 
only if ubiquitination alters the activity of Gpa1, but if there are binding interactions 
other than those between Gpa1 and the ubiquitin ligase and deubiquitinase that utilize the 
ubiquitination domain.  We propose to do a mass spectrometry screen of proteins that 
pull down with three variants of Gpa1: Gpa1, Gpa1 without the ubiquitination domain, 
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and Gpa1 with a lysine-less ubiquitination domain.  This approach would elucidate 
whether there are interacting partners of Gpa1 that require the ubiquitination domain as 
well as whether there are interacting partners that require ubiquitination of this same 
domain.  We predict that signaling proteins that interact with Gpa1 at the plasma 
membrane would not recognize the ubiquitination domain, while proteins responsible for 
trafficking and endosomal signaling might bind the ubiquitinated form of insert.  The 
binding partners of Gpa1 that we would look for in our mass spectrometry screen include 
the pheromone receptor Ste2 (286), Gβγ subunit Ste4/Ste18 (287), GTPase accelerating 
protein Sst2 (288), non-receptor exchange factor (Get3), two subunits of 
phosphatidylinositol 3-kinase (Vps14 and Vps34) (260).  Other proteins and enzymes 
involved in post-translational modification of Gpa1 include the N-myristoyltransferase 
Nmt1 (329), palmitoyltransferase (330), de-palmitoylating acyl-protein thioesterase Apt1 
(331), Ubiquitin ligase Rsp5 (284), and Ubiquitin ligase SCF Cdc4 (280).  There is 
precedence in other Gα proteins for another post-translational modification, 
phosphorylation, leading to changes in interactions with known binding partners.  Gα 
phosphorylation leads to a loss of interaction with Gβγ (263), loss of interaction with 
RGS (264), loss of guanine nucleotide binding (265), receptor desensitization (332, 333), 
and loss of interaction with downstream effectors (334).   
Finally, we would like to use the yeast system to understand how changes in the 
α-helical domain impact Gpa1 signaling in vivo.  S. cerevisiae is an ideal model system 
for understanding mechanisms of signaling pathway output and regulation.  We have 
already established that changes in the helical domain change the activity of Gpa1 in vitro 
and that the unique ubiquitination domain of Gpa1 does not significantly contribute to its 
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activity or biophysical properties.  Together, these data indicate that despite the extra 
ubiquitination domain, Gpa1 can be used as a representative Gα for studies of α-helical 
domain modulation of Gα activity.  We propose to test two types of Gpa1 mutants: [1] 
the cysteine mutations we have already characterized in vitro and [2] α-helical domain 
chimeras of the A/B helix, similar to the ones published in Jones et al.  (250).  After 
incorporating these mutants into yeast, we will measure pheromone pathway activation 
(Fus3/Kss1), gene transcription (beta-gal), endosomal localization, and possibly 
morphological changes or mating efficiency.  We expect to see a phenotype consistent 
with Gpa1 activation or inactivation, depending on how the mutants or chimeras were 
shown to alter Gpa1 properties in vitro.  These data would represent the first in vivo 
evidence that changes made to the α-helical domain influence the activity of the Gα. 
 
Conclusions and Future Directions 
While the studies in Chapters II, III, and IV have contributed to our knowledge 
about the regulation of the GTPases Ras and Gpa1 specifically, they have also 
contributed to our general understanding of GTPase regulation.  We first see that 
regulation by monoubiquitination is not only site-specific, but protein specific even 
within the same classes of proteins or isoforms of the same GTPase.  Our work 
highlighting the differences between mutation and monoubiquitination of Ras at K147 
may explain why K147 is conserved across a number of small GTPases.  There are over 
150 identified GTPases, and 70 of them contain a lysine at the equivalent of position 147 
(Table 5.3) (120).  We mutated K147 to a number of different residues and did not 
observe any significant change in intrinsic or regulator-mediated Ras activity (Table 5.4).  
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The adjacent Serine (145) and Alanine (146) in the SAX motif have validated roles in 
coordinating the nucleotide and contributing directly to Ras activity (183, 184).  
However, the mutation to the lysine does not significantly contribute to Ras activity, 
suggesting it may be conserved for regulation by monoubiquitination.  However, further 
experiments are required to determine the role of monoubiquitination in the regulation of 
other small GTPases.  Often, it appears to be a small population of a given protein that is 
monoubiquitinated at a particular time.  As highlighted by our kinetic modeling in 
Chapter II, however, a small population of an active GTPases can have a large impact on 
signaling.  Therefore, monoubiquitination may be more prevalent in GTPase regulation 
than we currently know.  Our mechanistic studies suggest it may be worthwhile to 
determine if other small GTPases that have an insert domain or lysine at the equivalent of 
position 147 are substrates of monoubiquitination. 
Furthermore, our work has contributed to the understanding of cellular 
mechanisms of regulation by monoubiquitination in general.  We used chemical 
ubiquitination approaches to mechanistically show that monoubiquitination can directly 
enhance the activity of its substrate upon modification.  While there are more advanced 
methods to chemically ubiquitinate proteins that use either the enzymatic linker or a 
similar linker, we demonstrate that the linker generated through the formation of a 
disulfide accurately mimics native ubiquitination.  These data should be applicable for 
the study of the biochemistry of other ubiquitinated substrates as well.  It is also of note 
that this approach will be useful in characterizing the differences between regulation by 
monoubiquitination and other small protein modifiers such as ISG15, Nedd8, and SUMO   
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K147-Containing GTPases 
Di-Ras Rab10 Rab21 Rab33A Rab3D Rab8A Rap2B 
Di-Ras2 Rab12 Rab22A Rab33B Rab41 Rab8B Rap2C 
E-Ras Rab13 Rab22B Rab35 Rab5A Rab9A RasD1 
H-Ras Rab14 Rab24 Rab35 Rab5B Rab9B RasD2 
K-Ras2B Rab17 Rab26 Rab36 Rab5C RalA RhoA 
Miro1 Rab18 Rab28 Rab37 Rab6A RalB RhoB 
Miro2 Rab19 Rab2A Rab38 Rab6B Rap1A RhoC 
M-Ras Rab1A Rab2B Rab39A Rab6C Rap1A R-Ras 
Noey2 Rab1B Rab30 Rab3B Rab7A Rap1B RRP22 
N-Ras Rab1B Rab32 Rab3C Rab7B Rap2A TC21 
 
 
Table 5.3.  Small GTPases Containing a Lysines in the Conserved SAX motif.  The table 
lists, in alphabetical order, all small GTPases that contain a lysine at the equivalent of 
Ras K147 within the SAX motif. 
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Table 5.4.  Mutation of K147.  Summary of dissociation and hydrolysis data for various 
mutations at position 147. Results are the mean ± SE (n=4). 
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whose functions may, in some cases, be distinct from monoubiquitination (5).  
Furthermore, our work highlights the advantages of coupling observations of 
monoubiquitination in vivo with computational and biophysical studies on a particular 
substrate in vitro.  
One of the next steps in advancing the study of monoubiquitination is the 
development of a database that treats monoubiquitination as a post-translational 
modification distinct from polyubiquitination and that recognizes that the outcomes of 
ubiquitination are substrate dependent.  As studies that address the mechanisms by which 
substrates are regulated by monoubiquitination become more prevalent, new trends may 
emerge not only in the outcomes of monoubiquitination, but in the mechanisms by which 
Ubiquitin acts on its substrates.  While a few small databases have begun to recognize the 
importance of differentiating between monoubiquitination and polyubiquitination 
(UbiProt), the largest databases do not include these details but primarily focus on listing 
substrates that are known to be monoubiquitinated (hUbiquitome and PhosphoSitePlus).  
On the other hand, databases of phosphorylated substrates, like PhosphoSitePlus, catalog 
proteins that are phosphorylated, listing both the sites of phosphorylation as well as what 
type of process the site-specific phosphorylation regulates in vivo.  A similar resource for 
monoubiquitinated substrates would aid in elucidating patterns in mechanisms of 
regulation by monoubiquitination. 
Understanding the diverse mechanisms by which monoubiquitination is used to 
regulate substrate localization, binding, and activity becomes more important as a role for 
ubiquitination is emerging in the study of cancer and developmental disorders. There is 
already evidence in the literature for the role of ubiquitination and its misregulation in 
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disease (43, 89-92).  However, successful drug development studies targeting 
monoubiquitinated substrates will likely be case-specific, rather than designed based on 
general principles.  This is due to differences in the way each E3 ligase interacts with its 
substrates as well as the fact that monoubiquitination does not act on its substrates 
through a single, conserved mechanism.  With the ability to perform structural studies on 
monoubiquitinated substrates coupled with a knowledge of the mechanisms by which 
monoubiquitination acts, inhibitors of high priority targets could be developed using 
fragment-based inhibitor design approaches (335).  Interest in understanding more about 
monoubiquitination is not only relevant for drug development and disease related 
purposes, but for understanding normal cell maintenance and functioning as well.  Small 
populations of a substrate may be modified at any time, meaning that knowing common 
mechanisms of regulation by ubiquitination as well as the sites of ubiquitination will 
contribute to identifying potential candidate proteins for regulation by ubiquitination.  As 
our knowledge about this post-translation modification increases, so will appreciation for 
the complex and elegant manner in which monoubiquitination fine tunes cell signaling 
regulation. 
 
Methods 
Thermal Stability of Gpa1 
The fast quantitative cysteine reactivity (fQCR) method (182) was employed to 
measure changes in Gpa1 thermal stability. Briefly, 2 μM protein was incubated with 1 
mM 4-fluoro-7-aminosulfonylbenzoflurazan (ABD–F, Anaspec) at pH 7.0 in the 
presence of 20 μM GDP or GTpγS and 2 mM MgCl2 at the desired temperature for three 
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minutes. When the assays were performed at pH 6.0, 2 mM ABD-F was used.  For assays 
with AlF4, 10 mM NaF and 30 μM AlCl3 was added to the reaction in the presence of 20 
μM GDP.  The reaction was quenched with HCl and ABD-F fluorescence was measured 
on a PHERAstar plate reader (BMG Labtech, excitation at 400 nm and emission at 500 
nm). The data were normalized and fit to determine the temperature at which half the 
protein was unfolded, representing the melting temperature (Tm).  
NMR Experiments with Gpa1  
For NMR studies, 15N– enriched samples of Gpa1ΔNΔL were produced using 
standard protocols in M–9 minimal media (181). 1H–15N 2D HSQC experiments were 
conducted on a Varian 700 MHz (pH 7.0) and a Bruker 700 MHz (pH 6.0) with a 
cryoprobe in 20 mM Phosphate Buffer, 100 mM NaCl, 5 mM MgCl2, 10% D2O, 1 mM 
TCEP , and 2 mM GTPγS at 25oC and with 100 μM protein.  
Intrinsic and Regulator-Mediated Ras Activity 
The rate of nucleotide dissociation was measured using MANT-GDP (BioLog: 
San Diego, CA) as previously reported (194, 195).  Briefly, MANT-GDP-bound Ras (2 
μM) was added to 1 mL assay buffer (50 mM Tris, pH 7.4, 50 mM NaCl and 5 mM 
MgCl2) and exchange was initiated by addition of 2 mM GDP.  The rate of MANT-GDP 
dissociation was measured as a change in fluorescence intensity over time (LS50B 
Perkin-Elmer Luminescence Spectrometer) at an excitation wavelength of 360 nm and an 
emission wavelength of 440 nm.  Fluorescent nucleotide dissociation curves were fit in 
GraphPad Prism (GraphPad Software; San Diego, CA) to a one-phase exponential decay 
curve.  For GEF-mediated dissociation and binding, 200 nM Ras and 0.2 μM to 20 μM 
Soscat were used.  The nucleotide dissociation rate was plotted as a function of Soscat 
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concentration and fit to one site binding in Prism to determine the binding affinity 
between Ras or mUbRas and Soscat.  Results are the mean ± SE (n=4).  
Single-turnover GTP hydrolysis assays were done as previously described (196), except 
that the phosphate binding protein Flippi 5U (Addgene) was used to detect inorganic 
phosphate released upon GTP hydrolysis (185).  Flippi 5U was purified as previously 
described (185).   All buffers were made phosphate free by extensive dialysis with 1 U 
nucleoside phosphorylase and 2 mM inosine (Sigma, USA).  For GAP-mediated 
hydrolysis, 50 μM Ras and 0.1 μM (1:500) GAP-334 was used.  The ratio of fluorescence 
emission was measured at 480 nm and 530 nm with an excitation of 435 nm on a 
SpectraMax M5 (Molecular Devices).  Fluorescence ratios were converted to phosphate 
concentrations using a standard curve.  Hydrolysis curves were fit in GraphPad Prism 
(GraphPad Software; San Diego, CA) to a one-phase exponential association curve as 
shown in Figure S2.  Results are the mean ± SE (n=6).     
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INTERACTION SURFACES BETWEEN RAS AND RAS-GEF OR RAS-GAP 
 
Ras Residue GEF Residue Distance (Angstroms) 
5-LYS 910-ASP 5.52 
5-LYS 911-HIS 5.67 
17-SER 942-GLU 3.87 
17-SER 938-LEU 5.42 
17-SER 939-LYS 5.76 
21-ILE 939-LYS 4.38 
21-ILE 942-GLU 5.18 
25-GLN 944-ASN 5.86 
30-ASP 945-PRO 4.83 
31-GLU 944-ASN 4.36 
31-GLU 963-LYS 5.89 
32-TYR 944-ASN 5.41 
32-TYR 939-LYS 5.52 
33-ASP 963-LYS 5.6 
33-ASP 940-THR 5.77 
34-PRO 939-LYS 4.04 
34-PRO 936-ASN 4.85 
34-PRO 944-ASN 5.55 
34-PRO 967-ILE 5.9 
34-PRO 940-THR 5.98 
35-THR 936-ASN 5.25 
35-THR 916-LEU 5.59 
37-GLU 913-LYS 5.72 
40-TYR 911-HIS 4.91 
40-TYR 910-ASP 5.78 
40-TYR 939-LYS 5.96 
40-TYR 913-LYS 5.97 
41-ARG 910-ASP 5.06 
41-ARG 911-HIS 5.96 
54-ASP 911-HIS 3.81 
54-ASP 910-ASP 5.63 
56-LEU 911-HIS 5.02 
57-ASP 939-LYS 5.66 
58-THR 935-THR 5.98 
59-ALA 939-LYS 5.18 
59-ALA 935-THR 5.85 
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59-ALA 942-GLU 5.95 
59-ALA 938-LEU 5.98 
61-GLN 935-THR 4.68 
61-GLN 934-LEU 4.99 
61-GLN 932-ILE 5.21 
61-GLN 912-TYR 5.8 
61-GLN 929-PHE 5.94 
62-GLU 810-THR 5.52 
62-GLU 809-TRP 5.59 
62-GLU 938-LEU 5.9 
63-GLU 825-ILE 4.17 
63-GLU 826-ARG 5.17 
63-GLU 815-GLU 5.44 
63-GLU 814-LYS 5.91 
63-GLU 829-THR 5.96 
63-GLU 809-TRP 5.97 
63-GLU 822-LEU 5.99 
64-TYR 828-THR 4.28 
64-TYR 934-LEU 4.74 
64-TYR 825-ILE 4.86 
64-TYR 821-LEU 5.42 
64-TYR 929-PHE 5.81 
64-TYR 824-MET 5.83 
64-TYR 829-THR 5.84 
65-SER 829-THR 4.48 
65-SER 1002-GLU 4.79 
65-SER 833-LEU 5.71 
66-ALA 832-THR 3.88 
66-ALA 829-THR 4.72 
66-ALA 836-GLU 4.85 
66-ALA 833-LEU 5.01 
66-ALA 876-SER 5.72 
67-MET 876-SER 4.11 
67-MET 912-TYR 5.29 
67-MET 872-LEU 5.35 
67-MET 832-THR 5.46 
67-MET 828-THR 5.76 
67-MET 929-PHE 5.99 
68-ARG 1002-GLU 4.92 
69-ASP 881-SER 4.37 
69-ASP 880-SER 5.14 
69-ASP 882-PRO 5.67 
69-ASP 1006-THR 5.71 
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69-ASP 836-GLU 5.81 
70-GLN 879-ASN 3.96 
70-GLN 876-SER 4.72 
70-GLN 875-VAL 4.95 
70-GLN 905-HIS 5.17 
70-GLN 912-TYR 5.33 
70-GLN 908-SER 5.5 
70-GLN 872-LEU 5.64 
71-TYR 929-PHE 5.06 
71-TYR 912-TYR 5.43 
71-TYR 932-ILE 5.67 
73-ARG 884-TYR 5.44 
73-ARG 881-SER 5.49 
73-ARG 879-ASN 5.95 
95-GLN 1007-ASP 5.08 
95-GLN 1003-LYS 5.28 
95-GLN 1006-THR 5.96 
98-GLU 1003-LYS 5.75 
99-GLN 1002-GLU 5.75 
102-ARG 881-SER 4.52 
102-ARG 1006-THR 5.2 
102-ARG 1011-ASN 5.31 
102-ARG 1007-ASP 5.38 
102-ARG 1003-LYS 5.45 
102-ARG 1010-PHE 5.95 
103-VAL 881-SER 3.29 
105-ASP 1019-ARG 4.45 
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Ras Residue GAP Residue Distance (Angstroms) 
11-ALA 790-ALA 4.89 
11-ALA 791-THR 5.78 
17-SER 949-LYS 4.49 
21-ILE 949-LYS 4.58 
25-GLN 949-LYS 4.9 
25-GLN 948-ALA 4.91 
27-HIS 948-ALA 5.54 
29-VAL 949-LYS 5.26 
30-ASP 785-THR 4.76 
31-GLU 785-THR 5.65 
31-GLU 944-VAL 5.91 
31-GLU 894-ARG 5.92 
31-GLU 948-ALA 5.93 
32-TYR 902-LEU 4.78 
32-TYR 785-THR 5.5 
32-TYR 942-ASN 5.59 
32-TYR 894-ARG 5.62 
32-TYR 897-SER 5.62 
32-TYR 789-ARG 5.65 
32-TYR 788-PHE 5.83 
32-TYR 938-GLN 5.94 
33-ASP 949-LYS 3.83 
33-ASP 944-VAL 4.92 
33-ASP 942-ASN 5.51 
33-ASP 938-GLN 5.69 
33-ASP 939-ASN 5.83 
34-PRO 902-LEU 3.53 
34-PRO 942-ASN 4.82 
34-PRO 789-ARG 5.11 
34-PRO 938-GLN 5.26 
35-THR 949-LYS 5.05 
35-THR 789-ARG 5.93 
36-ILE 938-GLN 4.01 
36-ILE 906-CYS 4.31 
36-ILE 902-LEU 4.41 
36-ILE 935-LYS 5.1 
36-ILE 910-LEU 5.24 
36-ILE 934-ALA 5.46 
36-ILE 931-ILE 5.87 
37-GLU 928-ARG 5.1 
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37-GLU 931-ILE 5.36 
37-GLU 935-LYS 5.5 
38-ASP 935-LYS 5.1 
38-ASP 950-GLU 5.72 
38-ASP 949-LYS 5.95 
39-SER 950-GLU 4.09 
39-SER 935-LYS 5.65 
39-SER 928-ARG 5.67 
39-SER 831-SER 5.82 
40-TYR 950-GLU 5.73 
40-TYR 951-PRO 5.86 
40-TYR 949-LYS 5.97 
41-ARG 833-SER 5.44 
61-GLN 902-LEU 5.52 
61-GLN 791-THR 5.74 
61-GLN 789-ARG 5.79 
61-GLN 903-ARG 5.96 
62-GLU 750-THR 4.8 
62-GLU 799-GLU 4.88 
62-GLU 791-THR 4.89 
62-GLU 796-THR 5.63 
62-GLU 903-ARG 5.73 
62-GLU 749-ARG 5.99 
63-GLU 907-PRO 4.59 
63-GLU 903-ARG 5.04 
63-GLU 795-SER 5.21 
63-GLU 799-GLU 5.36 
63-GLU 802-MET 5.46 
63-GLU 803-LYS 5.83 
64-TYR 902-LEU 4.59 
64-TYR 907-PRO 4.84 
64-TYR 910-LEU 5.34 
64-TYR 906-CYS 5.69 
64-TYR 938-GLN 5.81 
64-TYR 903-ARG 5.83 
66-ALA 911-ASN 4.79 
67-MET 910-LEU 5.17 
67-MET 911-ASN 5.76 
70-GLN 927-ALA 5.18 
85-ASN 782-ASP 5.64 
86-ASN 790-ALA 4.33 
88-LYS 790-ALA 3.29 
88-LYS 792-THR 4.01 
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88-LYS 791-THR 4.62 
88-LYS 749-ARG 5.14 
91-GLU 749-ARG 5.83 
92-ASP 749-ARG 4.97 
92-ASP 791-THR 5.22 
92-ASP 790-ALA 5.92 
95-GLN 749-ARG 5.8 
117-LYS 786-THR 5.31 
120-LEU 783-GLU 5.76 
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NMR BACKBONE ASSIGNMENTS FOR RASK147A 
 
Ras Residue 1H (ppm) 15N (ppm) Peak Intensity 
4 8.77 121.94 1.63 
5 9.13 124.59 1.41 
6 9.45 126.27 0.95 
8 7.17 112.41 1.58 
9 9.17 120.66 1.52 
10 7.13 107.55 1.57 
11 8.76 121.57 1.37 
12 8.61 106.28 1.65 
13 10.57 115.01 0.95 
14 7.67 113.46 1.69 
15 8.57 109.51 1.08 
16 10.57 125.40 0.71 
17 9.34 120.48 1.32 
18 9.49 125.41 1.26 
19 9.06 120.44 1.90 
20 7.71 116.93 1.49 
21 8.90 120.66 1.47 
22 7.91 120.69 1.41 
23 7.67 120.63 1.58 
25 9.00 115.88 1.10 
26 7.95 116.48 1.56 
27 6.79 111.82 4.71 
28 8.59 122.51 1.26 
29 7.83 126.48 1.02 
30 7.81 122.25 1.59 
31 7.67 119.30 2.11 
32 8.82 125.69 1.41 
33 7.86 128.81 1.09 
35 8.98 109.94 0.99 
36 6.84 120.92 1.01 
37 8.41 131.92 0.87 
38 8.16 124.44 1.63 
39 8.39 114.01 1.38 
40 9.09 121.39 1.87 
41 8.38 120.23 1.63 
42 8.66 122.01 1.59 
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43 8.93 128.95 1.21 
44 8.68 121.06 1.17 
45 8.05 120.92 2.15 
46 8.11 125.61 1.61 
47 9.55 130.74 0.78 
48 8.30 133.99 -1.48 
49 7.67 122.14 2.26 
50 8.89 125.68 1.82 
51 8.69 123.46 2.75 
52 8.85 128.99 1.91 
53 8.99 123.31 1.38 
54 8.73 125.51 1.39 
55 9.17 123.65 1.71 
56 8.76 127.57 1.02 
57 8.47 129.17 0.77 
58 6.89 110.32 2.34 
59 7.88 120.43 1.26 
60 8.28 108.07 2.45 
61 8.58 119.01 2.10 
62 8.76 120.60 2.25 
63 8.29 120.02 2.96 
64 8.28 121.23 1.75 
65 7.91 120.03 1.66 
66 8.00 120.62 1.97 
67 8.23 117.73 1.90 
68 7.82 123.79 1.75 
69 8.11 118.40 2.13 
70 7.82 117.49 3.19 
71 8.23 119.78 1.67 
72 8.54 118.82 1.13 
73 7.96 115.36 1.58 
74 7.90 107.76 1.28 
75 7.98 111.20 1.23 
76 9.01 122.33 0.91 
77 7.16 131.95 -1.69 
78 8.16 121.31 1.06 
79 9.17 125.96 1.36 
80 8.66 124.19 1.58 
81 8.98 125.97 1.51 
82 9.27 123.83 1.46 
83 8.85 128.78 1.48 
84 8.24 126.32 2.20 
85 7.84 117.18 1.52 
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86 7.95 119.30 1.95 
88 8.43 124.04 2.32 
89 8.08 114.29 2.13 
90 7.39 124.65 1.39 
91 8.47 121.64 1.66 
92 8.44 117.31 2.03 
93 7.57 120.55 1.98 
94 7.78 116.89 1.45 
95 7.45 116.65 2.20 
96 7.53 119.20 1.79 
97 8.36 118.79 1.75 
98 7.97 117.45 1.87 
100 7.76 119.94 1.40 
102 7.78 117.65 2.21 
103 8.35 118.43 1.44 
104 8.04 116.70 1.53 
106 7.47 109.07 2.64 
107 8.35 122.01 2.39 
108 8.40 121.08 2.68 
109 7.58 122.20 3.59 
113 8.79 129.04 0.85 
114 9.18 128.21 1.36 
115 8.02 114.57 1.12 
116 8.71 121.61 1.58 
117 9.10 120.87 1.89 
118 7.09 114.51 1.44 
119 8.72 116.74 1.36 
120 7.75 120.94 1.87 
121 8.16 122.92 2.07 
122 7.71 121.53 2.87 
123 7.99 119.74 2.45 
124 9.08 113.76 0.65 
125 7.65 124.59 1.28 
126 8.73 127.35 1.72 
127 9.41 121.77 1.61 
128 8.63 117.86 1.85 
129 6.77 116.90 2.08 
130 7.03 123.48 1.96 
131 8.56 117.83 2.19 
132 7.84 119.73 1.92 
133 7.47 123.52 2.15 
134 8.39 121.83 2.01 
135 8.46 118.27 2.31 
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136 7.92 117.75 2.18 
137 7.60 120.07 1.92 
138 8.30 110.93 1.57 
139 8.04 113.04 1.77 
141 8.19 120.10 2.39 
142 8.45 129.93 1.47 
143 7.85 124.44 1.65 
144 8.29 122.24 2.91 
145 8.05 118.16 1.92 
146 8.15 122.75 1.84 
147 8.02 117.70 1.70 
148 7.74 118.74 1.14 
149 8.64 111.53 1.28 
150 7.36 112.40 1.18 
151 8.83 114.65 1.02 
152 7.09 120.24 2.15 
153 8.24 116.70 1.97 
154 8.10 116.32 2.49 
155 8.50 124.04 2.20 
156 7.15 112.78 0.76 
157 9.61 119.23 1.49 
158 8.51 117.02 1.54 
159 7.16 121.47 1.81 
160 7.50 118.85 1.65 
161 8.13 119.16 1.44 
162 8.12 118.21 1.57 
163 8.11 121.94 1.16 
164 9.41 123.50 1.72 
165 7.61 115.59 2.36 
166 7.67 124.84 3.40 
 
  
 APPENDIX C 
 
NMR BACKBONE ASSIGNMENTS FOR RHOA 
 
RhoA Residue Amino Acid 1H (ppm) 15N (ppm) Peak Intensity 
2 ALA 8.27 125.05 1.45 
3 ALA 8.19 123.46 1.67 
4 ILE 8.25 122.16 0.85 
5 ARG 8.54 128.19 0.62 
6 LYS 8.82 123.68 0.50 
7 LYS 10.57 125.08 0.29 
8 LEU 9.45 133.75 0.32 
9 VAL 8.01 125.80 0.39 
10 ILE 8.85 123.58 0.39 
11 VAL 9.18 130.47 0.36 
12 GLY 7.44 113.49 -0.06 
13 ASP 8.78 121.45 0.26 
14 GLY 8.86 107.38 0.33 
15 ALA 10.34 124.28 0.14 
20 CYS 8.32 110.14 0.18 
23 ILE 6.98 113.71 0.21 
25 PHE 8.79 113.75 0.36 
26 SER 7.63 113.73 -0.21 
27 LYS 8.53 122.48 0.14 
29 GLN 6.55 113.46 0.71 
30 PHE 9.07 128.76 0.46 
32 GLU 8.09 121.70 0.69 
33 VAL 7.97 116.83 0.35 
34 TYR 7.89 120.31 0.59 
35 VAL 7.85 127.20 0.67 
40 GLU 8.74 121.14 0.15 
41 ASN 8.96 115.11 0.45 
42 TYR 7.75 125.14 0.26 
43 VAL 7.51 126.51 0.33 
44 ALA 8.99 130.81 0.39 
45 ASP 8.29 121.11 0.70 
46 ILE 9.08 122.73 0.64 
47 GLU 8.16 127.06 0.95 
48 VAL 8.53 123.56 0.58 
49 ASP 9.26 125.30 0.54 
50 GLY 8.79 133.38 -0.49 
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51 LYS 8.19 121.71 0.83 
52 GLN 8.29 122.22 0.72 
53 VAL 9.14 126.69 0.55 
54 GLU 8.92 127.29 0.43 
55 LEU 9.33 128.19 0.47 
56 ALA 9.40 129.93 0.47 
57 LEU 8.96 123.66 0.23 
62 GLY 7.90 115.66 0.19 
64 GLU 9.08 119.52 0.45 
65 ASP 8.56 120.18 0.33 
66 TYR 8.07 116.58 0.47 
67 ASP 8.82 124.00 0.28 
68 ARG 8.54 112.17 0.37 
69 LEU 7.78 111.75 0.38 
70 ARG 6.92 112.21 0.14 
73 SER 8.14 113.73 0.42 
74 TYR 6.67 118.68 0.35 
76 ASP 8.87 117.06 0.30 
77 THR 7.40 116.52 0.69 
78 ASP 9.00 122.61 0.30 
79 VAL 7.86 116.58 0.52 
80 ILE 6.53 115.56 0.55 
82 MET 8.25 125.77 0.50 
83 CYS 7.80 116.37 0.49 
84 PHE 9.13 114.77 0.32 
85 SER 9.30 113.70 0.29 
86 ILE 8.79 111.96 0.42 
87 ASP 8.32 115.00 0.26 
88 SER 7.92 110.25 0.60 
90 ASP 9.02 118.49 0.66 
91 SER 8.35 117.48 0.45 
92 LEU 7.14 124.48 0.42 
93 GLU 7.86 119.84 0.45 
94 ASN 7.53 112.93 0.51 
95 ILE 8.41 123.68 0.40 
97 GLU 8.74 116.26 0.24 
98 LYS 8.80 115.58 0.33 
99 TRP 7.67 125.88 0.38 
100 THR 7.97 117.41 0.07 
102 GLU 6.92 116.50 0.48 
103 VAL 8.59 117.02 0.43 
104 LYS 8.67 116.96 0.52 
105 HIS 7.73 116.82 0.27 
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106 PHE 7.48 113.30 0.29 
107 CYS 8.73 117.46 0.41 
109 ASN 9.13 127.28 0.39 
110 VAL 7.09 122.16 0.69 
113 ILE 9.20 127.36 0.47 
114 LEU 8.43 130.39 0.36 
115 VAL 9.08 128.37 0.31 
116 GLY 8.44 112.16 0.24 
119 LYS 8.74 117.00 0.39 
120 ASP 7.96 118.11 0.40 
121 LEU 7.11 121.23 0.69 
122 ARG 9.20 130.03 0.36 
123 ASN 8.48 119.67 0.65 
124 ASP 7.56 117.16 0.13 
125 GLU 8.12 118.27 0.23 
126 HIS 7.38 118.03 0.62 
127 THR 8.33 117.83 0.43 
128 ARG 8.27 118.91 0.51 
129 ARG 8.39 120.92 0.63 
130 GLU 8.39 120.08 0.55 
131 LEU 8.46 119.54 0.55 
132 ALA 8.13 122.31 0.73 
133 LYS 7.49 119.60 0.78 
134 MET 7.40 116.19 0.98 
135 LYS 8.02 114.73 0.50 
136 GLN 7.90 116.16 0.63 
137 GLU 7.69 111.55 0.34 
142 GLU 9.53 115.03 0.51 
143 GLU 7.27 118.94 0.47 
145 ARG 7.68 121.15 0.59 
146 ASP 7.95 118.78 0.53 
147 MET 7.60 120.26 0.57 
148 ALA 8.21 121.60 0.66 
149 ASN 7.80 116.04 0.81 
150 ARG 7.57 120.43 0.51 
151 ILE 7.91 109.00 0.42 
152 GLY 7.64 110.53 0.43 
153 ALA 8.57 122.05 0.47 
154 PHE 9.76 125.04 0.30 
155 GLY 7.31 129.46 -0.52 
156 TYR 8.28 119.95 0.68 
159 CYS 8.09 120.46 0.55 
160 SER 7.78 112.33 0.40 
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162 Lys 8.24 123.12 0.15 
164 LYS 7.81 118.15 0.39 
165 ASP 7.92 121.98 0.75 
166 GLY 9.14 115.43 0.44 
167 VAL 7.39 120.09 0.67 
168 ARG 8.70 119.12 0.40 
169 GLU 9.39 118.39 0.39 
170 VAL 7.86 121.33 0.58 
171 PHE 7.03 116.54 0.43 
172 GLU 9.04 124.23 0.49 
173 MET 7.98 119.65 0.56 
174 ALA 8.21 119.13 0.75 
175 THR 7.84 114.49 0.42 
176 ARG 8.21 120.77 0.52 
177 ALA 8.02 120.56 0.65 
178 ALA 7.83 119.05 0.61 
179 LEU 7.84 116.08 0.91 
180 GLN 7.43 118.14 1.21 
181 ALA 7.71 130.00 2.21 
sidechain  10.05 128.26 0.53 
Sidechain  10.19 117.02 0.11 
sidechain  6.70 117.02 0.19 
sidechain  7.64 114.18 0.62 
sidechain  7.88 113.15 0.88 
sidechain  7.80 112.84 0.69 
sidechain  7.59 112.79 0.64 
sidechain  6.98 114.18 0.64 
sidechain  7.00 113.15 1.04 
sidechain  6.92 112.80 0.57 
sidechain  6.88 112.84 0.81 
sidechain  7.55 112.35 1.56 
sidechain  7.62 112.19 1.72 
sidechain  7.69 112.02 1.70 
sidechain  7.55 111.87 0.31 
sidechain  7.23 109.38 0.44 
sidechain  6.83 112.34 1.31 
sidechain  6.75 112.20 1.46 
sidechain  7.01 112.02 1.57 
sidechain  6.83 111.86 0.24 
sidechain  6.75 109.37 0.33 
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